var title_f15_30_15840="Buruli ulcer foot";
var content_f15_30_15840=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F77234&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F77234&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 476px\">",
"   <div class=\"ttl\">",
"    Buruli ulcer on the foot",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 287px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Tjip van der Werf, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_30_15840=[""].join("\n");
var outline_f15_30_15840=null;
var title_f15_30_15841="Interferon alpha multi-subtype (natural human interferon alpha): International drug information";
var content_f15_30_15841=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Interferon alpha multi-subtype (natural human interferon alpha): International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4302619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Multiferon (BG, IN, MX, SE, ZA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F4296617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Alpha-Interferon Multi-Subtype;",
"     </li>",
"     <li>",
"      HuIFN-alpha-Le;",
"     </li>",
"     <li>",
"      Multi-Subtype Alpha-Interferon;",
"     </li>",
"     <li>",
"      Natural Human Alpha-Interferon;",
"     </li>",
"     <li>",
"      Natural IFN-alpha;",
"     </li>",
"     <li>",
"      nIFN-alpha",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F4296618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Interferon",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F4296619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     First and/or second-line treatment (rescue therapy) of viral and malignant diseases include: Chronic myelogenous leukemia (CML), hairy cell leukemia, hepatitis B, hepatitis C, malignant melanoma,  and renal cell carcinoma",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F4296621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: SubQ: High-risk malignant melanoma (after resection and 2 doses of dacarbazine): 3 million international units 3 times per week for 6 months",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F4296622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, solution: 6 int. units/mL (1 mL) [contains albumin]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10460 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-3918385851-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_30_15841=[""].join("\n");
var outline_f15_30_15841=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4302619\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4296617\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4296618\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4296619\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4296621\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821257\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4296622\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10460\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10460|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_30_15842="PUPPP halo";
var content_f15_30_15842=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F68906&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F68906&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    PUPPP",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 332px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In fair-skinned patients with PUPPP, a white halo may be present around the erythematous papules and plaques.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_30_15842=[""].join("\n");
var outline_f15_30_15842=null;
var title_f15_30_15843="Lymphocyte depletion HL";
var content_f15_30_15843=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F53036&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F53036&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lymphocyte depletion Hodgkin lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 252px; height: 285px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEdAPwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDJEFpBdwh7qCaIMWmMRwcAYAX2IFYuqWdgxnfSGBLfPEJBh8E8hvcetXtD+zJrENvBpxuYZWAaOU4wv99j2rQ13wbf3mnzXPhq3k3W7Hz7dZAxC9ip7rXop2erPrOeMJasw72W7sNDRruMziD5wUONpPAY/nXYfC7S7Pxdpa3Wo6eodJjb+a7ErIcA5J9RmuDt/EepQD7LqFrFKUH+rnTBdemG9eK9RXxNFp3gKzsvC+kwWfmsf3gl3IjHqT71NRNKy3Mq/tXZQ2ZlfEWw0PUtbMEDSTS2sX2KSaMfK+Oje5XofrVrQkl8K/BzUbTXpLa6+0zMbGI/N8mPmI7jmuJOi69pXjaA3e/yEAkWQkMroe49a9J1GJNct2tdUgFxpy2hMZt0BljlJ5YHPT1qZaJK90Yyivd7I818H2Nvq2oWWn6lqCW1vctuiaCXLwt2BHv69qv+Nry11TRhoPh2L7JomnXBkkVjumnbu59TWRrmkw+FYYGiLzXRyscmMIFPp6n3rbn0XRpGs3sbu5XUpgiizkTAnYjOQ3bpWjaupG7tNXqGdrV63ibwpbmLzIL/AE4qtsrSH95GBj5fcdTV648HLqWk2EqyxLrbgCdGb5Q3Uc1gX/hzUoNTbzYjB5bFmmkbAZs/cH06VfvbyPR7K1j0+5N6omE2yQbot/dSPSna1uVlcnWm/wDIreLbLVtQ8QpfapcxTGHy4pruE7o0RcAH2xW5Z30Wi67Jd6NeR6msUTxBhxkMPvY9s4P0rq/AviOw8dJrWkap5NprUsbGIwxhI5FX+Ee+cVmW2g6fb+GJtX8TTNZWNujII7NdsjSBioUt6nFQ5/ZkjKFSFnGenSxleHRbalr0QvV2QjJXzXzuY8kZ644/Wue13XL3+3rsTRQR2xwiwouNq+ox3rem17w1Zabpt1Z2F3FbzMcC4bc4I/i+laXiPQPC15Fp+qR+ILWDz5AnCksxPtTTSd5I0jUgmnrY5O9hsoUMF7cFPNTce5HpXZ+EtDsLjwc8VjfI8KZndd2xrmQ/wkd8elL448AaXYPGItTia8niAwvzKO+fbjFcFrlrDoWjpHZXfnzCbBmQFQD/ALNCaqJKLHOSrRUos7zwXqE2h6zB/aEqxRqzFC7cKCehrY8Q6tbaPcxnzUvrq4kLxQ2zAlVPb6Vx3hW1t9Y8NjUNYlnZPtBidgcELjOc+5rKl1dYtUuP7ESHT3t8eUMbmmwedzdxjFTyXkS4RlLmNjwzcz6l4rvdEmdLZtRLIPO6RyYJC59TjFcfqej6j4fmvI7pCrRybMBshWDcg16KmlzeJtR0XxhodsY5pSDewp8qLOvG4Z9TzgVjfFHdoHi6RrlBNLeBZLyFuQXzk49MirhL3rL+rBCrzTt+HodnfaFDqWh6FqGI2tLiBRhDhgcHIFeaa3Yagl+q2M+7RoI18xlxtiYdn/2i2MV12o+IkvfBlpNpaTxWtgNkZ+6sbn+DPrU3wssdO1HWp21Oz84LZ+b5MjZSaYYwxHcg1EW4JtkJyjFyb2/zLHhjULHxdc2MUk6We0fvg3DZUcgfXFXvDHiHRp/ifBFpejSeWN8U99I2XG0Z3KOw4/WuQ1e0uNN1RdYNuLaW0uVNwIhtUgnjC/TFO8SXd5oPjK91HT41jeaISphfvBv6n+lJwUtF1Q5UlLZ7os+MvC1/4l8YfaIdtquqkyRPNlQR0Bx79awviHpFz4StbPw88iGIL5ryK2Q7H+KtnSfFWpa34g0+DVmd3izIZpBgqACdg9u1Yd9PFqmsb/Eb+UrI21m7ruOMCtIcyaUtkaUozi1fov8AhjY8BbrTwrIDc+bDcSlxGVyMLwOvckg49qm1/Xb/AEhdPugbc+aGWTy41G/HIBJHr6V03gyz0KDw1Dp8MzTxSyvIsoOTn3HpXJ+OpbWW7ntY2WSKKApEFGMOO4qE1KbujODUptNGdofmQ6BqUl7G8P24FbckYVyTyK5rR7edtTRLdpIpVJG4DAGP7vpWvNHqM/8AYlxe7/7OjdQzA4VPXj1qzZ6nB9uuSttmAu7rI643D6dq1TaudC1k5WEuIZ/tsNrDriCZlJYSkbSx6Lz3q2/grW4nYSm3V2+YjzwOo9O1ccr/ANqaqUs7ZY5HbKohwPzrYge6s2mgvZpYZVkPysxbjA71TTWzG9NVI7SLwvJDN9ov7mCyu57fyi6uFDYGOfrWd4UvZLPTJbfT5p7SZJhBK8rcPk8de1cv4gstQsbiI3nm3CPyRKTjr6UlvLqLaVPCEKoX8xZSPmbHYVnyXWrIVPSzZ0fxCeW2F5Z3yiaSZlijv4hwxH8IPv3q58PtCGlN9j1FxLNd4ZrcAlF7j8aTwfHqVvpl1e6upaFvlt0lXcC3cjPSuq8CTpDol7fWLxXWoxMfMV/mZV7n6+lRKTjHlRjU0Whi3l9p1p4jk029upT5a4DSDmIjsh9Par2r68k1tFcWyvZvtMUohIxInZuO9b3xDi0zU9I0+bUrTzZDEWQIoSTf2B/WvH7uAwtL9oYgGNXSMZAJ4z9KmCU1cqhFVUmzYu9U06eKCDxILjywpWKRGyV7htv+NWBdW2oPZTaEtzJfWGGX7T13fh2pt3oun31vHdvbXM8aRht24DAxzkegp8N8ZLIR6a9vplpIpV2B+bA7E+tXpbQ0tfZEnjbUNT8QWdna6hp0/wBoilLG2gXru7qfqe9Zdv4S1i5upor4R6eJsPho9yoQOMkcA+tSrqclrKfLuBdOyBc20v7zb6c1oz+KbgaBNpdu+px5XbIGQEjPXLEdfemuaKtEPZzjbkRf0LRtC0O7/te+ltrhrCNfN1DT58+W3QZjz+oFSeILj/hJ/AbrpxjubO6vgTEjgOhB+8w7Zrz7wxo8V09zpsOpJZfbP3ciyckqORn8QKt3Gh6jbRw6PZRMH8wkfZpeZyOrfXHahw97V6mHsdfeOl8YaRHcX9vo0NqJLa2RFHzbfLOOcetZfijw017JokujWSW1jbwLHIJXHEgPzfUnFczqKapayRyTregwYUSSg5DCvQfD3jCeDSrRtQhs9Ua4BihRRh4pDwNw9e+aGpRSa1NZ0ZRinHUxfF2pG8uPtOliT7ixyxSDJWRRjI9uBWZ5OrX8cNgbNZInYHy5Fwyt3x3r07w5pFr9v3zzJBqBH76GbG0+pB9qjkv7K416dY2gMsPMbA/dftg9wfSoVS2iQe2SXJFbHPar4avtL0O8tbdJVm8pJpbdhhNow3y478Vxmh2qam2+MSTSOwSRIV6Ie2TyK9D8J/EzVdI8SXFr47jS+hbAg2qN8Zz29Vx611ut6voV5Ilv4Wt0trxx5rqsPlnZnnPueaOeUNGvmcyq1E7Sjv16GJpVteNbW4uvNg021kAtbS37FejH1qp+0BZxataaZq9ghJwBNIylST75961ba9kXVpLgyGPTgfJjEjY3H+pq18U74S+AL+3bb57SRRKVx0JHOPas4tqomSm41Yu39M8pt5ooPhjqml3F5AmbmO4gGcljzuX9BirXgKN9O0K8124mkSx09g1u0bENPITjYPbJ5rAttDa4uLWzkBeK4IVmYcrjuPpz+deo3v2K6to9L8PrE1rpcY8y3I3bpMcZ9DXRNpK3c6Z+47dzC8ceI5PFMqqqR2sjhWkiQckYBbnvU+geKjrPkaLq2mC/j2mOG4VNk0YUcMSOciqfhIWZmninszJI4kMjOfnjPop9M1Rm4axdVaGUfKJN21i2SPlx3qLK3LYvkhb2aW2xQ1OdLTVJjbyAwICuGOSp9T7n0qlrcc1zbWt6AsiEbWAHO329K6rxP4XXTLWysiEmu71WnaR+M+31rm7WzxZtaM7hLc/fPqf6VpFrRouM4SSsO0S41DSLu2a3O1Jm8yNWIOMf/rranhs9WvNRv9Rne1QSIrRxL64yR9a4VtWkurjYFEaRg7eelekXlg2kfDa2kmOy4mczDcm5pPx9qJqzT6sUnHRrd6GLc6tZyXjNGs0lpF+6sreQcE9jitLS9KvfFpvrZVginskZcqRhz71zGlNBPawJcRvHMv3ZDwpyePxrvNC03TbOa2S/1ZbeO8kyfKf593fOKmfu7bk1G6exxL6Dqfh7UUgvrVYLlozskByCD3rp9Ct3n09Wlt43cEqSy7z+dafxcSAazosem/abmCKFkNwxypGT39aveErYWGjJEs8bZYuWdsZz/SplNyipGUqnNTU31IZfDmo6xcJdaxf2lq00QmhtEXedpHy8nGM+lc14vltvC939ljM07xIrSo6AeSzZx356V1eq6xGbbQ9e1XT7y3WBVhiktv3kUxUYUMOecis7xCPAvj2+n1RNWk06/Zds8M7bfNYdCM/yqYtp+9sTGc1a+3kcrYa9e6vHHDJODCc/u0P3RnBOKveAorvw1rV/LpVwZHu4mjXcvygdcn1PpWTayWHh6eaKzjtbi4mBjIEoYgHowbOM1t/DqzuX8QPHId8rwOFjJyUOOM9s1pKyTtsbVIpxbkj0/wAPCy125jhuDJcyIMtNI2SG71xOqBI7vUrnU7aeW3SdoUdIgycHbt45BrVsNTXwXYate6lZgXjAtBaqeVA6FvrmuE0zXp9cuJbqHUX04zOZZ7UHcrP14H9TWUIu7a2OaEZczcdi9qXhERapavorXFzHKBLsLZEXqGrqB4GTxLrMl7Y2Ue22cRXNjt2bDg8g9/rXHeFPEF9dauNNJk2ys0YOdrD649a1tJ8TXFrZ67pk15eQXkkweO63ENxn5GI6Zz19qqSmupvN1WrJ6oc3hC303ULmFdUVyu4NaGPZIrn7vPcDjmsi80TVbW32Xmrwxgg7t7HKr6HaDyal8SX03iCawOn3yT30UflzyMNkmfr3qjp+l61balErqflKiYEGQE5PP1qle12y6blFXk9fMji8N38jQ38VxbXTRNtDbCC4x93JHp+VIngHXJ9QivdPt3DJIJUjEy7kOc+vrXdrqto1y3h+/kJLYKXKgIdx6ge9c5q3grX5NTWHTftLXxdh9pWYrDIh+6evBHoetCqPq7ESq/zJL+vkdA2qXmjIg8WWU0L7gyzKvmQMR/fI5z+FZ3iRYr+5j1a1l0ZbdxudLdlUgj0HXJrrPD+h3Xg2xluvG2u2kkJ+ZtPZvMabjoFOcmuLvvEWh3nmDRvC9pZ7GZxPLGGbA9ulZx1ehFKXNLmgvmtv6+8p30N7cp5mlubi3uFO+X+JBjBBB+nWsjS9HvNN8TWnlOqxovm+bJ91Y8EEkevIqTRNda7n1EQN86wFw5Tahx22joKr6dKdQtXkurqQuz4dFQ7WHPQ/XFbJNXR0q7VlsbEvg2K91ZNRv4prfTgg/exNy+Ohx71o393LZ3s09pcKV8tQxHBUD7pqnBeXsuj3FtDOz3kUWyJGOMA9frx0qnost5BbG28QIPteN0cbAK5j9SPzqdXuZWtKzK/ivXr3UdLttNjMBv4JMqcZ87H8Xsai8TapqEAsrsRNBdG2UzxyjI3g7dwHuBWPq13Esg2sSobAKgZKg9M1c+16h4iaKK9aOG2K+SGfkqM8dea0UUrPoaRpOLv0Nrw7dG8uLKa4cRyuhYhBwpPGfarmirF4Os9Q0s38V1rWoMzv5Z3eWgU459TkGsbwzYahb+N/sqwERWal5f7vlqPve+c1i21lPceIWfTpEaa6dlB6bQfvH6AZqeVNtX0IlCNSSfRHQ6XqN7b6fNa6SYnvkgOJ15c8kvj35rndNl1C/khuGnJVSzMxHQj+pJFbGj6roOmamloYZ54UmWJr1HKyFicEqOm3PY16boGkWU/iVLPdaraQtIGXAVnZgCBjpnilKfJfQU60YttLQ4++0ybXLKwt5bq4kuwpz833G+tY72jWfi2w0uNzcRuVhbcMBn9DXpdssEGpyQW0YQ2br5iDnAHWuP8AHP8AxUPjy1g0dvs6zSLIHUcx7er8elTCTbt0JhUbdltY465sY5daVRE0bSzrmMLwq7hmug+Ims6lJ4vnhl3RaNZQC3giPCsu3qPfNdh4v8Lfb7We80e4dtQhAnKbQGkwRkjHc9cVmW/w41/xOi6hIGt0RcxQXxO6VuvTtk+tNVIuzkEqlOfLOTtY5p9UtP7DtYVW1hZsMQOXwO/tVXTtSsINQE1nG0TrhWmaQ73z1wKdqGkabaavLo99cRRar6RKSkUg/wCWZJ6k1kxW8N3dhU3290jYOxdwZh6AdK0SVjoiqdRe6zU1SZtAiu3ub6ecaoNyQspDBQepz+VdBoes2s2nRtZyxtEOMTr8yHuv0rk9Yu9SvtUttE1CSO+m3KI2K/MuccZ6/hVzS7UQQyQy28u+OQqfLUlT+VJxVtdzONNW1Z2FpFqfiPwN4X0rTZII7ZrlnhZeCrLzlvoeKm0zwLLpPilYNYSyS9uCxjkKb4JSR3Xs3pz61zry6lomlQwWDmOSxnItJ0wC/Oe/Y96t6Z4v1F9ZXUPE86ySwjzlhX5QOMAkf0rNqWvLsYctRaK3X72VPHfw3tfD026LVI5nJLOkY+4Kq+HbOC8vxb6J4leOYqJJPPjK7to55zzj0q7dWWteIfC93rmmQm4m+0lZ0j5ZE7cehq34W8C2cZs7jVNXNpcyIxSJlIWNj2JFVzWj7z1NVU5I2b166FSex1KK6tkR474XgLeaWP3QcEnPbnpV+28N3+nu99b22nBfuEsp+b/d5qze2EybdNt9QN+Y4t9vIGAQqTz/AC6Vbg157mOGyubKSOFIvLKhuSwHJzUOT6DlOTWhyHisjSki1DSV+z3JbBwctGx6kfWpPAjf21rQt9QeBJPLMio55lkUZCke9bk8Gm6l4du4rUJHdxnYJpDuPs317fhXEaDaXui3jamkkZns5AQzcgk5/EVpGzi11LUnJOOzL2laxdavq0tvqkcdraQOzXDRx7TGM4OfpSXDJFrzWthHqNvCh3wXjzZDj+9jHQ1NrHiqC9Qxx2n2Xz/nuZkALS8+vpVrw5p0etWV9YWshmvre3862e3l8tHYfwMDjnpTemrVgtKCUpOxLZatFfRCDU5i0z5MJkjw24dy1V9a8ReLNKuLPTby4vLfTLoq0ZxkMCcZU96q6V/auoypc+II44NOsvkYsgVpG6BQR1Oefwrptb1G2awSwuG+z7drLNPLuZSeflA5HFS7J7XJl71lBfr9xz974fvLK5kk1G7eSSM5SaJzKcnp/OtrR/DwurSW6utTEU0B27JGA8w45BHpjvUWvG1n0u0XwZqlvpdqq5uY7tykrSf3unQ1ymopJdy2okVJZCvz3KgAS+4z27U1eS7FxlOr7u3yOo8O+Dv+Jo76dqFm/mgoYy+Pvf0qv408P6rLNDZWMEUCI3lzbG2pvH8WfSsjSlg07U7eW5t7hoEkEh243YB6Jk459a3/ABbrS69qYurXTG0q08sIVkc/vMeuOval73NcTjPnt0LMLabZaY+mXz/ab+1i8uJk/iJ5JyOwPFZF5pkhhsb1d812qlURWyce5PaqUd1JZCciBEMpGwBTtxjqePWti5nVo/s0bCOWFBI8meAvfGfSizTHy8uxzZntBqYEEXmyNGRIuOc45wOxrutJ8GQWujQX+sOrSTRiYQu2MKeg+uKZpNholtoqa6k4e/u5TbRMoyqAfeY57nirGmXGm3+pRWk17vCKVXJJO7/ClKTexnOq5K0dLFHVLm2s/Dt5Jp5ntWwQxD7lIPRD35rI+HaWkX2nULuNpJYF2pEvBYkY4/DNR+Jb2OM3uhhhsjnUs3Te319B71kHVr+y+eylNtZiQyKQmVc5xz61UYtxt3NFB+za7nY2HhjRTqEF3bCYuH894pjiKNj6epp9xqsaeJtU/s1VeKBlVJCedy9WFZWveJm/sHT7y2jg8xnZXjRcBXHIYj3rL8MKC2ZyVmuZNhc9DuB/wpcrteRnTpqzbO28X28fiTw9L4k8Ni5g1mHC30cWQsi4+9iuW+FN8H1bUnnJe6a32Ru3UZzn8a63wV8QIfDV2dO1K1jTbmJiFyOD0PqPeu48PWnw+8V6nPqWhlIdRiUvNBC+zJ/vFe/PpWbk4RcWtDmqVJUE4Si+V7PcPB+lqUkvr64+zKF8tQ7YLP2/WvKvHniPV9F8facx1SSUWcyySRo3CvnkH14ql4y8UX+sa7cw3l29ra291st7WPP3gwwTVHxMiX3iR9R1Sd4troHXyz85QAYB7kgdaqnTs7y6lU6D5uaWtzrvibYWes+NNK1LSYGTUb4K5bGFPH32+ldDL4O8LWa21xd/vr0qDJ5Uu1Vb+8frW9pOt2/jTw5qFrpNglnd2SIFRgDIy47Vw2r2pt9ZuLaIuVaJMlurN3GKzTb93axlSba9mvdsYniq5vfDOrpf6dZwSCYbILspv2H+6PeoNAl8X2tk/wBhsLhIZZDLgxA5Jxk8109taNYeF7prwvIZ5lWKE8AEHO72waz9U8e61pN2bUxDYFBjLDOVxwa1TurJXOi91ypJ+pj+KDJYppa3VzBcedGZ0VDnyGPOQB1rDuzZfZWt4UZ7lwZJLqY/MfQAdhW5490iw0PV4NRaxe6tG2kRK5Vc/wB1qppGdZmuZ9H0eX7KgXzY928Qt7HjIq47JnRSnF2Or/Z/u5Tfa7ax3Jika1BiRz8uQQM/WrGp6LqE0ciIGNyX3yKMtkk9vrWc2jXOkaPJq988umWjNsgWOQLKzkdDjPFbXh2zjsfDq/2ZbsmtagdzSzXe/wApf7xOOM+lYyerkjnqNKbqRe5S8S+Hn8PwxXOoTrazQwljCpHJbGFzXn7atPPHHGRKVHyMytggV6Rr9gJsad4gnS3lZ/OWItvZePvu3v2FefSadNb3/wBpaJUtNpEMkPzop/vH3q6bVtTajP3ddWb3hXUdI0u5E2qGWG0dCuWTI3dOfetLRLme01Jr7w5po1LTLdGRmmUETLkHnPXHrXQX3w8n8beCdLZrq3s9QhLSRquMyqQASRn2zWP4nu5/Ckdh4dhDi1s7YrK6dJG7n61PMpOy3OVVI1JtIi1bUtI1TT5J4tKntZlY7lWFdozzgED1ri3kEM8E+mRzWDPJhjMCsZI6ciuqE0fiT4X62+lowuba5hnuEU4bylx0/KsOwinbwHZ6nAJTci+aL98w2SIACpA9ck1cdDopVFFuPnYk/sjxDcWB024025nka4F0hfKhAeA30Oal0fQNYt/Esscdxbm+VT5jSIJVC4/h3Zya6bS/H19Hafbxp4uNcVTAxm+6idM49OlcFqeua3q2qeU10jzSsUBiXaM55Bx2ojzu6Ki6mqaSRQ1GwmvdTkGs29xBeGT5FMRHmKOowf0rvPC1tpeqmygtYLhAsgGZlzGq55Ue9Vobadry1e8M8skTLtWL5mVu+T2Feh634o0fRNPWRdKWC7GWKM2FzjqBUzm3ZIyqNxdoK7fY8h8faZNefEO6srWKaO3V1SNFbGRgflmtrU9JutPaKK4lSS7RQ20gskA6AHsaoXfiCa71Ia1f3cBYtuWNeMAdABUF7d69qGuOl3tS1u4w5lK/IY+3Oav3tF2NFTlC1x+vumkxrdS3c636ZiaB1Xa+eQ6jH3aseFdB1LxLo+pzgpb216BCbqdgAoHpUF1oukfa7T7aS8bbNzJkpGmR1r0/4hWVylkltaNCdIMKtbLAMDbgVMp2sl1MpzcbQ7nnmpSaHonh+XQbC6a9mtuVuVBCPKx5FU/h/ibXXzbLJBDIiBk4fzDgE/Qd6luNF1LSSqXkTy2BbzY5IlDZz0GK1LSzmj0W8vLbT3siImCuW/eyk5PT9c07q1u4OyjaLMj4pWMmn+Kr+KDy7izvnWW3mTGGwOVzVWyg0yPSbeDXdUMCJcNIqxL5jRAg4Bx744qKw1iwWxhtNYMrhJQbdCdxUH7zE+nt7VQkjgSSS1SdpYll+6I+ZMf/AFqtJ25Wbxi5RUeqN7VdLttE0uKWQpfWV6N8MkYIzz1Oeh9qhvPslvFHFYowSRQyRscnI7g1natLdLHc3PnNJp0cYzBu4jY8KPrW/osFve+CV1WW1eBjK1qSpyCvBDj8al6K7EpKFlLcnlhstc0WS4JWDWLMgKhH+sQjnJ9RniuT8EQeTf6jKl01rdxQSPC6nGWHYgc1q6SYotSkErljIgP1I+9j9ar69pNxomqJrGkFLqwYh/k5KequtOOl4jkknZv0I7/Xk1TWotSuYBA7FBdhVGGZf419/UVofEbVL2zsLK10+YSaJcI1wGkjBZ33HPzYyPwqhptrp2p6hLcHiRGaZrXtIOxB9Pard5qxuLexW5tUe3hnDrG/OxfUe1OyurLYmcOayjpY7HQmsvh7JZ6vZtd3mo3VsskiTPgRRt/BgdTxXZwT6V4ms/7RtnOnX8smAs4yCTxxXn0+p2mvo+6TbP0RyMKR0A+lax0DNja2zXJt3Pzq4bg/Q1zyV9Xuck6aesnaXczvE+ieItN8S2umX2+W0nkAideQAepPoRXZ3P8AwjVt5UGuzxG8ijCdido6Z9619Ne78TeG3sJtTtraWFhHHdOmZCBwSBnr2zXGeL/h08OrhLNHuU8pd0r9XbualSUnaWhkqinaFR2a7HY/Ezw1aeI/D9xaQXMFtskR0uZR8qc9OOxrzHWNI0m20WPS9O8UtY26OWlkXP8ApDnAOQPmwMccd66fxJqM0Vv/AGC8xkvZ5HdGlGDDGg+diB97IBxXlumzW82qtPbiU20sjRyNLtBVRjlcjr1q6UXbc1oQfJyt6G+2lPdeEh4b8JWt/rd2ZjcXd60RSNfRU3YxWfpfhnXkhlt5rOSxbKiXzGwevXH9a9L8O+I9F0iO5tY9cu9KW3cSBmj3CeM85PuOlY/inW7nxB4msNRlkntLG5Hl2g8vcWjHWR8dAeetNTle1jSM5QfLay7u5zutaUb643jUWt3swEIuPmDD29/Y1Ut/C2pT2+1br/Q03K0ls+Rk84ZfWqL6iL27t9Pupl8qe83NNkZRc4PPcV3Gp6lpfgvxHJPOjT6fJG0aRRnAZf4c+pxg1Tco6I6JSlT0W5zs9rqw1Pw5fjUHtdPto1tlvASFjJdvlOOv8q7TxRfaf4um1VbdZDFpsXlvdp8vmzNj9MA1harpltrnh/R5/B+otPpSSFJbKQ/vIJWYn5h3BzgfStKxRovA2npp8AbzGe5vCF+ZpMgBfqMmok72fU5m4yfOt72I/hibOy1+z0+1h/cXCOt4joQGUrjJPfmuR1WxS98Q3Hhzy7jFjdPJZFZCoQcHnPAzxzXe+DNI1CbVRczw3EcOQWklTBxnpWB8Qb2xXxje3GkIkEgkEhlJOZWHBVl9DxTi/fYK0qjitbr8SxYeHY/Elu8+mXiRayjOrwzuFJcHOzPQjisvS7m28JO82swCLUJiY5Aqq+wZ7H/Cn3ekQiBEubrOoTk3O1JPKLluQF9BVFpLOG1a61OzM0jHbFbFyTxwWZvQfzprXTobR1Vm7oy9e8ZXdnrLHRi8EckWxZXO5nB746ZrGubbW5NJn1K+Wa9t2YIZyS5Q9cH0ruJtAt9b0u0v7GG1hiRWZIvM5V1xlOeo5rrfhx4cXW/B3iKynlksLSdjvk+8rMP4gPboap1IwV7CdWNKPP2PJNL0W2eeO4vJTJp+zLNGw3KcZAI64ro49IvZSk+l2rS2athokkyq+4Hb3FOh+GGt6fqKeXdW89kwOZ4jxx0GPUjFdjpMtroEkOnWsVyEl5kkYfKSR2NKc+zuaTxKkrwd2c5LrkWgrLbQ2tq13cxlA87cHP8ACq9APc1PbeJ9Q1T4OawPNVtT0yWMh0TlImYhgAPTHWsO+8N28fiNtT1K8lvdKjkwJOhjJPBPsDW14U8S6PoF/dw+HWku5bxSty1zCAjDJwAtJpWuldnPOPPG6WujKnwnvdR1VdWjuLtJsKoTzv4s54FX/FniWyhtZLaEolxCBHMCSfmA6YqG71K71C9nK2lpYXsThZHtU2KvBx7Vhahoeo6fr8N05gg0+7jLzTygSI7DqPZj6e9Fk5XZSjFSvL7jDWzS7m0+9e38i2JKuQc89jz25rtIbA+H9PRrm8tLyVnzG8BBdc84x1zXLaPNBqc40+1tZXcuQkxJwpJ9PSu/tdPsPD9xdC+YSXFvbq87SKMopYY49eaqo+htVai/0MwRi9FxaRWcCxTnzZoiAAcDr9arahcXK6Vp2lPb/Z4UjZ0QHgjPHTiuh0fVfDms/wBpieG4so3t3BMhxuUDhh+PauO1vTL3wtqFtepc/wBo6WYx5M3JCBum4VMdXZmUGpSs9GVLmxkj0tdXlVwuXUyhcpGwz8n1rEsr6axktLzzpSjyFTEwOCnrn0612ng7UZhovimFpWlhKC4SEqD5vIyQD0rl7fTbm80uNWbyxJlo4JBwRk/dPY1qnumawk22mS+J7SC0vv7SsnMKTIHVYjtx64/wqHQrG9v4ZRaKk084UDeclcNkf/qq5coLGwaxvf3rbMxrjJ47+1dJ4cs3t/A2papAMXCqHwg+ZcHr+VJytEqUvZ0zI1dE8MWMX2wLd3nnjziBtVBj7uK7PwXdxax4aRA4EVu24srcqx5Cgd+K890WSDxdut9VllivWOVnf/Vs3YH3Nbfh9z4Y0HVbmxcLcgqquVyI/fFTOOlnuc843jvqZ+rapqun/ERFjWR5gwjjQ5AZTz0/Gvo6x8QeZaQm4tV80KA3BODivK/C0n/CS6VZ61cp9qvra4ELSbQj7T3Pt71bsPHcCpNHYwYgjlZFMrjLY7/Ssai57JLVHLWpurZJaow/GQh1D/hJNev7SeK884W0J3fKseAMge9cdY3OjafoGkPqemmeOed/OlVucLjA9utL4v8AEn9oWEEGn3cz29y+6Qy5BznH5Vb8MW9vLpl7DfTedpcRSV4yg+ZucYY8j3xW6jyx1O+EXGnZf10NeGS1j1hV0kSXNrqSCLyZcGWND2XParb+Hbk3B0Kyl1VYEBDxzH90kffHrXCJqMesvJ9ni+x3lq+6NonJPl556+ntXsWk+IZ7/RRpE8qLJtRVlDZZkP8Atds9aiacdjOpJpKUde5wHinQ/D+j/Z2vL263Aqp+yQj93j6mrvi/TbPX/hy+raNLJcvZT73aRcOIzxz+Jqn4xsjq3iJtNtNgjtPm5dR5h/i5PHpiur8AaZF4f8DeI49UMb2l3sEgWQN5AJAALDjJyDihyslK+pE5v3Xe70Ob+A9lc239taxLmHTba33yyNwvGSMeprd8JazNpOqreJcMbO4ZT5OzLPuPXHbFYnjTxrpqaVp3hnwnG7aNa5M7sCPtEnUbj3ANNs722lSydZHgQwkNtG5wWHBJH8qJJyvJrcqNPmTclv8Akv1N7xz8Q5Y9YudNsd10d4EzRnoByqj8ev41wGpX0Op6dcao0ZimaXaApyMjr+NWbDw7ZRy2013d3BAkxsGEYqWySW9+a7a98KaQ9qqaYHt9vzDzssoB9/fHWmuSFki4clCyseZ6fqbXYubiWKO5u4YGkXfyF5AAA9gaupY3mqeGba9nZFheQw4HB2dSR7ZzVXSrBY/HVnZRDzoPN3PGo++uCWUflitXx/Mz+JZLrQkl07TYoxDHAAT5ZxypA6ZrR7pIp3vZFvXjd6ZoGn6BbqqajLuu5lzxEhHAJPritp/GGtad8MdOitYwpu5hBHGg+8MZZm+pH5Gl/t7w7rvh/Sm8VwuNSgiME86YzJH68dWrp9MsNC1PwfJYaFc/bI4pPOjDttk2gbQPYjNYSaSXMupzTdkuddfkYMPjGfS/As107BhcsI0gHBLg4b8B61zdhr2p+KdWMt1IltZpF5bpH1jHqPejXtPgup7TRohsuoQx8mM7gCfXtWx8OfC8l1oXiK3MWNUgTdDE/wAruPbP0qvcjFy6m/7ulFze7Oa8Q/b5rpLPTLa4ksf+WTNy3ByWYDNVdei0rw0YGjupb/WuC0Ri2xx555Oc/hiui8NXi/DpbvUtYWaXVr2Ix2toXBwp+8ZB2welc9H53iOfVNYvbcPexKJtv3VIFaRf3fmNOcttEuvcra9dX3idY5zPbW+0hFto/kX/AHsCtKeaWW2ggsLUzrbR+W08jkxE4+YgHrzmsPSZz4fuY3vbRWa4xtbuAfTPFen3EdjeR29wPNmgeMRxWtqmNsnct/PNE3y2VtC3KMWrI43whrMWnXX2yR0N0HEccSx/Ig/vVuardNrHjvULa1PnRavDGJJCuQCuGIz9RWNcX2tWF1HYWGmxizWT5Wkg5YE8hmxzXv8AqdrZWnha1urawtLe4EH2hlTAOcZ47nJrKpJRadtzmxNZRkpJb6HguheCdTv9eNjbNKFDbC0xxgbjnH4V6xqun6DDoet6ZDIby/S1KXCA5WNVxkoO5FeZWHiTX7yX7SLae3u55XhXEZDKAMkgHrwayvhdNeah8QmGJBE0Uy3IkY/KmOSfenOMpat7EVVJ2k3t2Ktr/Z9trNoIbnz7KbCmRTgEdwffHWrWoaHd+HdQOrXl4rWczZs1jkyxGehHYCtfWfh+8WlRNZSkQFmnUMACOwrBazvdWurWDVY5YoYFCeYBkbe5z0A960Uk9UzrUlUalfbctLGsviKJ43xMEKkMNy5PTmvTrCxWys0WOTzbR49lwCNoDEc/UVwz3Omadqz22gIksNtz5zuXe4Yjv6Cp9c1m8udMs/tKPHEo+WEHC5zySP4uc9ayknKxnVTqWtsQ6b4Juv7XnbTtUsZoJnKrab9sjL1+UY6in+J9Tg0TSIxo9hGIr9y1x5o+Z9pwwOegz2rY0fTLaTU9NuJVlidNtwrIACDz3p/ibw6PEviCE6tO6A75QY1ARVHPT39aOb3veMuZKVm9DK8MeJ1g0+7Nra7I5E3OjEsXyNoUe1cOus3RLhStuoYhYk6KK6ufxDp1vBNa6XB5SkCE5CksQfXtWNpdgdShkuEhQr5hUHdjOMVrGyu2jojGzcrWNbUPDFjaNaW2sXCW0OzO8jj65FdHpdvCivHFbwStcW/k2sDjY0rjpx9K80TWbqHTLW2KFTbx+ZF5nLSfXNdZdX0s+kaPPHGYZpUMaxt8rREYII/M1M4y6sTUnaLZu3ukaHo15LdSWsSXjwbJY0jJCnocDPesPw/r/wDZmoTG4gKxrGUVduOM8cfTFdX4e8XW7aNcwa2CH8xh9pdc7jnG0n0FcPrsUM6XENgokilZVaY43A5zgVEddJCpxbvCaNjSLG7bWz9nVLm7MbykyLhFVuisexzin+EtK8ZQwa1Z67pE40a8hkknjZPkDqMqQfbH5Vf+LWnXej+GdHt9MilimuLYT3csYJeQjGAfpmuO+GnirWNLvZJbi7uJbAI0MtvIxKsGGOh7jNNXlFyRk+aquaH9WMe20aFNHgvruRoop5GEaKeMD1+tbujwLfRtBamWKZ8MjhMggcHPp1HNbs2i2umfD69n1CaX7Ul7sjgDAZjbBO3J6YNc3NqUOmaNcx6DPLM9woWV2+/GP7vvV83PsdXtOe6h3O2s7Qn+z7FrdLu8mkIuVxhsL0wfTAyTTfEviuy0rT77RLKG4uL2QtG+R/qOB0PevOtI1O78yOI3kzSlhGrq+CmT0qW5u7Cx1f8Asy5iullEo3ySn+I9yO4qfZ66kSpRUrzZY0w3Gn6zpFw0bRzxyKVnkHfPOfwzW14h02ZvEupCS5V4piJR5R4bcf51myXN5qtybeWRbmG0k2iQtsVV9vpV26isNDghlkk8qWZC8c8GZWkXJBznGBxTd7msn7y7nHxGK7KW9vDGkqS7Mls7vUkdq7rwdoJtRcXd2rQAjCmIkIR03YrOs4dEu5JJ7dx5EoANohCSlupO41qWEtw09zf6ZZtbiMlriSWQCPbgjHXkn0FOcrqyMZOTTRavRoFsk0mms5uA+JZoAWkYEDJBPSqV7rEv2iJ7LUpo5pFCEdJlX29a5a8urjUL2MQmPZIdohB2jceh969EiuLDwhpVvFYafDPqcg/0u6mO4gf7OfrUNcvqKfuWT1ZjWPhC1v7iG9vdYeDVmG+OO9TeGI7n8OcVs+ELbTNSv9X0tFVbEws11qly+GlkHQIoxgZzxWnLpel654Ln1S/CRxxswDLkYfnGD9a8o07xBKLC60BoftenXDEF/KzMjngMp9sdKFeaepK5qsZWeqH6hopurie3Wdb6+jlzbTQShlVewcdh0rqPCnhXxsbeBLCaCCeKUvJMZAQg/wBr8e1cZeadY+H3e1ikklufL3O0i7SCf4cV65o9pq2h/DXS7bw1aSprutyli7tkxL2J9AaqpJpK3UVZuEVLq/uMXVNa8ZaD4lt08QpDqWnSsqqYEBixnk8Dg/WtTxfqt3caz9su2j8lAUt41bC7OuMewFcx4GfXk8Zy2OsW9w8S7obofeDyV1/ivRntrSB0t5fKQmF2K7tuPu//AK6zlZSSMlyqaTtcXWNSa98JQ3k0pSXT5UuYp0UBlHofXpise38VeH9WhZ2hke/lO1jAmxpPrj9a1NHMCq2mzwySteQn5cfdYDhh9Kzo9ItGuRGtnAZLZcTLDOC7qOrBex9RSVtmCUVozYtfEOl6fpElxfLMtrGm3a4yy54xjuO+a5K78X6dqlsyW4VbAsA4UYLnPCn0Bq34nl0lPDOp3N1M8dhcbYIcDLFsjjHauJ07SrfTb6zjeUvYyqtzIwGcqDxz2NVCEbXZdKCcm0eg3FvZTW9pd2lvBZADoi4Ix1ye4rL8Sxxz6bBfRalZR7HOIpG+Zq53x3rV34t1ZIdKtDZ6TZxBYYgMHb6ue5NY8elXMkosDcli0ZlwTnGBnA9DVxhs2zWEGo8zdj2Q3S3thp13phiMCgJK0ZyMev51N4nu7ayFjLcM4aVBbsUGea8z0TXLnTNOisQka2pO5AQVZWHZh3zVPX/EOoarqy2NxJOkX3CY1wM45+tR7J38jJUNU29DSbSNG/teTTtLnfU9RuHIRiNsMIP3iT6ivTfDOl6D4f0mOxJj1BgSzTRnjJ6j8K8P0+S5sZ2t7aSQee4/cp95VBwSWHTIrpdLiuY7dlkvJ4jvPyIc4H+NXUi3o2a1abqK3Noa/jvU9LtfEkNva6THGbMLbReaMsVXuc8Vd16SBtaVb5AYfIE/yqcE44Cns3WpvFNtpWq6bb+IRMsV9dsyyqoyS45fb7dSKteHtKV7ddR8SqkP28qLK3kbOIxkbW9CetZ3SSMYyUYqXy87nMWslrcaJfGUuJ45SQuARhufx5qjftZ29vYqz+XJFaSvcrEuWDDJVv5VZ8caDf8AhO5tGe2mOkzSiSMg/MqA42t9a5nUDPNql49ryGb5mB3DyiB8pPtWkUnqnodMGp6xe52vhzWL/WPh3c6g2rvc3ulyFHt5P9ZHEcYbd3FVvhndQ+IPGqyX9vFNaRBpJiqhVVVB+Yiq/gDU7CMax4Ys7ASC4tZgbkH55TgH8hin/DPS2tvh34t1Kb9yWgMcT5wScdKUkkpf1ucyTjGUfO33k1pPBrfi6bWr5EuNPS4KW9mcsEQHG7H4Zqtq9zYDUJV0qH7M1rISInQgup64rf8ACOsWWh2hktdPiiupI41uN3R4woPBPvmsDxnrtj4n8UvdQ2stoswVF3jlOCM4AHFJXcrW0N4p+0tayS/rQo6pFa3NzBc2qWsfmZEsYGOfrU11PcaldQwLpto17GFjW6nJ3lfU54wPWseWxOnPGxnYvGSpj6nH96r+j3Nvd3E0Mc0yRqAnzRlpOf7vNXbS6NWo272LviO6ghstO0a3hj2Rt+/mXkyE9cfjWFc6hHJqQaXAt7dPLRCeSByciu3j+F3iK43JLLEkzjMKbskx+5/has5PCGneHJjLqTS3V7byB2ts8KM8ketKM4LZ3IhUpJ+67sdZ+BTf6eup6srafHdMGtoQoMjL6kdQvFSePNKuGsludKuYbnRYFCCK0UlrcAck/wB7J6t2rY+J9xe6hEt/YzM8DxR+XGOCVx0/Djik8E/bNPtHvbqKJbueIA2qD92ygYYsOxIzUKTtzP7jD2s2lN/ccH4C8Max4l10XWlxB4YyN80o4XHYV399p0aaktrr6m2aM7UeTgH3z0Nb93410TSILVtEhhs7ZeHVDtVW7j3Oa6y4OnePfBBe/hQKUJZyvKkdwaidWTd2rIwqYiaknKNov70eWeMr6PWbS18KaFeRQafF+/vJgdwAHQZHr1q54On0meSTQdC0yR3tQSLgqD57AAlmf+H2Ga5hNF0m3ugkKCazUGO48lyrSKOcj/aFW7jUJLfwKui+H7p4rzUbgmOUgK0idApbt6fhV20sjecYxhaP9ebLVn4J1bWPE91f+JbT7M0koSJS2VB6jnv0r0i+v7SyvLDS57y403VLZG2XUaiRShHOQcjOOma57wbr03hew0vwtrzPd6o5LAyPuWFj90E1wHiKa91PW7p5bwi4jmZZCwwCQcbfoKhpzeuyMbSxErT0S2PRh4g0/SkMWi+fcORzcS/ediTlifWuf1/xLqOm6lBdR3iC3MJW5SbLJIcgYx9e9ZUgllsVuIFZ5o4wfKThnI/hH1rm/iDd3ktvaC7hMGRuMTdR/jVQpps2pUYcyR6L4N8TaO19NNJC8Go3aGK33n5BngsDXM6X4Mt/D3iKTWdV8SwP5TtII4ATLKx6Kf61yWh3VglrG81xJ9ph+YRyfc/OtC4VbxxLDK6tK29mHIUdxmr5OVuxcsMudu7RvXn9g6v4Tu9O1O/W3uBO08CJy4b0I75qvo+m2LaPFPel4wqbIg4OHUHn/ePsKiSTS38Of2bHpR+0+b5r3gOSV9KxogsdwkckNxeRI2F8xivlL6g9AfwppaWLjBK9r7m3rgeygQvCbRbjiKFuZpAP4iB0H1rKXTZmul8wyw7F8zzyuCRjIBHeszUlnj1jdJPKZJj+7R23uU9Ce1bHhcXI1SO3S6jaRQUa3mbJcHsCe9VblVzS1olWWxa7mL3947yk71fbjj2p9nZWeRMNYbevGx0LA/7IPc/Sqcsst1BrawQNCmnsIwCeUXJ4+mc11Xgu6sNJ8I3mqRwzyaxPuhifaGW2UEfMMjgkUSbSI9o+X3TI/tLTLa2aDT7Fjeucy3D8cD/ZqSFbIRKPtpLgfOVOAWrR1rV9LvIjqrQH+0WCoSi4BOANxHaqaeDru5UXFujhJRvxwOTUprroErcvvaG74P8ADo0/w9opMyas/nTSSWikgxsEJ4z196PBn2vxFcXlnfkyW1sHlDOcNFz09xxVvQ9esJbqKzW1milhuw0UiN+8QnjoOqnpVnSZBonjvxNpUkJW9vIh5Jz1Q84xWbbd77nN8MXHr0+//gkviHWoF8PI9/LPc28I2vJk849v0rzDT9Ss0luhFCySXhAh3cYRjjketeq6JZwTTTaXGn2p5Im8yFvmXd/SuNXQ0WNrfU7cDWIps2e4hN/orewPSnTaV0VSajdFnwpc2nhHUZp7pYmkvrN44mK4bdj1qtpusw6v8MNYsoYPs1/DNHvjQ/6yLIywqtPpN9eXtno92yR6jaW7ErJyuOpJbt9ag0mxm8OFhf7Bp+oRb1kVty+WeeGHXn0qrJ69TRxTne+uj9bHTo+j3Gk2SXVhuBZMSK3KjoQw9Ditvx5Joq3NvBYWcPnrAqwGIAhCcAsT+PeuJ8HX8bPdxynzYrYebwMkoCe3Uj6dKp2N15Wom6mmjEd0p27iBlgfuj6+tTyakun7+r2/U3vFXgrQ9PsIzNqjmeKLzJ1UZLEnrntzW/8ABLwhAon1iaF1VciBX+8P9o/0rkbZD4w1V4pIDb2llAz3kwY7mQdF54yegr2nwnqNhqvhyVdO3qwXb5RbbjAwOaipKUYctzHFVJwp8rd29/I5Lxj4gmt5jJZK4t3BIZpeAR2rmrXWbzxNZaJFq1pbyfa7nyYp4RtkAU/xetUdX8H65q2sTWdinm2jNkYZlMYzyxOcA/411/hnwzF4UbTX1q5ija2kLwx+YGbcT3xwB3p+7GOm5N4QilHf8TubzWPC2kSyaRemzEMagvG5BIbHpXGeN5BrHhW7Hgby97NslMTAts9B3Fcr8QPDeq/2lfXllafboLxjLFcRR+btB6jI79K4rwnpus3GtxQ6THc211GVUmMlP3gI++KVOkrcyZFKhFLnUv8AI77SvAFmngqzk1i5WG5WTezTj5EbNbd/4ij8HeHIbfQLqPVbxpl/doN6lP4uB0zxVz4qQPPplroUJ3XlyUE0i8gPj5sVwPhjT7V1uNEsLsWniK2kkS3m7TZ5A+vBoXvrmkawSqw9pN3V728v8jV8TeJxe3sFnpXg/wDsvULtwfMkGXkb+6vYVx3iXw7qNmbeLUykEcLkght0kfOSAB1NenfDeW4F9dWOruiTpEgtkuVJkS5BBLDdyBx1rjviNY6xN4te5t9Pe5iLBXxldrnglfrVwlaXKi6dSMZclrJfP8znBdx/2xHry3k921tKsg38M5X7orrI/EPh3xILy/1KzOkyIxlkaM7zO55Khe3NJF4FfQ72JNSlFol4oaJ58bY3/u/mfyzXECxNlr0sOscSpKyyoOAcH7yHuMcir92ezNv3VTZ/cdjp2q2ep3l7cWGIIYAjL5rAMV5yfr7Cr2rpL4vs7ZNOhN7qUY/dwomcJnq2eK8vs7OS+8QSx2g82CJ93BwCuepxXVa1eXXh8EaXcz2myby5VR8GQDpk9fwpyhZq24SglK8N+hVvvCerza59l1s2OnxQOvmAsFCLwTgD72RXdWvh611a7aPQ4pF0wHYpPLBR1YnpiuVSRvEts0Ly73hUuJSu9x3IJ9qg0ifULESW9rqkkoC828Tbcr7gdKUrtbiabV1LX8C3rsNwniAaRYPDCQQj3MZwSpbABqW/k0SKVLTzLue8jlETNKdqEjrgd6s6Do41fQHuoyGvf7Qjik5+ZVI/irI+JGlCy8UgRpLDHgbA5yXIH3uPekrN8o1JOShfY7s2vgmPU4dOm06W6vJgFFwXO5CR1Fch4k0SDSfFGoWKQzTNDGsguUPzAYypx2Nb/gi0vdS8R6fMqRG5U728zpgf1qL4xWj6H4wudRNwUj1GJXIB+4y4BUe3FRF2ly3MYPlq+z5unc57wRqen366jomqaZ9nudSU7r3kMxHTIqBYZ9MuBaTokDMxUbX3A/7WBXSeEr2x13wdr7zmO3ntIhsvXXJTPfjntXI6dpl3e6neM1tPJNaRhJWUE7T03fj2rRbvobU3FOXQmnS3trK5EzSwXCjMROdsjf0NaXhG41BNIBZWnLuW3Hn04rM1ew1LTrgS6krmAKpiaYfdHcEeuOma9C+FeuWFh4SiguoopHErkM2CcHGKU3aN9x1pNU7pXOSsrHXYfiFM07Q2ektcrJ5gUbWjLZj2evUV6DqGp2TfGXyyVTVbJMyRuu77THt+6h/vYrk/CdpH4k0mSdRLI1mqouJOYgB29qxfiVMbDxfofiHT5R5xiRw7tuJdDgjPrg1NuaXKcs6bcnFPWzR6Poo0pNYuNc0bV7eGOUMwJbDRkjoR61keJdP+0aT9pspDd3vmGSaQtl2XqWX0rC8UWFhaeJNQ1Cxtl+w3IRgueFkZcuB+NZGp6LqCwDUfDV9M01rb/aWjQkMignOMdenIpKKuncpQtaaf3/kPstSfUtVil3ol7NbyWZP98EcE+/GKi8JWuraj4b1DTNQS4Mumwf6KGxmPawYgDuMA1DcW1xq3meI7WxNtbzR7nTO35x94gfXFavhLUpZvD2oX3z77XIaQHhs8D+daPRaG84JxU4mTZ6m9l4ptdc0eGKdXUs8L8CRAoDqy9uc1Jr+kaTqy2+p6fdNaae5Mi20jZa2fug9Qahs7yLSknuZLK3aSZcNgcjPerviHQWtrCwvbKNLmKYLIdmPkJ/vDt9ad9R8qTSZ2Ph+8Fh4HdLW3QDVSxeUr85VTjk984qnol5dWN7HPp4QMn/LIjhqy/AN5eve3mn6nv8ooRDAekb47H3rRtdUtbLVoY5kChZdox2Y8c+1ZSjZtGMoWcla9zoPEXxGeTwdtubYWeqeZgR2nV8c5+nFZum6fFfaRHd6+zTSXoMuS3JB6A+lcprkIt9b1u6jvfL+z7Eyeck8bQPStDwh4ujt7L+yfEdqRaglob1OfL9iO4+nNHs7R90PYqEP3Xr5nWWem+HYFaCWfUdOaPDJ9mlJX8qtX8HiKwjkutF1BdYtgP3j+SFuFiI+8D/Fj6VWjhsNZs2SxuUuZANyS20nzj2I6kVt6B/a+gzwyz3ts0YURfZpCNxHXtyDWTdv+Cc0pNa3u+zPn+CXVNPnuZhqLywGXzY5MlnDhjg47H1rcbTZLXT49e0yZftUUkc1vfGUeZPKT80e31Fd9e30HhTxXLqtlpkF7ZXxP2y0CgiM/3kJ6e4rhvHWh2us2M2veH7cWqvmVrJOq+rL6e4+ldCnzWvsdalouVWX9af1oelWPiCBtB1bxhc6a8WuOVtWRh8ocL95R6dzXLeD/ABdc6neQ22vnZcyXSlJgcqyk9MVN8Lbl7z4e3emX5dp1l86AyDgoV5GfWq3hbwXqreKbDy1RLG3kMh3cbD1/EVnaK5kzn5YR5ubT/K2h6p8c7R7z4e3zxQiWSB1lXAyQAcE/ka8M0HxF9uhfRdVhgns5YyEmkX95CSOCrenavfbjUprqLULK5EX2d4niYKMhOOpr56utFCXCRLdRTIg+6j7SR9e/4UqFuVxZOBVqbpy6O50GjeDjFpmoXOmhQ6xkBjy2D1Gfyqzo/hyaLRQPEN5bvp0ynaZD+9Vs9R7ZqP4b6xJbT3elzTCWxfI29dr+maxdVu76y1G5R9PuGmhG+NtxKsTznntWnvNtHRJzcnFsS6a18OawZdL85rZR5b/IVBBHP4H1pX023upTqOiX6xRONkkAX5xnqM9xXV+AtVvPEMC2GpJDeJuCgumSM8sufSuT8SSadpHjG8s4NOmS2gbYywOQ0bHuD3ppu9upUZc0uV7/AJnWaNqOj+DLOE3moiWJysktnCNzO+Qcn0IrqX8SeF9bdtT0yAX9wgMmyaP7hxxxXjt8tt9ukhYNvJ2u5+Usvr71Y8JQXGl6+IrCaOeOXnBbDKP8KmVNPVvUmphoyXPd3NTw94o1TWPHS3+kmHTr1CSYpExG4H3s+ma6X4rR6h4i0/Tr5LJWlj3DaPmGTx+NZ1prnh3UtB1WS0snm1azV1jhVeXY8E8ckCtv4anUIPCLRaxIUlHKLI4DgH2zkcVMtHzJWsYzaTVRLbQw00l9M8I6lpcwhivNTTHljCruABC+1cp4f1XWbBLu1v2ktXugkJYjDOY+ApP9a9Y+IXhOLULdL/7NJd220SsI2weB1JFeXeJ9Xs9R8JC8trc2jwzrGg3lwxHYE9TVU5cy9TWhNVFfvv5DNV1K9m8P6kLyIOzFVXccng9frVHw9MJNNU+YsZDEEE49K29T1fwzqfhNGE13ba35YzCqblLDuD71xGmlHhdnwMucY/CtoK6eljqpe8mrWOq064/4RbxLPLp9yupWrxsl7BathkVuoP09azrbUI4PFK6TcwxXmlzyZiaYEGMt0f2IrQFla6Nr19qM9pfW4kd0ZCwbh/vDHcc9a5LVVuH1qKaxLTouBGTzj0FEVzGbvNXe56JLobWOm3Hn3UzidgfMJ3bx7Dtj2qzoF9qmkatZNp8RdF+/5i4OzHQ/WjwbZ3erWUlxrCOLqM7Y4XOAi46gdq0Lm01uLzDbsGUJnzm4UY6D61i3rZkOad4ydxPH+u6ppdnFF4fsrZ0uDumXZuOD2x/D36VDqGlwWmg6bY6OVje6Zbm+UHcN5XhfoD/KuR1GfWDqyW18xUNhTITxg9GJrp4NGtU0B5YZLp78SGIMThEUjGT65otypC9kqdnc4/xLaapEn2SGxaSMnmWIbjmvQW/sq++FN1FZytHqVlDDFchR8oYZ+XPeuEvPC3iPS7USWb/aIwcs8Em5wPQitq0v71PD+qWd7A1m12i70KYJYHg1UtUrMucee0k9megfCzQ7bU7FLvUtxnkGxMcY4xn61478SoJ/D/jC5sXeV5LeXchYY8xT0J969F+HfjljpxsdVjNtDC+UeMYOQeQa7PVLDwJ8S7qW3ScPqtvGC0qZWRVH164rJTdObclocjqTo1ZOafK/wPFY/O15beC4aCDURAfMmblNg+YMffArd8Dadp+taPrAg1Rbu/slEiRmLbvT+IgH8a2bjR/Dtvexf8I8/wC6hRlcs29pwBg7vrXnmka5o/hzXptR0ixu0uAHhjiY7ovmyD9R7VrfnTUTeU5SilApw6nYS30qwwS6Zdx5/fwSlcn0IFatvpupLIuoR3dy8Z5BkYnJPGM1fkt/Dk5iv7fT5/tLqXk2OPLB9Wz0rXs543tX2r5Ma4cspyrE9R9aqUuyNvaNHB3mq3di8ga6k8ncUkiJy341u+GdaTfdSRXY2zdIpEO5fbI4wan1K3tNQjlN7YRKw+RJo8lj7t7e9QaTb6HoNhqFnqSyRamj7obiPk4xwEbp1xmhtNbalTlzLY021G6tJCtvEpt3XBgZxlG9Mjinj4la/ZmZHOyLG1AYshPfPem+FLeXVNLu9PS705dQkQTh5H43f3PrWVaSW9nrDQ3M9v8AaZFKiBX3gHvnj8hU8qd00Q/ZttSVyTT/ABlc3v2221O9SC1vT8zw5DA+tc/cmX7bKlhFJJDINm6RcE47j09a6KHRotU1APpE0N06/wCskddmD6YPQ0y40XVJ1xpltHOBIVmYyjchHUEdqpOKehbdOOyNPwl4a8Y2djLrVvo8bRzJhW3At9dn9a07ubSfFssNpqsl7o+r243SQMpxJj0PpTPB+j+JrG3Y6dqN9Y6QQWuPLfchI/ujqKrWN14RGqRz6lreo2epE71nktsEfjn9Kzbu2/yOaUk23Lfyv+O53/w4sotOnaeKSGW2+YrNGPlBAwFzXmOl2viaHx5Jq+s2kslhHcOznYGVl7duR05q34l8I3mlLJqen3w1PQZ5RI6RymIHdzyOcVU0SW3t/EVnDZvqEFrL+6u0ll3rErfxq3cCiK3ad7iVNO9RO9y54qgstU0OO+mkt9Ona6ZQc/JEDk/N6f41ymnWFzoOrXF8JVuILYBgUbduz/Q16H4j+GV1/Z13Zw6xmyJE0MQ+dGIH3ieoJrhxpN9p15Z2gtbu3uY4DDKrjIlyThgPTmrhJONkzSlNSXuu6L3gmaLwv4kj1u2uFurQO8jqI+PmGAob15/SuL1Se8uNaupRLMLiSZ5MrIeAWJxj8a3LO0bSrp7UyubaVTvUcA89CO1dNpPh5dY1G3t7WNFLIXLN/dFVzKL5mapQpvmkuh0ngD4hp4b8GzW3ixp5Uw3kMuGLqf4Mf1rLv/G/g7xD4WfQbfQLi2ijUlJG2nyz/eyB1rN8X6Rol19mtZLj7FIjbNgbecDr+dc7rNifCGnRXmnBbuKR9u51+6B3YfyrOMIN36s43Sp8zqbX1K+jeHtY1V549FsZLqG2TaH6Abu+e59qpSadfWEslrewyQzxnDIV5FehahrcukeC4r2y86G3vsP5ecZfA6HsKm0yfw74p0631HWZp47/AGCOXB+8R3rRVGtWtDrWIktWtPxMz4vahDo/iTTV8uRrWS2SYsOGyRyEPepNIs9J07+z9RtN02nXcLTIlyQGQ98k9RmkvtatdS8PiLxBCLiOxPkxTouWjB/hI7Vk+IYY9b0hns2+yxWiCJBIeGjHOPrzUJOyizGFKcdG9NjuPChhurzWYW1BIpJoRMikZ5I4A9QCRXI6m3jHTdFvtDvFmljRxciURliAeOB3Heur8FaakPh+w8Tbo5vsMTRrIf4znuPauC+IGveIbzxD/abX8+9UG0x/KFX0x0NKCvJpCjHnm7a2/NHReELdm+Hl/deKLhYIN4FvPImXjAPOfX2FdtrOnPe+D7OXw25vIbu0fMy9Sw6HHr2rk9DvLnxh8PL2y8UoyRI+6O4RQjyMPu8dD3/Osbwrrl54cYSWt3OYLIKk9uxxGi7wMf7xHNS4tt90zFxne/Z7GX4J1G4sYb+zkaaOUuF/eZ3KR1wO1dZqd1cyaU5upFWJ+Gmlb5iOox78VLr3xU0mc3t0mgpb6rAwMe5RiTPdjWZDPp3xLn0/7bbXVnMhaOX7Ow2v3HGMdjVu7fNJWNlNt3cbGf4Zt7ubQ/7SAR3N8YY1deZRt4IP+RWx8ML95viAthcNtuL2OW3k8qPDRcDB3fnmo/EciR/ZhpNvcW1ppoEIYgq2FPLEe/rV74byw3mq3UjQNGZ18qOdThyP4vpnjn2pSd4tjmpOk2zmdW1pNF12/WFVkeGRogUOUzyKr2fhW1uIrUT39zBelvNJ2Zjw3ICHsc16V4l0zQNKKwX/AIZhSGXLpcOWGMdyc96uaH5Nxeq9xGn2CaASFVXPkqvAwfwpe1srxB11y3ivy/4JwFv4Sjht9Q0tr/y7uZA8JkXKtjqDWDothqmgeIbSG+uF+yyzLvjyWR1z2HrXdrqGjeJtfWPRdTxNECnl3aeWeDyQe9VNbg+1eMBYWQVpkUqJOig4JOPfAPNUpvZjhU52+Y3EsrLz9Sk0O6YaekwS7e4wileuwbvvdegqLU/DNlrvhZ30m48h4X2xx3AyXB6njp7VyEOo6daaPHoup29zcw29y9yrxyfMWPBDDv0rsdYkt7fwUdS0st9l8vfEqH5z6Ej0rNppoicZRa16nI+HvB/9nanFeXWq2EkNuC8sUKkvtUZyDjBPFatl4J8P3+oxeINB1cTsT9oNk/zNCxJ5bHbjpXO+EYb6SwOoSsZWmY7Qgzge49Kx7G71PTPEtn/Ysf2G+nm2quRtJz0x6H3rVqTb1KnGUuux6ZKNMn0qaykt8NK5M7KmZGP9445Ncr4h0R9M8P3mrW0scw4SDB2u/PJdeuRXuumSWMLXVpYzadNryoHlhQAsrHqPpXM+NPs1t4aup777L/aLSCNMKGVM9enoO9YRqO9jmhiG3yrS54r4Y1nxNpskOo6VfXD3jKRLCSWXHoVPH4Vu6v8AEbVr6Ff7X8O6ZMYm5ke1AO73OKuWto8+kDUCjmyt1/eiH5ZJCD/KuTn8Y6lrviIQW9oHtZ3EcVoiZYdh9T610WUne2x1ynTuuaN33Okf4nLqWmjSr7TLe0sJCBK1vkkD2H9KwftdlJL5GmalLFIz7Y1ZP3TZ9e4rZ+IPg1tPv7SGGGK2nMQaXngt6fWvPbeeTT77cERmU4wRwaqEYtXib0lScb0tLneSHxhbrNJbO5S2TZILeQNlfoD/APqqNPEWtzafBfaNPPda3BIRciUeZL5eBjAPbrnFcjDqNxFevcR3E8UxBwdx4P06V1U8Mqi11FbyGyuFAJnt3+aRv73/ANahxtuiZ05PSSQ/Ur60tb2JNVjnF1qdvvORhY3Pt161t+H9WutK0iG8eJeIzGJI1y0br2Yf7QHf1qhqvibWr+KP7UulX1xbptiuHjxKB6jt+lczrE91brDsNwIpPmmAYEF/wFSo82jCNKUlyzOuniRI72/udPSS7u4fNhDHhg3YHtjGfxrDtr68FpJYXNg+/aTvYlsf7JFdJ4He51Xw/el5/MhtkIKOvK56YNWvC8KS37S3e6SBEJLP047fWpvy3TMnaHMn0JfHPhvULv4YeG4YrZjdpIZJVGFIQjjisvwf4Wng0YJfM6ThzlPLY7enGa0NT8XXr6kREHkiOIo425wvrXYX/iG+0ZoLYtHKWiWTKKCBntUc01HlMHKpTVurPKNImGp6DdG6ZN5kWGXIwsoGMEe4qBkn0q1kjZ5H0udGdVxgCT3rT0CP7VJqlp5MccDfuVU9UlBzu+tSyfvtJvtPuAguLTbuEkmDIWzggfhWl7Ox2wlbToO8XeJ5JfDGmaRpNv8A2dp8lshmWMYyeM8+vc1j6Hp13rnha90uGV4ts4VZ9uQy9QD7VbttNmu9Gt2feWaYxlM/xqDx+lP8BTXWlTX3lFiCjqkbfwzDopHrmjRRdiJwioNR6Heapoc1h4Hi0q0aKe9tFQ+axw3mYOSPf2rz2bQJNR0m7ufKCXgGSJJAA+OwNa3h/W9T8T+HL9ryWT7Va3QG7aP3gOcj6jFc/wCIYpF1iDTp4ZAXXEOG4DE/ePqMVME07dSMPFpctyPRvAWteJphJYkTI7Ktztx+5A74710kk0eha5eafpsElubGXy0Mn3iQOXP1rH8NanrPhzxA0LRyLetgQMjHYcdeBw2RivT7Xwvf65qw1XWZ7dNRvE8y1tx1kRRj5vzoqSafvbE1Z+zl7/w2ORHiu21mR9I1K4jjZxtafy9ofPZjWbc6LdaObKM32y3k5iuIfmBAPAHvWRqHhjUoNXu7C6s3WaAtPJIh+VVJJA/3T0rq/COpWsGjTW87Bo48hY252t7E/wA6bSivdKfuL3NjY1Lxte2ugeRqs8N/ggKZYAW2/TvWdoPiFfNN7JvFncIbOePbtAVidp9sZrznVr3U7nWpbaFfP2OEV8d6htri9s/Ot3Ls4Ysyucrxzkj1pqirFxw0eWyW512keH7bwx4teOO5XVJf9bGE4jjB/idj3FJbQXuta3Mmi38KLuIimmYxLPJjlVPoBke9ZFvLqupaJBpdonmz3b5CQD539mPYe1dDr3w81Wxt7BG1GG3dIy32R33eXgctxxQ9H7z1BpU9OZXZma1pmueHZYrHX7S2smuiXW4YBiR3IanaD4vt9J0x9L1AtcQ+aUMqHIC9itWfE2zUobG01TU9S1W4iQRmWNVEcRxwoB5JxisM+CdT1XVP7MsIHeWP5Y5Au1Sg7tTXK17xSkpw9+35He+H5vDSI9zBqcSR4YgSnG08npU97Z2v9p6NrFm9o8lo5mZmIKvGB1YevpXK6boulaRp10usxx3FxGyxRoB8p9T65qx4qeOz0q1l0/SiVnTyyq5BUewHUH+lZ297RmEorm0bYngCDz7/AMQ63p955t8xlEWW2kK3Vsdzis/wtcDTNA1DT/Ecj3NndSD7GGc7kkzywPvW34P8BXkNpHqsuo/2UzgvFa3ShWYfQ9fSr+s6PpMn2SXVbh9PmViwXy8hh/eB+tNyV2iXKDlpr+ljauvEmmaHp1uNStooLOWMRxgL/rm+nt3PvVnQ5fD+jPDrVhaW/wBru8hdqcqD1I9K4n4haLa67olhPp2pRSpZL5Ssx5YeoFYvh1L3TbVZLmcypbOFXjAUenNT7NOO5mqKlFu56949v9Lj+wrq8MdxHMQA8LYdWPdWrzvUvDfgm7u3Ftqdy967FvL35H1Jrau4NM8SrAn2oR3SkhYi3OSOCvY4rzPxLps+g6z9nUAOARlOMk9CB3FOlHonZl0KdkoxbuS+IvDf9lLBI0U/kSAskv3kb2z2q3oj6Vqtt591NHbXcI8tFY4BFdR4MuNbv/D02m3cUbxNx5kwC457Z4x71ieIPAN1o6nUrSa01C1z++itnDvGD3K9x9K057+7J6nXGtze5N2YeI5YL7UdOt9PlhglityXdlysn5dK5bULuZn+z3StBIv+reM/Kc+vrXVeHNM0zWnexZfKlCFjKrlVT1yT0rd1jwHZjQVuLPxFa3UAGEd0GG7YVh1oU4x0ZHtIQag2Z3w8u7jSLeUKQ9tLugnU4+8RkHH410UNjHYoIRNi9uFI8gNkAfXtXHaV4fuLq5i0z+0I7Hygz75MHzPrVAw3en6hcOl3+8Qn97vyswzwQKlxUm9ROnzyeup1lnYSTXk9tcWp3xoT06mue0bxNqssdySPlE7KqsMlQMcV01n4t1IxJNbhJQYsBpkC4kxjjHWqM+kXl84uNOtYzG4BkZTgM/8AEcUR/vEKPve/oXINLub3QNRuPD9nLPdwaojsFHzMDjJHrXDeIL8X3iDVpZItkkXAK8FSMZro9K8Va1d+CrrV9UnlWXTtQV4Sg8vf0JQjuKjaCx+IVjc6vZCOx8QRRs97boP3cw7MPQ04Xi9RUa3LO8tEyrpHiDUrWwwj77GaVWTK5JdD94+ldDrWnQPr8es2tyYoNQi3uucYkA5I/KvP/D95LJbvY5LKDvjGcYevQ/ho51WyjtJkSe8tXlR0bqVxkFR9TRUXLdo1rfu5OSMeUaxbadZvatBE18zLDPnasp7lh2b3rt9H0mBZ7aO/8ua7Sy+e4ZtwUDqR6HNecrrk/iLxBFp19bNLAZDF5SLhgBnCqOx71HpH2++l1zSbe+lN6kDRWpZ9u9Vb5kbPfaDSlBtdiKkXJN7NDdQvNQGsm5kCi2gl3wMD8xGcZHr0qbxH4i8SWniuwvLS+uRcwQ4tY0AwpbGRjuDUD297F4L0a41K2bzhcNbxHOXkQc447ZJrrb62aSz066uLb9/AQsg7qvUZ/Km2lYb5ZxXMu5B4r8TyXeqaLb62WTUAobVPJUqr9wo7msgLDYX9u8xb7HqYWcQ4wYcsQA47A4Fb/wARrBdQs7DxHZxeTJCwiIjBYOR0PsTXD6g02vF7hFfz40Essar/AAA4JH0ogk0rFYeEXFW0Wz9SXxiLxvES2Om2pikDgFkGFkc9CK1tJNpq14+nauxgvpIkgSRF4DK3zhvXI71i+NvFt9Pf6TFHMvlWNuio6DHmZ6k+pxWl4Bhi1Px7CXlGER5k/wBohMgfnVNPku+g4v3G3uka/gqS4h8eafB4ZjUxRTkhpeVcDhhmvXbm28Oaz4jvLS4gu5NRaMu9xFzHgcFQfb0rz34RaZ/wjeneJ/E+pSCRY4HSJEPK5J3H27VyPwx8ZapZ6zJFa3EkVpcNuaJjlQc9QfXsaxnDnbcehxVIurJuLs1p+p7W8fgjSJYlMkQu4QMI/wB/Pv71cttYt3tNb1SIxRTw2h2LGvK57+/avCfGuoRXvia4n8wwtK4Lbv4XHXn0r0L4a3Cab4e1GbxaV+ysnlOVIOR7Y7VnKlaN2yKmH5YKTbbOV8G6TfaprNmNQjW4DNvfd0y3APv1rbh1+Kf4iQWCW8clnFcCBtw5JX0HYZrqxa+HhoM2p+H1e4WzRpkgUkFioOBn8K8G0fXZzezXalEvAfN85RtZSSSR/IVpFe0uzeDVaT06WLHjzxNqur+NtSuI2mTy5GiihY/6pQegHauh+HWpS+OI7vwzre+5u0Qz2bnggqOUJ9CK5zxBb6rrms3Os2FjJLHeNuZ7aMlQ/cH0P1rf+H/gjXtI8SW2q3lrPbxwYlDdN+T90/WtpcqhbZm9SMY0lZpNIqf2bdiea2mtZbdoXPyvwMr2HtWxpF/pX2OPRteiJIdmJjb53BBx+uK7b4kvsurSS1Qm7kJnkifO0bsDAPTtXnmvfDnxBPdW+q29svl3DqzbHyYcdfwNZRkpr3nYyVVVIJy0udv4b0Kz0S0u9V1uWGw0UL+4LMGlz3B+orO1fxx4P8QW23SdKMmoWpHlm5jxujB5YN+PeiTw23jPRLrQdOme3m0kh0Dn91K7dcn1FcNrnhC98KailhbTqbq6h5kxlXTuAfrilBRk/eeplCKnUvKWvY7Ow8O3nn3uqfb/AC9OuAYdtwSBlhnag7hfX2rMtfBsENxDcRa1I8MG4s4JHygcqa7PRLi38R+CLXTNTnkh1nRozIflwCgGAfcY71z2j2tlqtv/AGfo2sWssodnlt3bbuz2yaSk9RxqPVN2t5GZaP4Z1TS5gbqSyheMpdiJfnJzxtPfOK5rU9Qhj06w0/RoJ7XRrIsyyznMkkpzliO3oBVGG0tZrMb547a6WdgxJ+XGcYP+NdBbeFmvLC6l1K7azS2AYHbuEq9j781tZRep2uFOD5pMy/D8moXYku4IxcXkZ4M/3EH98/SptKj0/UtJ13XdXupboWZSJVgXaoyev0HpXpGjaZoVh4Vn/tMyJbaimwSb8HOPve30ryG51Wy0yybR9Lhka0WctO7Nk3OOFyPSiMuduxjzyqTfJokdAdTNxpmniJfMtSxCSKMPj3FTWHi4abE1sk27a5JOO9c5p895NNFHDbKzPhYbaIfc5zzjoKfDc2Ns88d/ZC5uPMJaRWx6cYquRGkoaWZZ07Wp7/VLWzuVElrcXCh7cjA+bCk47HvXRfDeYaV4+1TSbGygW3vC9iPm3EHGRn2561m6Tp8Vz4l0powXmJOSON7LyK6TwRfWFx41glbSpG1kSEQ3UKlVDZx8y9+nJqJtWdl0MsSrxdux59o+lXaa48CRFru1keOaNeu4Z5A710nhGSewM2vadvF9aOTtI+UleSrfWrfxFnj8M/FrVLqNfIZolmwnIMhHJ+hyah8C63DPeSxhj9lvFKTIRwkhJIb8zTk3KPMaSm6kOZrc9UFroA1LR/GlnEkF3cwG6+zgYBYDkj0rxK2vR4k8XapfxQC2EsEsyRxjGcA9P512mszz6B4fjW7gebTLUvHbyocPHn+Bh6ehrkPh/Jar4rsrmGNltpmMBz2JHp7+lZ042TZlQg4qUk76fgXPBk97eeEhDFsb7NfGcNIcleAMDPTkGl8e6jd6HaR20pcXl5Gs5Kk4x2Jr0tL3QdFvDDFaxieFXmNsFxvP94/0FeTXVq/jHUrmawhmnn84rDFIfmVB/CB7VUHzS5mtBU5KcuyLGheINYt/BWqlJcPLKrFZAGD+uAe+PStr4UJa65Z6y43RalBasGiAyHjPp365qUaZ9hsYdFW1Ju1RnmMi4MeR0HvWT8IfMt9a1a+kVVihtpUbtweKJNOMmi5/BJwOLEB1IRWzrHHLCCnmH0HrT7fUrjRdQafSVdJBmJX255K4OK6iWz0zX1lsbKJodWhQvuPAnHXA9+9ZEIfSbO2llTzZIJcyo45A7H+lbKV9Dq5lO6SO1We/1SOLRbOMCU2YW8MZ/dRknJLVQ0Xwv4dk1N7a21tftasV8tzsQsOevpmtjwhdWl208UYW2MmS4U4L8cfzrhNT0ebT9fnVkkKeYGxu5cZznOKxju1exypNNxi7HRfEzwwReRi2khbZbLKxXIDc4xk+44rB0u6vtGgutLvT5tlIFaZEfe0PvjtXQfEs3jafoGpsqpYNHs25yWYE8kdwPSuY8L2tjFe3WoTSTXDxlgyjhZQ3Q+w9quHwa6lwcnBXVz2r4KNYwi4s/tsU8Mw3QoerZGGH5Zrzv4h/DaXw/qV69n+/huJS9vtPzLH1O4DvnIFQ/CrxNZeG9duBeRubWX+JRuNv9fY1v6NqWteJ/EN/JrSg6YZGdZWbgJ2C1laUJuS2OeUZ0q0pr4WU/BPivUfh7bz3OrwK8F3IHNojgMTg/MR2Nd03xKsfFWmW6Rw3en75VO5yCv3sHJryjU/Ds9/4gls9jzRbswyDJ3H0b2Fb+laZBb3tzAZSmn2BRZCePMkIBJHsM4FE4QfvdRTo0pPna1On8calcxa7dRRTRSRFN0UbjlAAOT9fSuW0d9dj8U6Nql5cXTWrkBkiJCKh4wR0710EOsWPiG4urGSaAX4DJExPzrgDb+NJZ6DqV14TWW9uDDFayna/mYAK9ahe6rMKclCHLK3Y1datrvQfBfiAW58i7acuo6F0Y5/PBrhrZ72PwPDHeI9z+8k2s7DzIVOOATyK0PEniuPWpSl9KDZRIvlMPlOVHJb19q5PQLG41DUZNQaze6hRiRbyybVbjqauEWldmlGk1Bup6/8AAO08IXcHh3wxqur31syM8awKbiXJKHB2ZPXPtXL6V4PfWdKfU9HmSLThOZJI2wJoyewYdQKh0jwfqfjCW88pJokzvht2Ylcev0FVo31/4eatJYxvFMMhp7dW3AjscVaWr5XqU4cspcklzdjL1i+sbq6SWwgcJEfJuFdflIB4bitaa9FzrMGnLJcTackORHG+CG2967G10zT9a8NXerxaeNNnu5ESa2f7jkHll+ua5XULd9G1PUrm3sZIrOJAm52AY+4FNSUtC4TU/dlui143upmsW0ozB44FRYkH3lOM/wBa4zS9KuJ3EcFrI8rNt2qu6Rj6KP611Wn6ZPBZNqt5LGZ7tFk2Btzxrk4Y+h44rovhM7ax4q8SalLIsd3bWzyIw+9HkdRRzckXYp1I0YNrp+Za8PfDmVobm++2myuUjEXkQcvHuH8RPU89ulTafpNt4cSWwmfT5JRIXdpkDsScdTXN2Otazpl2kdvMVtJCZriXOfOUc7vY5rDu9ZeW/u5YydryluvsKhRnJ6sxVOrNvmZ1MDx6Tpuk3iQ+VMLxJPlGSu0g4P1AqHXpZbHVLbXtDN1aWczmRFLHCNn5skdj710iJpt/oDNqdybe2Wc4lAxuDd+fTNMtLxD/AKFpG3U7SHAktHiPzIe/1+lTfyM3K/QzPFug2Xj+5t9dg1OOzuI4xDcx3B2hiBwQfQnFecJodxprl2meGZtwCj+PB6g9x716R470DSI47e0i1A6ZLIfOaCX5sAjhT7c1naBpbPaahpMs6zXFpGZrZyc7lxyAT0+lXCdo6PQuhJQV1sb8niCLVvh0thqMtq73sO1WZsOJRXmXhpbrTtRhnmxG9tMpEXZiD3Fbd54ReXwjpGrwSCYwSGS5t4uXVs/pWXdbBqQ1aZmkuhIZWgQcAHnBqoJJNI2pRUeZR2PSLvwlPq/iTUde06/gZLmHPk+YAyOR056c1nfC+FfDkWoNcJLFrJJCEryPXGP51x9xrd5ZeK7O8RStpLho4wcCQ+h+lejWnizHiVYZoIoYjbMz7gN+SMYz7561nKMlG3Q5pQkk47op2XjLT7oa/Ok7SX6xEAshZ/TC/j1rl/Ct75Xw28XS26F9QIEZP91GJycdaZ8M9WttM1nWZLbR3adA27ed2ELYC89Dmui125k0nw9rN7pNjC15dhDIkS7jbbs53DoelNpRfKl2BO0XG3b8DmrCXT54NKvr62uftnlbZTE5RWI6MfQ1r6zocmqaHdXkjQQOoBSOMklxnAz6nFdB4GtheeAi+pWu2d0bdvXBbPTArJmm8nw7DGWzcxPtYr6Dpmlza6dC4VHf3ejMf4d6fZy6pDdanqBtzZt81uD/AK0Doc9BST3t/rPxAWyFwiW812IhFsJAVj6/T1rGL6rb6jJd29vG8YUO0YAIdfXFXtM8VRT+JrPUGs7e1MbjeqkgFuz/AFrRp3cjepTlJuce33Hpv7QOjxaf4L0eOyhMgt7rykQDluB2714/okLrc2MDo6m7kO6HbtO3HpXafE/xZd69ZtrEVwYLXTpEislI5mmP3nx6AY5rhbS9vL+/02/tFmfUQRmRRnaQeT+tKjFqFmY4RTjT5JPXX8TS1PRW0XR7u4tzLJC8gjWcrg8dVJ9azbW8utNw+neaYjGDMm7O1ia9I+J0mzwtaaZZAbRc/bLgZy2T1OOy5NeXOfI+xJ5jE3OZ5ivHGSAP0qqb5o3ZvRlz07vue5fbbrR/CelLp0cKXF0oluJZPvEnk49BVfVr6wvtD1W9nWIX8EW9yi8E7eM479KZBp1x4l8O6LDbny2xgZOcIO5qDWNYtPDmn6ipjt7lFG3CkfMegB9a5ktdNzz1FN2XxX/U8z8KWsmnajHq19Kq2hfzjNgGT2C9xWprniLXPFEcUNvDLaadK5Kqgx55J6+la3w88H3Xj2eS91A/YtDgJ3FfvSd9q9gPU1v+NNX0q+t7nRNBbdPbJtiEKYACdQp9vbrW0prn2u/yOlzhCoo2u1+Bwem+Gbj+3EsZXt7p5R8r+Zu2kDhcdM1fj0h10e5/tDVktZpphFFk7AoB5LY5qjokQgtBPOCUL7Y5EyCrdcj35q74osU1DQ2nuQzzQoJwM4YLzkH9Kbbbs2aVZSb1Zv6P4xk8DXFzbQGPVbSONFe4j55wMKP61pal4m8K+JI01S/s/sTBSj3Drzu7AY5NeS6Fc3WoaNHZW6+XKtx5pdU4KkdGNamo3unNfwaTaSuh34dZk43kDOD/ACpOkr+Zi6cNJbSfU2fiVqcmtxaemjyRx6HCyPzgHgjP+9j0rHtbVPEvjPUb7fMtgibmLOAWCrgDB7HFXtW0NF8OrDZajbRi2cl5pztHPXr05xWR4ftpNKt5ZbiFbl7tBFb7HLLKc5JyPSqiko6DpxjF2juaOmTzavqOowWpQpPhVz/dHRB7moPhxrcvhP4l3Au48WUshtLtB/CrHAYfQ4/CtXR7uLwzcI9+EWDorQruKSnufQisd4pr/W73UQVW2NwZHnGPlX0YH1o0d10KqxVS66HceINON1e6vFpLpNHp0iqY8jLoxzwP7vOa5W+0G7v7uSSK2ESqdm1EXHA96zND1+Wx1yS70V1DyAoyTsSJl3Y2nPI4rvbDxRJdW6yR2kIPRuf4u9TaUNiXGUNtTltY03xFH43bTNTheXTQ7eTGOIgvYj6f0qW9e90/xZew6JMNPntY0USM2FYnufauu8Ja1NqnhGLxVqiLc3MFw0CwHhNpPf3rm/iFKj+IrvVFiVfOijVoeoweozSi23ysijLnbh/Vw8QTX3iq4sV1XSwuuRxbBdRNiOcdRx61c08339kX1q+mLbX6QMr3LHaJCOgHo1Nj0h9Ujha3vJbNk+6UG4j6Vzd7LcrJeQPeXMmxSdzSE5IPHFNK+iNoU0/dj0Oi0e8+waENodluEKybG5z7jtXN6ffw2d+LoKJIGjYDsW9UPvViRW/smxvmfJmmCugGAcDrWVqkgXTDLCoj/wBL37RyAaqMbnRCnq/MvWsQmihn1CZIrJZhJFGx+dBnke1dl8RtHsr2XRry2nltlltioZV+70Klvyrgrq+89IrhoU242NGeQR3+hrc0/VZhd6ctxungnVSY2c/KT6GlKLupIzqU3zKS6XKNlfS6dqcI1KE3toCGMsa7XJz1bHWtFviJpWiatd/2JptwyXLgTbpsiUe4xXOanp09l4puUtr6ZUM3I65BOcHnmrt4EsdTWGOKFnVNySNGCymq5YvcUqXtFZ/8Oeqap47to9M8yfSTP50Y8hB8jRgjnd7j1rldAsxqsRg06KTzbgt8hOQB7HvXMRazJIbxrqNZ0VFUKx7nkn9KqwyX8WmNc2WoTWjOxwIiRt+hzWap2WhMcPyRajueiaH4Q1C0a7i1hha28UbMkjnqR/npXn+v28NjdRXbQhrab5gV7EHpViPxjq1z4Mvvtc5nvY7hALmQkttIPykHgjiqvhyObxBoeopczhFg+YBUzk1cYyi25BRlOL5qhc8UBL3R2MbD7KApj7DJ7/XNQafrS6BNoVpZxpLPMoa5VxgYY8L+FVpS6wadZSyNJbrlinQHHtXQ6VYafqd9bTyWYW48vYH3k7cdDijRLXY0qRShYp+K7e4t/EeoCeWSKx8nmQnI5P8AkVq6Doul+JL+xYXUj6dFCZZ02bSSvRR9axfidJOLqLTzMxt7VFXGOZGxnc1PsNWl0nQtPtLFFjKr5jyd5CSev0os+VNbmaU3BcrO/wDFXi630vS4tE0gC1mSItcLGNpjU9Fz/OvMNXlNxp8MI+5I4JdOcVh2VzNqGvzS3cjSPKSHJJya9Bv9Oi0/w/FDb4G/99G2OY+M49+aXIqdkFKEaVktzvfE1l4h0zwPpejeBrbNo1ti5lBG4luw965Hw3ZL8N7S71nVYYH1afMMEG7d5f8A+vvWPrPiXW7m3jtTqMka/Z1bMY29PYVzdrrTm0jvtXi/tI2zFVjlcqCSRyce1TCm+WzOeFJqLU9uvdmpZXV/4i8a2yzRsY428wwwfKijGSQPrmtfTtWHiifXFKpCLZQkDbcDbyNrGtrxS1v4P8N6p4g0e2WO6vVitkUscQB0BJHqea4HSbgaZos8kCEvqDRrISx46nj8RVL3ldFxqRqS9xWtYi05L2Kwn8mCWKSxmYOR90DPIb3HarOnRLd6kupXtp9suYSDFu4ST03CrWka1NHfzxPFHLFqIeWcOMkkEgYNQahNLBxG21cZwBjp0q3dnU7Sbi0ac62MmnTR3MMstjdAhYoziaGT+7juPeqEN3baKbFZ7OcW1hG3lbmyWdjkk+g5qnoutSadqttfzxR3YY4ET8Kv0xVz4kXQuLOG5t41tvM+V0TkEdalR1syKkHCWxR08S699oggjWNk3TNIx7dcD1NaXh4aXew3NrqzvAViO238sgPgdR7+1N+FMC6rDrEM7MJBbOUlB5U44NVPAgdpJmvJpLlmdI1Ltyvcnv6Y/GnLquxMqu8VsY+nWIvbhYLKF4YFfLXErYwM5BP4V3uqWF9LcgeFLaQ6XGixrKRzKwHzOfqf5Vm/ZRew4LmNLm/MKogwsYDYyB0JxXqWkW8kNhGkc7BR7VFSdtSa1T2drH//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Numerous Reed-Sternberg cells are seen in a background of fibrosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Warnke RA, Weiss LM, Chan JK, et al. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_30_15843=[""].join("\n");
var outline_f15_30_15843=null;
var title_f15_30_15844="Papular sarcoidosis - face";
var content_f15_30_15844=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F78691&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F78691&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Papular sarcoidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Papular sarcoidosis. Multiple round papules are present on the eyelids and central face.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc. Original photo provided by NYU (Tisch) Department of Dermatology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_30_15844=[""].join("\n");
var outline_f15_30_15844=null;
var title_f15_30_15845="ECG sinus arrhythmia";
var content_f15_30_15845=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F65949&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F65949&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1070px;\">",
"  <div class=\"figure\" style=\"width: 500px\">",
"   <div class=\"ttl\">",
"    Electrocardiogram (ECG) rhythm strip demonstrating respiratory sinus arrhythmia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 480px; height: 87px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lead II showing normal sinus rhythm with sinus arrhythmia in a healthy 26 year-old woman. Note the marked variation in the P-P intervals induced by respiration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal rhythm strip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 165px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton F Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_30_15845=[""].join("\n");
var outline_f15_30_15845=null;
var title_f15_30_15846="Artemether and lumefantrine: Pediatric drug information";
var content_f15_30_15846=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Artemether and lumefantrine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?36/58/37798?source=see_link\">",
"    see \"Artemether and lumefantrine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?7/57/8085?source=see_link\">",
"    see \"Artemether and lumefantrine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7695214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Coartem&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F7765626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antimalarial Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F7765637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/58/37798?source=see_link\">",
"      see \"Artemether and lumefantrine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Malaria, uncomplicated",
"     </b>",
"     (due to",
"     <i>",
"      P. falciparum",
"     </i>",
"     , including chloroquine resistant",
"     <i>",
"      P. falciparum",
"     </i>",
"     ):",
"     <b>",
"      Note:",
"     </b>",
"     Not for treatment of severe or complicated",
"     <i>",
"      Plasmodium falciparum",
"     </i>",
"     malaria or prevention of malaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants &ge;2 months, Children, and Adolescents &le;16 years: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     5 kg to &lt;15 kg: One tablet at hour 0 and at hour 8 on the first day and then one tablet twice daily (in the morning and evening) on days 2 and 3 (total of 6 tablets per treatment course)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     15 kg to &lt;25 kg: Two tablets at hour 0 and at hour 8 on the first day and then two tablets twice daily (in the morning and evening) on days 2 and 3 (total of 12 tablets per treatment course)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     25 kg to &lt;35 kg: Three tablets at hour 0 and at hour 8 on the first day and then three tablets twice daily (in the morning and evening) on day 2 and 3 (total of 18 tablets per treatment course)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &ge;35 kg: Four tablets at hour 0 and at hour 8 on the first day and then four tablets twice daily (in the morning and evening) on days 2 and 3 (total of 24 tablets per treatment course)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adolescents &gt;16 years  and Adults (&ge;35 kg): Oral: Four tablets at hour 0 and at hour 8 on the first day and then four tablets twice daily (in the morning and evening) on days 2 and 3 (total of 24 tablets per treatment course). If patient is &lt;35 kg, refer to dosing in children.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F7726707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Coartem&reg;: Artemether 20 mg and lumefantrine 120 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F7725447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F7765638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with a full meal for best absorption. For infants, children, and patients unable to swallow tablets: Crush tablet and mix with 5-10 mL of water in a clean container; administer; rinse container with water and administer remaining contents. The crushed mixture should be followed with food/milk, infant formula, pudding, porridge, or broth if possible. Repeat dose if vomiting occurs within 2 hours of administration; for persistent vomiting, explore alternative therapy.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F7765634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F7765627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of acute, uncomplicated malaria infections due to",
"     <i>",
"      Plasmodium falciparum",
"     </i>",
"     , including malaria in geographical regions where chloroquine resistance has been reported [FDA approved in children &ge;2 months (and at least 5 kg) and adults]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Not approved for treatment of severe or complicated",
"     <i>",
"      Plasmodium falciparum",
"     </i>",
"     malaria or prevention of malaria",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F7726710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Palpitation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Chills, dizziness, fatigue, fever, headache, insomnia, malaise, sleep disturbances, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Abdominal pain, anorexia, diarrhea, nausea, splenomegaly, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hematologic: Anemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hepatic: AST increased, hepatomegaly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, myalgia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Cough, nasopharyngitis, rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rare but important or life-threatening: Acrodermatitis, angioedema, agitation, ALT increased, asthma, ataxia, back pain, bronchitis, bullous skin eruption, conjunctivitis, constipation, clonus, dyspepsia, dysphagia, eosinophilia, fine motor delay, gait disturbance, hearing loss, hematocrit decreased, hematuria, hyper-reflexia, hypersensitivity reactions, hypoesthesia, hypokalemia, impetigo, infection (viral/bacterial/parasitic), leukocytosis, leukopenia, lymphocyte morphology abnormal, mood swings, nystagmus, peptic ulcer, pharyngolaryngeal pain, proteinuria, QT prolongation, tinnitus, thrombocytopenia, thrombocytosis, tremor, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F7765629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to artemether, lumefantrine, or any component; concurrent use with strong CYP3A4 inducers (eg, rifampin, carbamazepine, phenytoin, St John&rsquo;s wort)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F8094592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients receiving CYP3A4 inhibitors, substrates, or inducers as loss of concomitant drug efficacy or QT prolongation may occur. Use contraindicated in patients receiving strong CYP3A4 inducers. Avoid use in patients receiving medications metabolized by CYP2D6 as plasma concentrations of these coadministered medications may increase. Do not use within 1 month of halofantrine (not available in the U.S.) due to the potential additive effects on the QT interval. Drugs that prolong the QT interval (including quinidine and quinine) should be used with caution following treatment with artemether/lumefantrine due to lumefantrine&rsquo;s long half-life and potential for additive effects on the QT interval. If mefloquine is administered prior to lumefantrine, decreased lumefantrine exposure may occur due to mefloquine-induced decreased bile production; encourage food consumption and monitor efficacy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     In the event of disease reappearance after treatment with artemether/lumefantrine, patients should be treated with a different antimalarial drug. Use caution in patients with severe hepatic or renal impairment as it has not been studied in these populations.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F7765630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     QT interval prolongation has been reported in patients taking artemether/lumefantrine; avoid use in patients at risk for QT prolongation, including patients with a history of long QT syndrome, family history of congenital QT prolongation or sudden death, symptomatic arrhythmias, clinically-relevant bradycardia, severe heart disease, known hypokalemia, hypomagnesemia, or concurrent administration of antiarrhythmics (eg, Class Ia or III), drugs metabolized by CYP2D6 known to have cardiac effects (eg, flecainide, tricyclic antidepressants), or other drugs known to prolong the QT interval (eg, antipsychotics, antidepressants, macrolides, fluoroquinolones, triazole antifungals, or cisapride). Concomitant use of agents that promote hypokalemia or hypomagnesemia should be avoided.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F7734090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antimalarial Agents: Artemether may enhance the adverse/toxic effect of Antimalarial Agents.  Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antimalarial Agents: May enhance the adverse/toxic effect of Lumefantrine. Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): Antimalarial Agents may increase the serum concentration of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Artemether: May enhance the adverse/toxic effect of Antimalarial Agents. Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Artemether may decrease the serum concentration of Contraceptives (Estrogens).  Management: Consider the use of an alternative (i.e., non-hormonal) means of contraception in all women of childbearing potential who are using artemether.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Artemether may decrease the serum concentration of Contraceptives (Progestins).  Management: Consider the use of an alternative (i.e., non-hormonal) means of contraception in all women of childbearing potential who are using artemether.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Moderate) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Lumefantrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Systemic): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Systemic). Specifically, concomitant use of antimalarial agents with dapsone may increase the risk of hemolytic reactions. Dapsone (Systemic) may enhance the adverse/toxic effect of Antimalarial Agents. Specifically, concomitant use of dapsone with antimalarial agents may increase the risk for hemolytic reactions.  Management: Closely monitor patients for signs/symptoms of hemolytic reactions with concomitant use of dapsone and antimalarial agents, particularly in patients deficient in glucose-6-phosphate dehydrogenase (G6PD), methemoglobin reductase, or with hemoglobin M.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Topical): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Topical). Specifically, the risk of hemolytic reactions may be increased.  Management: Closely monitor for signs/symptoms of hemolytic reactions with concomitant use of topical dapsone and antimalarial agents. Patients with glucose-6-phosphate dehydrogenase deficiency may be at particularly high risk for adverse hematologic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May decrease serum concentrations of the active metabolite(s) of Artemether. Specifically, concentrations of dihydroartemisinin may be decreased. Artemether may increase the serum concentration of Etravirine. Etravirine may increase the serum concentration of Artemether.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of Artemether.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: Lumefantrine may enhance the QTc-prolonging effect of Halofantrine.  Management: Halofantrine and lumefantrine (as artemether-lumefantrine combination) should not be used within 1 month of each other.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumefantrine: Antimalarial Agents may enhance the adverse/toxic effect of Lumefantrine.  Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nebivolol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nebivolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives with less of an inhibitory effect on CYP2D6 activity when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F7765633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administration with grapefruit juice may result in increased concentrations of artemether and/or lumefantrine and potentiate QT prolongation (avoid grapefruit juice).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Absorption of artemether/lumefantrine is increased in the presence of food. The bioavailability of artemether increases two- to threefold and lumefantrine increases 16-fold (particularly with a high-fat meal).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F7725577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7725578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have demonstrated increased fetal resorption and postimplantation loss during the period of organogenesis. Safety data from an observational pregnancy study included 500 pregnant women exposed to artemether/lumefantrine and did not show an increased in adverse outcomes or teratogenic effects over background rate. Approximately one-third of these patients were in the third trimester. Efficacy has not been established in pregnant patients. Treatment failures with standard doses have been reported in pregnant women in areas where drug resistant parasites are prevalent. This may be attributed to lower serum concentration of both artemether and lumefantrine in this population (McGready, 2008). Use during pregnancy only if potential benefit justifies potential risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F7765867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for adequate food consumption and efficacy.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F7765635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Artemether and major metabolite dihydroartemisinin (DHA) are rapid schizontocides with activity attributed to the endoperoxide moiety common to each substance. Artemether inhibits an essential calcium adenosine triphosphatase. The exact mechanism of lumefantrine is unknown but may be due to inhibiting the formation of &beta;-hematin by complexing with hemin. Both artemether and lumefantrine inhibit nucleic acid and protein synthesis. Artemether rapidly reduces parasite biomass and lumefantrine eliminates residual parasites.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F7765636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Artemether: Rapid; enhanced with food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Lumefantrine: Initial absorption at 2 hours; enhanced with food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Artemether: 95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dihydroartemisinin (DHA): 47% to 76%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Lumefantrine: 99.7%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Artemether is hepatically metabolized to an active metabolite, dihydroartemisinin (DHA) catalyzed predominately by CYP3A4/5 and to a lesser extent by CYP2B6, CYP2C9, and CYP2C19.  The artemether/DHA AUC ratio is 1.2 after one dose and 0.3 after six doses which may indicate autoinduction. Lumefantrine is hepatically metabolized to desbutyl-lumefantrine by CYP3A4.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: Absorption is increased in the presence of food. The bioavailability of artemether increases two- to threefold and lumefantrine increases 16-fold (particularly a high fat meal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Artemether: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     DHA: 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Lumefantrine: 72-144 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Artemether: ~2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Lumefantrine: ~6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: No excretion data exist for humans",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F7765868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/57/8085?source=see_link\">",
"      see \"Artemether and lumefantrine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not take medication with grapefruit juice. Take medication with food. Inform physician if flu-like symptoms, vomiting, fainting, change in heart beat, or loss of appetite occurs.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Alecrim MG, Lacerda MV, Mour&atilde;o MP, et al, &ldquo;Successful Treatment of",
"      <i>",
"       Plasmodium falciparum",
"      </i>",
"      Malaria With a Six-Dose Regimen of Artemether-Lumefantrine Versus Quinine-Doxycycline in the Western Amazon Region of Brazil,&rdquo;",
"      <i>",
"       Am J Trop Med Hyg",
"      </i>",
"      , 2006, 74(1):20-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/30/15846/abstract-text/16407341/pubmed\" id=\"16407341\" target=\"_blank\">",
"        16407341",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Guidelines for Treatment of Malaria in the United States,&rdquo; Treatment Table Update, September 23, 2011. Available at",
"      <a href=\"file://www.cdc.gov/malaria/pdf/treatmenttable.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/malaria/pdf/treatmenttable.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Treatment of Malaria (Guidelines for Clinicians).&rdquo; Available at",
"      <a href=\"file://www.cdc.gov/malaria/pdf/clinicalguidance.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/malaria/pdf/clinicalguidance.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Makanga M, Premji Z, Falade C, et al, &ldquo;Efficacy and Safety of the Six-Dose Regimen of Artemether-Lumefantrine in Pediatrics With Uncomplicated",
"      <i>",
"       Plasmodium falciparum",
"      </i>",
"      Malaria: a Pooled Analysis of Individual Patient Data,&rdquo;",
"      <i>",
"       Am J Trop Med Hyg",
"      </i>",
"      , 2006, 74(6):991-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/30/15846/abstract-text/16760509/pubmed\" id=\"16760509\" target=\"_blank\">",
"        16760509",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McGready R, Tan SO, Ashley EA, et al, &ldquo;A Randomised Controlled Trial of Artemether-Lumefantrine Versus Artesunate for Uncomplicated",
"      <i>",
"       Plasmodium falciparum",
"      </i>",
"      Treatment in Pregnancy,&rdquo;",
"      <i>",
"       PLoS Med",
"      </i>",
"      , 2008, 5(12):e253.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/30/15846/abstract-text/19265453/pubmed\" id=\"19265453\" target=\"_blank\">",
"        19265453",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Omari AA, Gamble C, and Garner P, &ldquo;Artemether-Lumefantrine (Six-Dose Regimen) for Treating Uncomplicated",
"      <i>",
"       Falciparum",
"      </i>",
"      Malaria,&rdquo;",
"      <i>",
"       Cochrane Database Syst Rev",
"      </i>",
"      , 2005, Issue 4, Art. No.: CD005564.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/30/15846/abstract-text/16235412/pubmed\" id=\"16235412\" target=\"_blank\">",
"        16235412",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Toovey S and Jamieson A, &ldquo;Audiometric Changes Associated With the Treatment of Uncomplicated",
"      <i>",
"       Falciparum",
"      </i>",
"      malaria With Co-Artemether,&rdquo;",
"      <i>",
"       Trans R Soc Trop Med Hyg",
"      </i>",
"      , 2004, 98(5):261-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/30/15846/abstract-text/15109547/pubmed\" id=\"15109547\" target=\"_blank\">",
"        15109547",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;World Health Organization Guidelines for the Treatment of Malaria Second Edition,&rdquo; Available at",
"      <a href=\"file://www.cdc.gov/malaria/diagnosis_treatment/treatment.html%20\" target=\"_blank\">",
"       file://www.cdc.gov/malaria/diagnosis_treatment/treatment.html",
"      </a>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12805 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-A6750C7309-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_30_15846=[""].join("\n");
var outline_f15_30_15846=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7695214\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7765626\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7765637\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7726707\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7725447\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7765638\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7765634\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7765627\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7726710\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7765629\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8094592\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7765630\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298772\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7734090\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7765633\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7725577\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7725578\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7765867\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7765635\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7765636\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7765868\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12805\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12805|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/58/37798?source=related_link\">",
"      Artemether and lumefantrine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/57/8085?source=related_link\">",
"      Artemether and lumefantrine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_30_15847="Approach to patients with chronic hepatitis C virus infection and normal serum aminotransferases";
var content_f15_30_15847=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to patients with chronic hepatitis C virus infection and normal serum aminotransferases",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/30/15847/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/30/15847/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/30/15847/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/30/15847/contributors\">",
"     Adrian M Di Bisceglie, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/30/15847/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/30/15847/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/30/15847/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The observation that hepatitis C virus (HCV) infection could exist in persons with normal serum alanine aminotransferase (ALT) concentrations was first made in otherwise apparently healthy blood donors who tested anti-HCV positive. Subsequent studies found that 40 to 70 percent of these individuals were repeatedly anti-HCV and recombinant immunoblot (RIBA) positive, while the remainder had a false positive test for anti-HCV with no evidence of circulating HCV-RNA [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15847/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 65 percent of anti-HCV and RIBA-positive individuals with a normal serum ALT are viremic [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15847/abstract/2\">",
"     2",
"    </a>",
"    ]. The remainder, it is assumed, have either low level viremia (below detectable levels) or resolved infection. Although the serum ALT concentration is within the normal range in these patients at the time of diagnosis, these values may occasionally fluctuate out of the normal range. However, it is unusual for the value to exceed 1.5 times the upper limit of normal [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15847/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;HCV infection with a normal ALT is defined by the following [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15847/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Detectable HCV RNA",
"     </li>",
"     <li>",
"      Serum ALT concentration that is persistently within the normal range",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Using this definition, approximately 25 to 40 percent of patients with chronic HCV infection have persistently normal serum ALT [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15847/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a general rule, the cutoff values for normal in the laboratory reference range should be used. However, there are data to suggest that lower values for normal should be used [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15847/abstract/5\">",
"     5",
"    </a>",
"    ]. It has been proposed that the upper limit of normal may be set too high because of unrecognized fatty liver disease among apparently healthy individuals who were included in the cohorts used to establish the normal range. This is supported by a study in which a fall in ALT levels was noted in patients with \"normal\" ALT levels who achieved a sustained virologic response after undergoing treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15847/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reasons why serum ALT concentrations are normal in some patients and elevated in others are not well understood. However, several intriguing associations have been noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The serum HCV-RNA concentration does not correlate with the serum ALT [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15847/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In one report, anti-HCV positive blood donors with normal ALT concentrations were older and more often women than those with abnormal levels [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15847/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study from Japan, HCV-infected patients with a normal serum ALT were much more likely to be HLA-DR13 positive than those with an elevated ALT (42 versus 4 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15847/abstract/9\">",
"       9",
"      </a>",
"      ]. The possible role of other host factors is uncertain [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15847/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Viral characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of viral characteristics in determining the likelihood of a normal ALT state is unclear. In one review of 341 anti-HCV positive patients, those infected with genotype 3 were more likely to have a normal ALT, while those infected with genotype 2 were more likely to have an elevated ALT [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15847/abstract/10\">",
"     10",
"    </a>",
"    ]. However, others have found a higher risk of having an elevated ALT in patients with genotype 1 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15847/abstract/11\">",
"     11",
"    </a>",
"    ] or, more commonly, no relation to viral genotype at all [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15847/abstract/12\">",
"     12",
"    </a>",
"    ]. Other virologic characteristics, such as quasispecies diversity, have not been found to differ among patients with normal or increased serum ALT [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15847/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with chronic HCV infection and normal serum ALT concentrations are usually asymptomatic. Most patients are discovered incidentally when anti-HCV antibodies are found after blood donation. Symptoms that have been reported are generally mild and nonspecific, including fatigue, headaches, anxiety, and drowsiness. In one report of voluntary blood donors, the frequency and severity of symptoms were similar among anti-HCV positive patients who had a normal serum ALT, mildly elevated values (&lt;2 times normal), and more marked elevations (&gt;2 times normal) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15847/abstract/8\">",
"     8",
"    </a>",
"    ]. However, the significance of this finding in light of the nonspecific nature of these symptoms is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Liver biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many anti-HCV positive patients with normal serum ALT concentrations have an abnormal liver biopsy, although the changes are usually mild [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15847/abstract/8,12,14-17\">",
"     8,12,14-17",
"    </a>",
"    ]. A review of 290 cases, for example, found the following biopsy results [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15847/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      27 percent had either normal liver histology or minimal nonspecific changes.",
"     </li>",
"     <li>",
"      54 percent had chronic hepatitis with portal inflammation, with or without mild periportal extension (formerly chronic persistent or mild chronic active hepatitis).",
"     </li>",
"     <li>",
"      19 percent had chronic hepatitis with moderate degrees of inflammatory activity but without fibrosis.",
"     </li>",
"     <li>",
"      One patient had cirrhosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The degree of histologic injury correlates roughly with the concentration of HCV-RNA, but there is considerable overlap [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15847/abstract/15,18\">",
"     15,18",
"    </a>",
"    ]. As an example, in a study of 22 patients with normal serum ALT, the HCV-RNA concentration varied from 4.0 to 8.0 (logarithmic transformed copy number per milliliter of serum) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15847/abstract/15\">",
"     15",
"    </a>",
"    ]. The level was lower in the three patients with normal liver biopsies (4.3) than in those with chronic persistent hepatitis with mild or moderate portal inflammation (6.4 and 7.1, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     COURSE AND MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of disease in patients with normal serum ALT is incompletely studied. As will be summarized below, the available data suggest that patients with a persistently normal ALT are more likely to be women, generally have milder disease, have a lower serum HCV RNA level, and have a relatively favorable prognosis, although up to 10 percent of patients have bridging fibrosis suggesting that the relatively favorable prognosis is not universal [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15847/abstract/19\">",
"     19",
"    </a>",
"    ]. About 30 to 50 percent of patients develop an abnormal ALT with extended follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15847/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Response to combination therapy with peginterferon plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    is similar to patients with an elevated ALT. Thus, the evolving standard of care is that patients with a persistently normal ALT should be evaluated for treatment based upon similar considerations as those with an abnormal ALT (including consideration of a protease-inhibitor containing regimen for patients with genotype 1). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38841?source=see_link\">",
"     \"Patient selection for antiviral therapy for chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Short-term studies suggest that the disease progresses slowly in the absence of regular alcohol intake. Most of these patients have been infected for 10 to 20 years before being identified as having HCV infection, suggesting that their overall prognosis is good [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15847/abstract/3,21\">",
"     3,21",
"    </a>",
"    ]. This suspected favorable prognosis was supported in a study of over 200 patients with chronic HCV infection, one-half of whom had a normal serum ALT [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15847/abstract/22\">",
"     22",
"    </a>",
"    ]. Over the four-year course of the study, the patients with a normal ALT had one-half the rate of fibrosis progression compared with those with an elevated ALT; severe fibrosis was associated with alcohol consumption in these patients. The projected median time to cirrhosis for those with a normal ALT was 80 years.",
"   </p>",
"   <p>",
"    Another report included 135 patients who were followed for an average of 3.6 years [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15847/abstract/23\">",
"     23",
"    </a>",
"    ]. HCV RNA was detectable in 69 percent. The severity of histologic injury was significantly lower among patients who were HCV RNA negative. During follow-up, HCV RNA status remained unchanged. A slight increase in serum ALT levels was observed in 21 percent of those with detectable serum HCV RNA. Findings on liver histology remained stable in 24 patients who underwent a second liver biopsy. A relatively low rate of fibrosis progression was also described in two other reports involving a total of 78 patients followed for up to seven years [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15847/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. A study that included 69 patients who were followed for five years found that 10 had a persistently normal ALT while 39 had transient elevation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15847/abstract/20\">",
"     20",
"    </a>",
"    ]. Approximately 90 percent of the cohort had normal to mildly abnormal liver histology. Overall, 30 percent were considered to have become candidates for antiviral therapy during follow-up.",
"   </p>",
"   <p>",
"    A later report compared characteristics of 480 patients with persistently normal ALT levels with 1993 with elevated ALT levels [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15847/abstract/19\">",
"     19",
"    </a>",
"    ]. Significantly more patients with a normal ALT level were women (59 versus 32 percent) and the serum HCV RNA titer was significantly lower. Patients with a normal ALT level had significantly lower inflammation and fibrosis scores but almost two-thirds had portal fibrosis and 0 percent had bridging fibrosis. There was no correlation between serum ALT activity, HCV RNA level, and liver histology among patients with a normal ALT. ALT activity increased above the upper limit of normal in 53 percent of patients during 72 weeks of follow-up while HCV RNA remained detectable in all patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Interferon",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard interferon monotherapy is almost never used for treatment of chronic HCV. However, as described below, initial experience with it in older studies of patients with a persistently normal ALT found a low rate of response, and raised concerns about worsening disease activity following therapy. This led to the recommendation against treatment of patients with a persistently normal ALT in guidelines originally proposed by the National Institutes of Health (which were subsequently revised) and have left lingering concerns related to treatment of these patients with interferon-based therapy. However, these concerns have not been observed in studies using combination therapy with peginterferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    &nbsp;(see",
"    <a class=\"local\" href=\"#H9\">",
"     'Peginterferon plus ribavirin'",
"    </a>",
"    below), and thus treatment decisions should generally not be based upon the serum ALT level alone.",
"   </p>",
"   <p>",
"    A review of the seven interferon treatment trials found that an end of treatment virologic response (disappearance of detectable HCV-RNA) occurred in 16 of 34 patients (47 percent) treated with interferon alpha at a dose of 3 million units (MU) three times weekly for 6 to 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15847/abstract/3\">",
"     3",
"    </a>",
"    ]. However, this response was sustained for 6 to 12 months after the cessation of therapy in only 14 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15847/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition, liver biopsy findings did not change [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15847/abstract/26\">",
"     26",
"    </a>",
"    ]. Nearly all responders had genotype 2 or 3 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15847/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nearly 60 percent of patients treated in these studies had a flare in the serum ALT concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15847/abstract/3\">",
"     3",
"    </a>",
"    ]. These findings were confirmed in two reports which compared interferon treatment in HCV-infected patients with a normal serum ALT to untreated controls [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15847/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. The first trial found that an elevated serum ALT occurred in six of eight treated patients (75 percent) compared with only one of nine untreated patients (11 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15847/abstract/27\">",
"     27",
"    </a>",
"    ]. In the second trial, an increased ALT occurred in 10 of 16 patients (62 percent) receiving interferon versus 1 of 15 (7 percent) controls [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15847/abstract/28\">",
"     28",
"    </a>",
"    ]. The serum ALT concentrations in patients experiencing a flare are generally less than three to four times the upper limit of normal and return to baseline following cessation of interferon. Interferon may induce liver injury via activation of the cellular immune response [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15847/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Peginterferon plus ribavirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of peginterferon plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    in patients with normal serum aminotransferases appears to be similar to the efficacy in patients with elevated aminotransferases, and has the potential to decrease HCV related morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15847/abstract/29\">",
"     29",
"    </a>",
"    ]. The largest study to address the issue included a total of 491 patients who were randomly assigned to no therapy or to peginterferon alfa-2a (180 microg per week) plus ribavirin (800 mg daily) for 24 or 48 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15847/abstract/30\">",
"     30",
"    </a>",
"    ]. All patients had at least three normal serum ALT values over an 18-month period. No patient cleared HCV RNA in the control group. By comparison, SVR rates were 30 and 52 percent in the 24 and 48 week groups given active therapy, respectively (13 and 40 percent in those with genotype 1 versus 72 and 78 percent in those with genotype 2 or 3). No treatment-related flares in ALT activity were observed.",
"   </p>",
"   <p>",
"    The authors concluded that the indication for treatment of hepatitis C can be evaluated independently (eg, histologic findings, ability to tolerate side effects) from baseline ALT activity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/45/43735?source=see_link\">",
"     \"Overview of the management of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Deciding which patients to treat",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to treat patients with HCV is complex, which we make with the patient after all the facts from the literature have been discussed. We feel it is unwise to adhere to the belief that interferon is contraindicated in patients with persistently normal ALT simply because interferon may induce a \"flare\" of the disease, as has been suggested in older studies of interferon monotherapy described above. As noted above, no flares in activity were observed in a large study of peginterferon plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    while sustained virologic response rates were similar to those seen in patients with elevated serum aminotransferases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15847/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with a persistently normal serum ALT who acquired the disease under the age of 35 years, are women, do not drink alcohol, and have no or minimal fibrosis on liver biopsy may have a slow rate of hepatic fibrosis progression [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15847/abstract/22\">",
"     22",
"    </a>",
"    ]. In such patients, it is reasonable to monitor the patient without specific treatment. In contrast, patients who do not fit this profile, and whose initial biopsy shows moderate activity or some degree of fibrosis, may be at increased risk of disease progression. We are offering therapy to these individuals. We usually treat such patients using combination therapy with peginterferon alfa plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    (plus a protease inhibitor for patients with genotype 1). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24314?source=see_link\">",
"     \"Treatment regimens for chronic hepatitis C virus genotype 1\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/37/600?source=see_link\">",
"     \"Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to treating the liver disease, therapy might be indicated, and life-saving, in patients with normal serum ALT concentrations who have serious extrahepatic manifestations of infection such as cryoglobulinemia with vasculitis or glomerulonephritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15498?source=see_link\">",
"     \"Extrahepatic manifestations of hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34040?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A 2009 guideline from the AASLD suggests that treatment be individualized based upon the severity of liver diseases, potential for serious side effects, likelihood of response, and presence of comorbid conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15847/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Follow-up of the HCV-infected patients with a normal serum ALT concentration should include counseling and monitoring. The majority of these patients are persistently viremic and therefore have the potential to transmit the infection to others. They, like any other patient with chronic HCV infection, should be counseled about this risk. While the risk of sexual transmission is low, and protection of sexual partners is not generally recommended for patients in monogamous relationships, sexual partners should be aware of the potential for infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15847/abstract/3\">",
"     3",
"    </a>",
"    ]. These patients should not donate blood, semen, or tissues, and alcohol consumption should be discouraged since it may increase HCV-RNA and the degree of liver disease.",
"   </p>",
"   <p>",
"    Although the natural history of the liver disease in these individuals is not clear, patients should be made aware of the potential, albeit small, for the infection to cause worsening liver disease, particularly if the serum ALT becomes elevated. Our approach is to monitor the ALT every 6 to 12 months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H388715895\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hepatitis C virus (HCV) infection with a normal serum alanine aminotransferase (ALT) concentration is defined by the following (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Detectable HCV RNA",
"     </li>",
"     <li>",
"      Serum ALT concentration that is persistently within the normal range",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The reasons why serum ALT concentrations are normal in some patients and elevated in others are not well understood. Available data suggest that patients with a persistently normal ALT are more likely to be women, generally have milder disease, have a lower serum HCV RNA level, and have a relatively favorable prognosis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Course and management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with chronic HCV infection and normal serum ALT concentrations are usually asymptomatic. Most patients are discovered incidentally when anti-HCV antibodies are found after blood donation. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many anti-HCV positive patients with normal serum ALT concentrations have an abnormal liver biopsy, although the changes are usually mild. The degree of histologic injury correlates roughly with the concentration of HCV-RNA, but there is considerable overlap. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Liver biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Response to combination therapy with peginterferon plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      is similar to patients with an elevated ALT. Thus, the evolving standard of care is that patients with a persistently normal ALT should be evaluated for treatment based upon similar considerations as those with an abnormal ALT (including consideration of a protease-inhibitor containing regimen for patients with genotype 1). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Course and management'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38841?source=see_link\">",
"       \"Patient selection for antiviral therapy for chronic hepatitis C virus infection\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H10\">",
"       'Deciding which patients to treat'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Follow-up of the HCV-infected patients with a normal serum ALT concentration should include counseling and monitoring. The majority of these patients are persistently viremic and therefore have the potential to transmit the infection to others. These patients should not donate blood, semen, or tissues, and alcohol consumption should be discouraged since it may increase HCV-RNA and the degree of liver disease. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Follow-up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients should be made aware of the potential, albeit small, for the infection to cause worsening liver disease, particularly if the serum ALT becomes elevated. Our approach is to monitor the ALT every 6 to 12 months. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Follow-up'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15847/abstract/1\">",
"      Rossini A, Gazzola GB, Ravaggi A, et al. Long-term follow-up of and infectivity in blood donors with hepatitis C antibodies and persistently normal alanine aminotransferase levels. Transfusion 1995; 35:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15847/abstract/2\">",
"      Prieto M, Olaso V, Verd&uacute; C, et al. Does the healthy hepatitis C virus carrier state really exist? An analysis using polymerase chain reaction. Hepatology 1995; 22:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15847/abstract/3\">",
"      Marcellin P, L&eacute;vy S, Erlinger S. Therapy of hepatitis C: patients with normal aminotransferase levels. Hepatology 1997; 26:133S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15847/abstract/4\">",
"      Inglesby TV, Rai R, Astemborski J, et al. A prospective, community-based evaluation of liver enzymes in individuals with hepatitis C after drug use. Hepatology 1999; 29:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15847/abstract/5\">",
"      Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15847/abstract/6\">",
"      Di Bisceglie AM, Thompson J, Smith-Wilkaitis N, et al. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon. Hepatology 2001; 33:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15847/abstract/7\">",
"      Martinot-Peignoux M, Marcellin P, Gournay J, et al. Detection and quantitation of serum HCV-RNA by branched DNA amplification in anti-HCV positive blood donors. J Hepatol 1994; 20:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15847/abstract/8\">",
"      Shakil AO, Conry-Cantilena C, Alter HJ, et al. Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group. Ann Intern Med 1995; 123:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15847/abstract/9\">",
"      Kuzushita N, Hayashi N, Katayama K, et al. Increased frequency of HLA DR13 in hepatitis C virus carriers with persistently normal ALT levels. J Med Virol 1996; 48:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15847/abstract/10\">",
"      Silini E, Bono F, Cividini A, et al. Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities. Hepatology 1995; 21:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15847/abstract/11\">",
"      Prati D, Capelli C, Zanella A, et al. Influence of different hepatitis C virus genotypes on the course of asymptomatic hepatitis C virus infection. Gastroenterology 1996; 110:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15847/abstract/12\">",
"      Alberti A, Noventa F, Benvegn&ugrave; L, et al. Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection. Ann Intern Med 2002; 137:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15847/abstract/13\">",
"      Shindo M, Arai K, Sokawa Y, Okuno T. The virological and histological states of anti-hepatitis C virus-positive subjects with normal liver biochemical values. Hepatology 1995; 22:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15847/abstract/14\">",
"      Marcellin P, Levy S, Benhamou JP, et al. Management of the asymptomatic HCV carrier with normal ALT levels. Viral Hepatitis Rev 1996; 2:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15847/abstract/15\">",
"      Naito M, Hayashi N, Hagiwara H, et al. Serum hepatitis C virus RNA quantity and histological features of hepatitis C virus carriers with persistently normal ALT levels. Hepatology 1994; 19:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15847/abstract/16\">",
"      Alberti A, Morsica G, Chemello L, et al. Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV. Lancet 1992; 340:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15847/abstract/17\">",
"      Kyrlagkitsis I, Portmann B, Smith H, et al. Liver histology and progression of fibrosis in individuals with chronic hepatitis C and persistently normal ALT. Am J Gastroenterol 2003; 98:1588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15847/abstract/18\">",
"      Puoti C, Magrini A, Stati T, et al. Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. Hepatology 1997; 26:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15847/abstract/19\">",
"      Shiffman ML, Diago M, Tran A, et al. Chronic hepatitis C in patients with persistently normal alanine transaminase levels. Clin Gastroenterol Hepatol 2006; 4:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15847/abstract/20\">",
"      Okanoue T, Makiyama A, Nakayama M, et al. A follow-up study to determine the value of liver biopsy and need for antiviral therapy for hepatitis C virus carriers with persistently normal serum aminotransferase. J Hepatol 2005; 43:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15847/abstract/21\">",
"      Jamal MM, Soni A, Quinn PG, et al. Clinical features of hepatitis C-infected patients with persistently normal alanine transaminase levels in the Southwestern United States. Hepatology 1999; 30:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15847/abstract/22\">",
"      Mathurin P, Moussalli J, Cadranel JF, et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 1998; 27:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15847/abstract/23\">",
"      Martinot-Peignoux M, Boyer N, Cazals-Hatem D, et al. Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA. Hepatology 2001; 34:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15847/abstract/24\">",
"      Persico M, Persico E, Suozzo R, et al. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology 2000; 118:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15847/abstract/25\">",
"      Hui CK, Belaye T, Montegrande K, Wright TL. A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase. J Hepatol 2003; 38:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15847/abstract/26\">",
"      Serfaty L, Chazouill&egrave;res O, Pawlotsky JM, et al. Interferon alfa therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity. Gastroenterology 1996; 110:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15847/abstract/27\">",
"      San Giovanni A, Spinzi GC, Ceriani R, et al. Randomized controlled trial of HCV healthy carriers with interferon (abstract). Hepatology 1995; 22:290A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15847/abstract/28\">",
"      Sangiovanni A, Morales R, Spinzi G, et al. Interferon alfa treatment of HCV RNA carriers with persistently normal transaminase levels: a pilot randomized controlled study. Hepatology 1998; 27:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15847/abstract/29\">",
"      Deuffic-Burban S, Babany G, Lonjon-Domanec I, et al. Impact of pegylated interferon and ribavirin on morbidity and mortality in patients with chronic hepatitis C and normal aminotransferases in France. Hepatology 2009; 50:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15847/abstract/30\">",
"      Zeuzem S, Diago M, Gane E, et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004; 127:1724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15847/abstract/31\">",
"      Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49:1335.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3667 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-197.136.42.3-80A65F7FBC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_30_15847=[""].join("\n");
var outline_f15_30_15847=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H388715895\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Viral characteristics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Liver biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      COURSE AND MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Interferon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Peginterferon plus ribavirin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Deciding which patients to treat",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H388715895\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34040?source=related_link\">",
"      Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15498?source=related_link\">",
"      Extrahepatic manifestations of hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/45/43735?source=related_link\">",
"      Overview of the management of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38841?source=related_link\">",
"      Patient selection for antiviral therapy for chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24314?source=related_link\">",
"      Treatment regimens for chronic hepatitis C virus genotype 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/37/600?source=related_link\">",
"      Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_30_15848="Symptomatic abdominal aortic aneurysm with rapid expansion";
var content_f15_30_15848=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F87327&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F87327&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    Symptomatic abdominal aortic aneurysm with rapid expansion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 468px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An infrarenal AAA is shown over a 17-month period. The earliest axial CT (A) shows&nbsp; the AAA measuring 5 cm. Ten months later, the AAA is marginally larger and measures 5.2 cm in diameter. Seven months later, the patient presented with left lower quadrant pain and a tender aneurysm now measuring 6 cm on CT scan (C). A new deformity in the anterior abdominal wall is identified anterior to the aorta (arrow) caused by the rapidly expanding aneurysm, which has an increased&nbsp;risk for rupture.",
"    <div class=\"footnotes\">",
"     AAA: abdominal aortic aneurysm; CT: computed tomography.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_30_15848=[""].join("\n");
var outline_f15_30_15848=null;
var title_f15_30_15849="Juvenile myoclonic epilepsy";
var content_f15_30_15849=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Juvenile myoclonic epilepsy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/30/15849/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/30/15849/contributors\">",
"     Christian M Korff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/30/15849/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/30/15849/contributors\">",
"     Douglas R Nordli, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/30/15849/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/30/15849/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/30/15849/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H6578890\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Juvenile myoclonic epilepsy (JME), previously &lsquo;impulsive petit mal,&rsquo; Janz syndrome, is one of the most common generalized idiopathic epilepsies of childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/1\">",
"     1",
"    </a>",
"    ]. It typically occurs in otherwise healthy adolescents and is characterized by the triad of myoclonic jerks, generalized tonic-clonic seizures (GTCS) and absence seizures (also called petit mal). Seizures characteristically occur upon awakening or in association with sleep deprivation, and patients generally respond quickly and completely to standard antiepileptic drugs (AEDs). Seizure frequency often lessens in adulthood but most patients require life-long AED therapy. The underlying cause of JME is not known and there are likely complex underlying genetic defects [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology, pathophysiology, clinical features, diagnosis and treatment of JME will be reviewed here. Other epileptic syndromes of childhood are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33769?source=see_link\">",
"     \"Epilepsy syndromes in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/57/921?source=see_link\">",
"     \"Benign partial epilepsies of childhood\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/1/23578?source=see_link\">",
"     \"Localization-related (partial) epilepsy: Causes and clinical features\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6578904\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;JME",
"    <strong>",
"    </strong>",
"    accounts for 25 to 30 percent of the idiopathic generalized epilepsies and up to 10 percent of all cases of epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/2\">",
"     2",
"    </a>",
"    ]. Based on a population risk of epilepsy of 1 percent by age 20, the incidence of JME is estimated to be 1 in 1000 to 2000 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The gender ratio in JME is generally considered to be equal, but several studies have reported a female preponderance of up to 2.9:1 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mean age of onset is 15 years, with a range of 5 to 34 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. The majority of patients are diagnosed between the ages of 12 and 18.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88578578\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY AND GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;JME was classified as an idiopathic generalized epilepsy (IGE) in 1989 by the International League Against Epilepsy (ILAE) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/1\">",
"     1",
"    </a>",
"    ]. In its 2010 proposal, the ILAE proposed changing the term &lsquo;idiopathic&rsquo; to &lsquo;genetic&rsquo; when applied to epilepsy syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/11\">",
"     11",
"    </a>",
"    ]. According to this report, JME would be included in the group of electroclinical syndromes of unknown cause with a high likelihood of complex genetic defects.",
"   </p>",
"   <p>",
"    The genetic mechanisms that underlie JME are not fully understood, and a polygenic or multifactorial mechanism is likely in most cases. Some JME cases are apparently sporadic, others occur in families with other IGE syndromes, and occasional families have a pure autosomal dominant JME phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/12\">",
"     12",
"    </a>",
"    ]. Fifteen chromosomal loci are suspected of playing a central role in JME; to date, only three are considered as putative JME-causing genes:",
"    <em>",
"     EFHC1",
"    </em>",
"    ,",
"    <em>",
"     GABRA1",
"    </em>",
"    , and",
"    <em>",
"     CLCN2",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/13\">",
"     13",
"    </a>",
"    ].",
"    <em>",
"     EFHC1",
"    </em>",
"    mutations are found in up to 9 percent of classic JME patients of various ethnic backgrounds [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/13-18\">",
"     13-18",
"    </a>",
"    ]. It is the only gene that has been exclusively associated with classic JME [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Seizures in JME are linked with cortical hyperexcitability, most prominent in the motor cortex and accentuated in the mornings and by sleep deprivation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/20-23\">",
"     20-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although routine MRI is typically normal in patients with JME, subtle structural and functional defects are well described using sophisticated imaging techniques such as diffusion tensor imaging and multivoxel morphometry [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/24\">",
"     24",
"    </a>",
"    ]. Most of these investigations suggest involvement of frontal thalamocortical circuits [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/25-40\">",
"     25-40",
"    </a>",
"    ] and dysfunction in the dopaminergic and serotoninergic neurotransmission systems [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/41-44\">",
"     41-44",
"    </a>",
"    ]. These findings are consistent with the neuropsychological and psychiatric characteristics reported in many JME patients. The underlying pathophysiological mechanisms are not well understood. (See",
"    <a class=\"local\" href=\"#H88577538\">",
"     'Clinical Features'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88577538\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88578549\">",
"    <span class=\"h2\">",
"     Seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typical patient with JME is a healthy young teenager with one or more of three seizure types: myoclonic jerks, generalized tonic clonic seizures (GTCS) and absence seizures. In three large observational studies totalling over 580 patients with JME, all patients had myoclonic jerks, 85 to 100 percent had at least one GTCS, and 20 to 40 percent had absence seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/7,8,10\">",
"     7,8,10",
"    </a>",
"    ]. Only 5.5 percent of patients had myoclonic jerks as the only seizure type recognized [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/10\">",
"     10",
"    </a>",
"    ]. Approximately one-half of patients have a family history of one or more of the three seizure types.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The hallmark seizures in JME are myoclonic jerks (or myoclonias), which are most frequent in the first hour of the morning. Myoclonic seizures are seen as isolated jerks preferentially involving one but usually both arms, sometimes as subtle as a finger twitch. Involvement of the lower limbs leading to falls is uncommon. The myoclonus in JME is epileptic, as opposed to physiologic or essential (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7689?source=see_link&amp;anchor=H8#H8\">",
"       \"Classification and evaluation of myoclonus\", section on 'Clinical and etiologic classification'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      With careful history taking, nearly all patients with JME have myoclonic seizures, but almost never in isolation.",
"     </li>",
"     <li>",
"      GTCS occur in almost all patients with JME, often as the index event leading to diagnosis. A GTCS secondary to JME cannot be distinguished from one related to other generalized epilepsy syndromes. Focal ictal symptoms such as head version or asymmetric tonic posturing or clonic movements have been noted in 16 to 40 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/7,45\">",
"       7,45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Absence seizures are the least common seizure type in JME, occurring in 20 to 40 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/7,8,10\">",
"       7,8,10",
"      </a>",
"      ]. When they do occur, they almost always precede the first myoclonic or generalized seizure, often by as much as five years. The onset of absence seizures at an earlier age may lead to a diagnosis of childhood or juvenile absence epilepsy; only a family history of myoclonus or GTCS will suggest the correct diagnosis (See",
"      <a class=\"local\" href=\"#H88578471\">",
"       'Differential Diagnosis'",
"      </a>",
"      below.). During video monitoring, clinical manifestations of an absence ictus can show great variation, ranging from subtle or no overt features to severe impairment of consciousness [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/46\">",
"       46",
"      </a>",
"      ]. Absence phenomenology can vary even within the same patient.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Myoclonic jerks and GTCS are most common in the mornings and are aggravated by sleep deprivation, alcohol consumption and sometimes photic stimulation.",
"   </p>",
"   <p>",
"    Absence seizures typically precede the onset of myoclonic jerks and GTCS by three to five years, starting as early as age six years [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/10\">",
"     10",
"    </a>",
"    ]. Delays in diagnosis are common, often because absence seizures and myoclonic jerks go unrecognized by the patient and family until a GTCS occurs.",
"   </p>",
"   <p>",
"    Rarer seizure patterns include episodes of nonconvulsive, generalized tonic-clonic or myoclonic status epilepticus [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/47-49\">",
"     47-49",
"    </a>",
"    ], and reflex seizures triggered or favored by various types of stimuli, such as writing, reading, praxis, or higher mental activities [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/23,50-52\">",
"     23,50-52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some authors distinguish various subtypes of JMEs based on different clinical phenotypes and their evolution [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/13,53\">",
"     13,53",
"    </a>",
"    ]. These categories include classic JME (accounting for 72 percent in a series of 257 patients), childhood absence epilepsy evolving to JME (18 percent), JME with adolescent absences (7 percent), and JME with astatic (atonic, drop attack) seizures (3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2859352\">",
"    <span class=\"h2\">",
"     Cognition and behavior",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with JME have normal global cognitive capacities. However, formal neuropsychological testing demonstrates variable degrees of frontal lobe dysfunction, typically mild to moderate, on tests of verbal fluency, abstract reasoning and mental flexibility, attention, cognitive speed, planning and organization [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/33,54-57\">",
"     33,54-57",
"    </a>",
"    ]. These results are likely influenced by multiple factors including antiepileptic drugs, seizure frequency, genetic variability, psychosocial conditions and educational level [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/54,58,59\">",
"     54,58,59",
"    </a>",
"    ]. However, in at least one study, cognitive performance was not correlated with disease duration, seizure frequency, seizure types, or treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/56\">",
"     56",
"    </a>",
"    ]. Sophisticated neuroimaging studies have suggested an underlying structural basis for these neuropsychiatric deficits [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/25,60\">",
"     25,60",
"    </a>",
"    ] (See",
"    <a class=\"local\" href=\"#H88578578\">",
"     'Pathophysiology and genetics'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2859523\">",
"    <span class=\"h2\">",
"     Psychiatric comorbidity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with JME are at increased risk for comorbid psychiatric illness and personality disorder. Up to 50 percent of patients meet DSM-IV criteria for a psychiatric disorder (mostly anxiety or mood disorder), and 20 to 35 percent have cluster B personality traits such as impulsivity, humor reactivity, emotional instability, and difficulty accepting social rules [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/61-65\">",
"     61-65",
"    </a>",
"    ]. Poorly controlled seizures and AEDs themselves may also put patients at risk for psychiatric side effects and mood disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/64,66\">",
"     64,66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=see_link&amp;anchor=H669264#H669264\">",
"     \"Overview of the management of epilepsy in adults\", section on 'Depression and psychiatric disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63733735\">",
"    <span class=\"h1\">",
"     ELECTROENCEPHALOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of JME in a patient with clinical features is supported by EEG. If routine EEG is normal in a patient suspected of having JME, an overnight sleep EEG should be performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63733775\">",
"    <span class=\"h2\">",
"     Interictal EEG",
"    </span>",
"    &nbsp;&mdash;&nbsp;The routine interictal EEG is abnormal in about 75 percent of patients with JME [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/7,67,68\">",
"     7,67,68",
"    </a>",
"    ]. This number increases to nearly 100 percent with overnight recording, when abnormalities are commonly seen in the transition phases from sleep to awakening [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/67,69,70\">",
"     67,69,70",
"    </a>",
"    ]. For this reason, a normal EEG in a patient suspected of having JME should prompt an overnight recording.",
"   </p>",
"   <p>",
"    The classic interictal EEG pattern in JME is 4 to 6 Hz bilateral polyspike and slow wave discharges with frontal predominance over a normal background activity. Less common abnormalities include 2.5 to 4.5 Hz bilateral spike-waves, single spikes, and irregular spike-wave complexes. Photosensitivity is traditionally described in one third of patients but may be present in up to 90 percent with prolonged continuous photostimulation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/71,72\">",
"     71,72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Focal or asymmetric abnormalities may be found in more than 50 percent of recordings and do not exclude the diagnosis, nor do they predict treatment response [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. In a study of 266 JME patients, focal EEG abnormalities consisted of amplitude asymmetry or focal onset of generalized discharges in 45 percent, independent focal spikes or sharps in 33 percent, and asymmetric photoparoxysmal response in 16 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63733782\">",
"    <span class=\"h2\">",
"     Ictal EEG",
"    </span>",
"    &nbsp;&mdash;&nbsp;An EEG recorded during a myoclonic seizure shows irregular 3 to 4 Hz polyspike-waves with frontocentral predominance. Jerks are usually associated with the spike component of the discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During a GTCS, the EEG will show attenuation and low-voltage fast activity with spike-waves of variable frequency and amplitude, indistinguishable from GTCS secondary to other generalized epilepsies.",
"   </p>",
"   <p>",
"    Absence seizures in JME are usually correlated with generalized spike-wave discharges of slightly higher frequency than the classic 3 Hz seen in childhood or juvenile absence epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In rare cases, focal findings on EEG evolve from generalized-onset seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/76,77\">",
"     76,77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63733789\">",
"    <span class=\"h1\">",
"     NEUROIMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRI is not required in the evaluation of a patient with JME when the clinical history and EEG findings are typical. The routine structural MRI in JME patients is normal [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/24,32\">",
"     24,32",
"    </a>",
"    ]. An abnormal structural MRI raises concern for an alternative diagnosis. More subtle structural and functional defects in the frontal thalamocortical circuits have been demonstrated using advanced imaging techniques. (See",
"    <a class=\"local\" href=\"#H88578578\">",
"     'Pathophysiology and genetics'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6578918\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Formal diagnostic criteria have not been established for JME. The diagnosis of is established by a careful history, supportive clinical features and typical EEG findings. In a recent survey of 69 adult and pediatric epileptologists, all respondents agreed that a diagnosis of JME can be made with a history of myoclonus, a single GTCS and a typical EEG pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/78\">",
"     78",
"    </a>",
"    ]. Most required a history of myoclonic jerks, the presence of two out of three seizure types, a normal neurological examination, and a normal background EEG pattern. The majority did not require an MRI for diagnosis. Thus, if the history and EEG findings are all consistent with the diagnosis, further studies may not be necessary. If a routine EEG is normal in a patient suspected of having JME, an overnight sleep EEG should be performed. (See",
"    <a class=\"local\" href=\"#H63733735\">",
"     'Electroencephalography'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The diagnosis of JME should be considered in every developmentally normal child with absence seizures beginning in the second half of the first decade and isolated generalized convulsive seizures, particularly if they occur upon awakening in the mornings. A detailed history of myoclonic jerks should be sought as this may not be volunteered.",
"   </p>",
"   <p>",
"    <br/>",
"    Delays in diagnosis are frequent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/8,79,80\">",
"     8,79,80",
"    </a>",
"    ]. Factors that may contribute to diagnostic delays include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lack of general awareness of the syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/80,81\">",
"       80,81",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The subtlety of some myoclonic jerks and absence seizures, which may go unnoticed until a GTCS occurs",
"     </li>",
"     <li>",
"      The focal character of some jerks or EEG features, which are wrongly considered exclusionary for the diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/8,10,79,80,82\">",
"       8,10,79,80,82",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The relatively non-specific characteristics of the seizures, which may be misdiagnosed as other (epileptic or non-epileptic) paroxysmal events",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88578471\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of JME includes isolated convulsion, other idiopathic generalized epilepsies that occur in adolescents, such as childhood or juvenile absence epilepsy and eyelid myoclonia with absences (EMA), partial epilepsies that share overlapping electroclinical features, such as idiopathic photosensitive occipital epilepsy (IPOE), and symptomatic myoclonus related to a more severe epilepsy syndrome, such as progressive myoclonic epilepsy (PME).",
"   </p>",
"   <p>",
"    Many of these syndromes have overlapping clinical features and resemble each other in the early stages. A thorough patient history, mainly looking for other seizure types, EEG with video recording whenever possible [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/83\">",
"     83",
"    </a>",
"    ], and time are the most helpful tools to distinguish between diagnoses.",
"   </p>",
"   <p>",
"    <strong>",
"     Isolated convulsion",
"    </strong>",
"    - When a child or teenager presents with a first GTCS, the history is the most important tool. History taken from both patient and family members should focus on clues to an underlying diagnosis of JME, such as prior staring spells, morning arm jerks, and a family history of jerks or seizures.",
"   </p>",
"   <p>",
"    <strong>",
"     Childhood absence epilepsy -",
"    </strong>",
"    Childhood absence epilepsy (CAE, pyknolepsy) is an idiopathic generalized epilepsy with a peak age of onset of six to seven years, affecting girls more than boys, characterized by frequent (multiple per day) absence seizures in an otherwise normal child. GTCS often develop in adolescence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33769?source=see_link&amp;anchor=H7#H7\">",
"     \"Epilepsy syndromes in children\", section on 'Absence seizures'",
"    </a>",
"    .) Myoclonic jerks do not occur in CAE, but the two syndromes can be confused when JME starts with absence seizures prior to the onset of myoclonic jerks (as it does in up to one third of patients). However, the absence seizures in JME are typically milder and shorter compared with those of CAE and have different EEG patterns. (See",
"    <a class=\"local\" href=\"#H63733735\">",
"     'Electroencephalography'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <strong>",
"     Juvenile absence epilepsy -",
"    </strong>",
"    Juvenile absence epilepsy (JAE) is an idiopathic generalized epilepsy with a peak age of onset of 10 to 12 years, also characterized by typical absence seizures that are generally longer and associated with more severe impairment in consciousness than those in JME. GTCS are more common in JAE than in CAE, and myoclonic jerks occur in one fifth of patients. The latter are typically mild and do not show a morning predominance. Like JME, JAE is usually a lifelong disorder and responds favorably to valproate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33769?source=see_link&amp;anchor=H7#H7\">",
"     \"Epilepsy syndromes in children\", section on 'Absence seizures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <strong>",
"     Eyelid myoclonia with absences -",
"    </strong>",
"    EMA is a generalized idiopathic epilepsy with onset in the first two decades of life, characterized by eyelid myoclonia, absence seizures, and photosensitivity. Myoclonic seizures occur in EMA but are infrequent. EMA is more likely than JME to be associated with mild mental retardation and treatment resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <strong>",
"     Idiopathic photosensitive occipital epilepsy -",
"    </strong>",
"    IPOE is a reflex focal epilepsy of late-childhood onset characterized by colorful elementary visual auras, often with conscious tonic head and eye version, triggered by photic stimulation. Interictal EEG shows unilateral or bilateral occipital spike-waves and generalized spike-waves. Myoclonic and generalized seizures are rare in IPOE but can occur, and there may be more clinical overlap between IPOE and JME than previously recognized. As an example, one study compared four families with IPOE to 40 probands with JME and noted overlapping electroclinical features, including visual auras and conscious head version in JME patients, and myoclonic jerks and GTCS without photic stimulation in IPOE patients. [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <strong>",
"     Progressive myoclonic epilepsy -",
"    </strong>",
"    Symptomatic myoclonus is a major feature of the rare, genetically heterogeneous syndrome known as progressive myoclonic epilepsy (PME). The most common causes of PME are Lafora disease, myoclonic epilepsy with ragged red fibers (MERFF), neuronal ceroid lipofuscinosis, dentatorubral pallidoluysian atrophy, and Gaucher disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/86\">",
"     86",
"    </a>",
"    ]. In contrast to JME, the myoclonus associated with PME is typically multifocal and induced by action or by somatosensory stimulation. PME can also be distinguished from JME by its progressive nature, greater severity of seizures, and accompanying cognitive decline. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/34/30249?source=see_link&amp;anchor=H3#H3\">",
"     \"Symptomatic (secondary) myoclonus\", section on 'Progressive myoclonic epilepsy and progressive myoclonic ataxia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6578974\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;JME patients generally respond quickly and completely to broad spectrum antiepileptic drug (AED) therapy, but most require lifelong treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1409477\">",
"    <span class=\"h2\">",
"     Valproate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Valproate is recommended as the first-line treatment of choice for most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]. It is a broad spectrum AED that controls all three seizure types in JME, and has the best established efficacy in JME. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=see_link&amp;anchor=H19#H19\">",
"     \"Pharmacology of antiepileptic drugs\", section on 'Valproate'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a large randomized study of 716 patients with idiopathic generalized epilepsy (119 of whom had JME), VPA controlled seizure in 80 percent of patients and was more effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/88\">",
"     88",
"    </a>",
"    ]. Valproate was also better tolerated than topiramate.",
"   </p>",
"   <p>",
"    However, valproate should be avoided in women of childbearing age, particularly those who are considering becoming pregnant or who cannot guarantee reliable birth control practices, because of its teratogenic risks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22633?source=see_link&amp;anchor=H6#H6\">",
"     \"Risks associated with epilepsy and pregnancy\", section on 'Valproate'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22633?source=see_link&amp;anchor=H12#H12\">",
"     \"Risks associated with epilepsy and pregnancy\", section on 'Long-term effects'",
"    </a>",
"    .) Valproate has additional side effects such as weight gain and hair loss that make it unacceptable in some patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1409484\">",
"    <span class=\"h2\">",
"     Other AEDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients in whom valproate is contraindicated or not tolerated, we suggest treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/52/43847?source=see_link\">",
"     levetiracetam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/89-93\">",
"     89-93",
"    </a>",
"    ]. All of these are broad-spectrum agents with observational evidence of efficacy in JME. Small studies also support a role for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/2/10279?source=see_link\">",
"     zonisamide",
"    </a>",
"    , particularly for GTCS and myoclonic seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/94-96\">",
"     94-96",
"    </a>",
"    ]. However, risks of metabolic acidosis, nephrolithiasis, bone disease and reduced growth rates may limit its utility in children.",
"   </p>",
"   <p>",
"    With insufficient studies comparing one drug to another, the choice of an alternative AED should take into account patient comorbidities, side effect profile and patient preferences among other factors. As an example, in an overweight patient with comorbid migraines,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    may be a good treatment choice [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/97\">",
"     97",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31818?source=see_link&amp;anchor=H5#H5\">",
"     \"Initial treatment of epilepsy in adults\", section on 'Selection of an AED'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One note of caution is that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    is associated with exacerbation of myoclonic seizures in some patients with JME [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/98,99\">",
"     98,99",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H982451\">",
"    <span class=\"h2\">",
"     Adjunctive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combination therapy should be considered after two single medication failures [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/97\">",
"     97",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"     Lamotrigine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/52/43847?source=see_link\">",
"     levetiracetam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/2/10279?source=see_link\">",
"     zonisamide",
"    </a>",
"    and benzodiazepines are all options for adjunctive therapy. Some considerations include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who fail adequate doses of first-line therapy are less likely to become seizure-free on a second single agent than those who are switched because of adverse drug reactions [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/87,100\">",
"       87,100",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The combination of valproate and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      may have synergistic effects, but caution must be taken given the increased risk of serious skin reactions with rapid titration of lamotrigine, particularly in children younger than 12 years.",
"     </li>",
"     <li>",
"      Two large randomized studies have shown that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/52/43847?source=see_link\">",
"       levetiracetam",
"      </a>",
"      is an effective add-on therapy for patients with idiopathic generalized epilepsy [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/101,102\">",
"       101,102",
"      </a>",
"      ]. In a secondary analysis of the 167 patients with JME included in these two studies, a &gt; 50 percent seizure reduction was achieved in 61 percent of patients treated with adjunctive levetiracetam compared to 25 percent treated with adjunctive placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/103\">",
"       103",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Failure of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/52/43847?source=see_link\">",
"       levetiracetam",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      should prompt the addition of valproate, even in women of childbearing potential.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/49/40727?source=see_link\">",
"       Clobazam",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"       clonazepam",
"      </a>",
"      may be especially useful as adjunctive therapy for myoclonic jerks in patients who are otherwise well-controlled on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/97\">",
"       97",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Vagal nerve stimulation may be indicated in the rare severely refractory cases [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/104\">",
"       104",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/7/19578?source=see_link\">",
"       \"Vagus nerve stimulation therapy for the treatment of epilepsy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1409491\">",
"    <span class=\"h2\">",
"     Lifestyle modification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be counseled to avoid common seizure precipitants, such as sleep deprivation, alcohol or drug consumption, medication nonadherence, and flickering lights in those with photosensitivity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1409498\">",
"    <span class=\"h2\">",
"     AEDs to avoid",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a general rule,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/25/40344?source=see_link\">",
"     oxcarbazepine",
"    </a>",
"    should be avoided because they may aggravate absence seizures and myoclonic jerks, although they may control GTCS in a certain number of refractory cases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/105\">",
"     105",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     Gabapentin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/22/26982?source=see_link\">",
"     tiagabine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/8/27783?source=see_link\">",
"     vigabatrin",
"    </a>",
"    are also contraindicated in JME because of their potential to aggravate all seizure types, including myoclonic or absence status epilepticus [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/97,106\">",
"     97,106",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6579016\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;JME is a life-long disorder. The majority of patients require continued drug treatment for years, even after prolonged remission of seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/53\">",
"     53",
"    </a>",
"    ]. However, most patients have a substantial alleviation of seizures by their fourth decade, achieving a five-year remission and requiring lower doses of medication [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/107\">",
"     107",
"    </a>",
"    ]. Some, 6 of 24 patients in one series and 6 of 31 in another [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/47,108\">",
"     47,108",
"    </a>",
"    ], can achieve long-term remission off medication, while a smaller percentage, 12 to 17 percent, have intractable epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/47,107\">",
"     47,107",
"    </a>",
"    ]. Risk factors for treatment resistance include psychiatric comorbidity and presence of all three seizure types [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/107,109\">",
"     107,109",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other outcomes are also favorable. In one long-term follow up study, 87 percent of patients had graduated from high school, 70 percent had been married, and 70 percent declared that they were &lsquo;very satisfied with their health, work, friendships and social life&rsquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/47\">",
"     47",
"    </a>",
"    ]. However, psychosocial complications (e.g. unwanted pregnancy, living alone, unemployment, depression) appear to be prevalent and influence prognosis in a number of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15849/abstract/47,107,109\">",
"     47,107,109",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6579030\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      JME is classified as an idiopathic generalized epilepsy syndrome. It is believed to have a complex underlying genetic basis, however the exact mechanisms are not well understood (See",
"      <a class=\"local\" href=\"#H88578578\">",
"       'Pathophysiology and genetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      JME is typically diagnosed in otherwise healthy young teenagers and is characterized by one or more of the following seizure types: myoclonic jerks, absence seizures, and generalized tonic clonic seizures. (See",
"      <a class=\"local\" href=\"#H88577538\">",
"       'Clinical Features'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Myoclonic jerks are the hallmark seizures in JME and often begin before the first generalized tonic clonic seizure.",
"     </li>",
"     <li>",
"      Generalized tonic clonic seizures occur in almost all patients, often as the index event leading to diagnosis.",
"     </li>",
"     <li>",
"      Absence seizures are present in 20 to 40 percent of patients beginning up to five years before other seizure types. Delays in diagnosis are common since absence seizures and myoclonic jerks often go unnoticed until a first GTCS.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The classic interictal EEG pattern in JME is 4 to 6 Hz bilateral polyspike and slow wave discharges with frontal predominance over a normal background activity. Sensitivity of the EEG rises to nearly 100 percent with overnight recording. (See",
"      <a class=\"local\" href=\"#H63733735\">",
"       'Electroencephalography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of JME is established by a careful history, supportive clinical features and EEG. MRI is typically normal and is not required for diagnosis. (See",
"      <a class=\"local\" href=\"#H6578918\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of JME includes other idiopathic generalized epilepsies with onset in childhood and progressive myoclonic epilepsy (PME). (See",
"      <a class=\"local\" href=\"#H88578471\">",
"       'Differential Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend treatment with a broad spectrum antiepileptic drug (eg, valproate,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/52/43847?source=see_link\">",
"       levetiracetam",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"       topiramate",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Valproate has the best established efficacy and results in seizure control in 80 percent of patients, however, its use in women of childbearing potential is problematic because of the risk of teratogenicity. &nbsp;Patients generally respond quickly and completely to AED therapy, but most require life-long treatment. Some patients require combination therapy after two single-agent treatment failures. Rare patients have drug-resistant epilepsy. (See",
"      <a class=\"local\" href=\"#H6578974\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cognitive, behavioral and social difficulties may occur, either directly related to underlying cerebral dysfunction or as a result of medication side effects. (See",
"      <a class=\"local\" href=\"#H88577538\">",
"       'Clinical Features'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6579016\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/1\">",
"      Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 1989; 30:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/2\">",
"      Hauser WA. The prevalence and incidence of convulsive disorders in children. Epilepsia 1994; 35 Suppl 2:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/3\">",
"      Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia 1993; 34:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/4\">",
"      Janz D. Epilepsy with impulsive petit mal (juvenile myoclonic epilepsy). Acta Neurol Scand 1985; 72:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/5\">",
"      Pedersen SB, Petersen KA. Juvenile myoclonic epilepsy: clinical and EEG features. Acta Neurol Scand 1998; 97:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/6\">",
"      Kleveland G, Engelsen BA. Juvenile myoclonic epilepsy: clinical characteristics, treatment and prognosis in a Norwegian population of patients. Seizure 1998; 7:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/7\">",
"      Jayalakshmi SS, Srinivasa Rao B, Sailaja S. Focal clinical and electroencephalographic features in patients with juvenile myoclonic epilepsy. Acta Neurol Scand 2010; 122:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/8\">",
"      Murthy JM, Rao CM, Meena AK. Clinical observations of juvenile myoclonic epilepsy in 131 patients: a study in South India. Seizure 1998; 7:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/9\">",
"      Canevini MP, Mai R, Di Marco C, et al. Juvenile myoclonic epilepsy of Janz: clinical observations in 60 patients. Seizure 1992; 1:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/10\">",
"      Vijai J, Cherian PJ, Stlaja PN, et al. Clinical characteristics of a South Indian cohort of juvenile myoclonic epilepsy probands. Seizure 2003; 12:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/11\">",
"      Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 2010; 51:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/12\">",
"      Zifkin B, Andermann E, Andermann F. Mechanisms, genetics, and pathogenesis of juvenile myoclonic epilepsy. Curr Opin Neurol 2005; 18:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/13\">",
"      Delgado-Escueta AV. Advances in genetics of juvenile myoclonic epilepsies. Epilepsy Curr 2007; 7:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/14\">",
"      Liu AW, Delgado-Escueta AV, Gee MN, et al. Juvenile myoclonic epilepsy in chromosome 6p12-p11: locus heterogeneity and recombinations. Am J Med Genet 1996; 63:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/15\">",
"      Bai D, Alonso ME, Medina MT, et al. Juvenile myoclonic epilepsy: linkage to chromosome 6p12 in Mexico families. Am J Med Genet 2002; 113:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/16\">",
"      Suzuki T, Delgado-Escueta AV, Aguan K, et al. Mutations in EFHC1 cause juvenile myoclonic epilepsy. Nat Genet 2004; 36:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/17\">",
"      Annesi F, Gambardella A, Michelucci R, et al. Mutational analysis of EFHC1 gene in Italian families with juvenile myoclonic epilepsy. Epilepsia 2007; 48:1686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/18\">",
"      Medina MT, Suzuki T, Alonso ME, et al. Novel mutations in Myoclonin1/EFHC1 in sporadic and familial juvenile myoclonic epilepsy. Neurology 2008; 70:2137.",
"     </a>",
"    </li>",
"    <li>",
"     Cossette P. Channelopathies and juvenile myoclonic epilepsy. Epilepsia;51 Suppl 1:30-2.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/20\">",
"      Manganotti P, Bongiovanni LG, Fuggetta G, et al. Effects of sleep deprivation on cortical excitability in patients affected by juvenile myoclonic epilepsy: a combined transcranial magnetic stimulation and EEG study. J Neurol Neurosurg Psychiatry 2006; 77:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/21\">",
"      Badawy RA, Curatolo JM, Newton M, et al. Sleep deprivation increases cortical excitability in epilepsy: syndrome-specific effects. Neurology 2006; 67:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/22\">",
"      Badawy RA, Macdonell RA, Jackson GD, Berkovic SF. Why do seizures in generalized epilepsy often occur in the morning? Neurology 2009; 73:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/23\">",
"      Vollmar C, O'Muircheartaigh J, Barker GJ, et al. Motor system hyperconnectivity in juvenile myoclonic epilepsy: a cognitive functional magnetic resonance imaging study. Brain 2011; 134:1710.",
"     </a>",
"    </li>",
"    <li>",
"     Anderson J, Hamandi K. Understanding juvenile myoclonic epilepsy: Contributions from neuroimaging. Epilepsy Res 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/25\">",
"      Pulsipher DT, Seidenberg M, Guidotti L, et al. Thalamofrontal circuitry and executive dysfunction in recent-onset juvenile myoclonic epilepsy. Epilepsia 2009; 50:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/26\">",
"      Deppe M, Kellinghaus C, Duning T, et al. Nerve fiber impairment of anterior thalamocortical circuitry in juvenile myoclonic epilepsy. Neurology 2008; 71:1981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/27\">",
"      Vulliemoz S, Vollmar C, Koepp MJ, et al. Connectivity of the supplementary motor area in juvenile myoclonic epilepsy and frontal lobe epilepsy. Epilepsia 2011; 52:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/28\">",
"      Liu M, Concha L, Beaulieu C, Gross DW. Distinct white matter abnormalities in different idiopathic generalized epilepsy syndromes. Epilepsia 2011; 52:2267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/29\">",
"      Keller SS, Ahrens T, Mohammadi S, et al. Microstructural and volumetric abnormalities of the putamen in juvenile myoclonic epilepsy. Epilepsia 2011; 52:1715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/30\">",
"      Mory SB, Betting LE, Fernandes PT, et al. Structural abnormalities of the thalamus in juvenile myoclonic epilepsy. Epilepsy Behav 2011; 21:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/31\">",
"      Kim JH, Lee JK, Koh SB, et al. Regional grey matter abnormalities in juvenile myoclonic epilepsy: a voxel-based morphometry study. Neuroimage 2007; 37:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/32\">",
"      Woermann FG, Free SL, Koepp MJ, et al. Abnormal cerebral structure in juvenile myoclonic epilepsy demonstrated with voxel-based analysis of MRI. Brain 1999; 122 ( Pt 11):2101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/33\">",
"      O'Muircheartaigh J, Vollmar C, Barker GJ, et al. Focal structural changes and cognitive dysfunction in juvenile myoclonic epilepsy. Neurology 2011; 76:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/34\">",
"      Tae WS, Kim SH, Joo EY, et al. Cortical thickness abnormality in juvenile myoclonic epilepsy. J Neurol 2008; 255:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/35\">",
"      Lin K, Jackowski AP, Carrete H Jr, et al. Voxel-based morphometry evaluation of patients with photosensitive juvenile myoclonic epilepsy. Epilepsy Res 2009; 86:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/36\">",
"      Tae WS, Joo EY, Han SJ, et al. CBF changes in drug naive juvenile myoclonic epilepsy patients. J Neurol 2007; 254:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/37\">",
"      Aghakhani Y, Bagshaw AP, B&eacute;nar CG, et al. fMRI activation during spike and wave discharges in idiopathic generalized epilepsy. Brain 2004; 127:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/38\">",
"      de Ara&uacute;jo Filho GM, Lin K, Lin J, et al. Are personality traits of juvenile myoclonic epilepsy related to frontal lobe dysfunctions? A proton MRS study. Epilepsia 2009; 50:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/39\">",
"      de Ara&uacute;jo Filho GM, Jackowski AP, Lin K, et al. Personality traits related to juvenile myoclonic epilepsy: MRI reveals prefrontal abnormalities through a voxel-based morphometry study. Epilepsy Behav 2009; 15:202.",
"     </a>",
"    </li>",
"    <li>",
"     Filho GM, Jackowski AP, Lin K, Silva I, M SBG, Guilhoto LM, et al. The integrity of corpus callosum and cluster B personality disorders: a quantitative MRI study in juvenile myoclonic epilepsy. Prog Neuropsychopharmacol Biol Psychiatry;34(3):516-21.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/41\">",
"      Ciumas C, Wahlin TB, Jucaite A, et al. Reduced dopamine transporter binding in patients with juvenile myoclonic epilepsy. Neurology 2008; 71:788.",
"     </a>",
"    </li>",
"    <li>",
"     Odano I, Varrone A, Savic I, Ciumas C, Karlsson P, Jucaite A, et al. Quantitative PET analyses of regional [(11)C]PE2I binding to the dopamine transporter - Application to juvenile myoclonic epilepsy. Neuroimage 2011.",
"    </li>",
"    <li>",
"     Landvogt C, Buchholz HG, Bernedo V, Schreckenberger M, Werhahn KJ. Alteration of dopamine D2/D3 receptor binding in patients with juvenile myoclonic epilepsy. Epilepsia;51(9):1699-706.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/44\">",
"      Meschaks A, Lindstrom P, Halldin C, et al. Regional reductions in serotonin 1A receptor binding in juvenile myoclonic epilepsy. Arch Neurol 2005; 62:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/45\">",
"      Usui N, Kotagal P, Matsumoto R, et al. Focal semiologic and electroencephalographic features in patients with juvenile myoclonic epilepsy. Epilepsia 2005; 46:1668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/46\">",
"      Panayiotopoulos CP, Obeid T, Waheed G. Absences in juvenile myoclonic epilepsy: a clinical and video-electroencephalographic study. Ann Neurol 1989; 25:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/47\">",
"      Camfield CS, Camfield PR. Juvenile myoclonic epilepsy 25 years after seizure onset: a population-based study. Neurology 2009; 73:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/48\">",
"      Dziewas R, Kellinghaus C, L&uuml;demann P. Nonconvulsion status epilepticus in patients with juvenile myoclonic epilepsy: types and frequencies. Seizure 2002; 11:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/49\">",
"      Larch J, Unterberger I, Bauer G, et al. Myoclonic status epilepticus in juvenile myoclonic epilepsy. Epileptic Disord 2009; 11:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/50\">",
"      Matsuoka H, Takahashi T, Sasaki M, et al. The long-term course of seizure susceptibility in two patients with juvenile myoclonic epilepsy. Seizure 2002; 11:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/51\">",
"      Chifari R, Piazzini A, Turner K, et al. Reflex writing seizures in two siblings with juvenile myoclonic epilepsy. Acta Neurol Scand 2004; 109:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/52\">",
"      da Silva Sousa P, Lin K, Garzon E, et al. Language- and praxis-induced jerks in patients with juvenile myoclonic epilepsy. Epileptic Disord 2005; 7:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/53\">",
"      Mart&iacute;nez-Ju&aacute;rez IE, Alonso ME, Medina MT, et al. Juvenile myoclonic epilepsy subsyndromes: family studies and long-term follow-up. Brain 2006; 129:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/54\">",
"      Pascalicchio TF, de Araujo Filho GM, da Silva Noffs MH, et al. Neuropsychological profile of patients with juvenile myoclonic epilepsy: a controlled study of 50 patients. Epilepsy Behav 2007; 10:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/55\">",
"      Devinsky O, Gershengorn J, Brown E, et al. Frontal functions in juvenile myoclonic epilepsy. Neuropsychiatry Neuropsychol Behav Neurol 1997; 10:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/56\">",
"      Piazzini A, Turner K, Vignoli A, et al. Frontal cognitive dysfunction in juvenile myoclonic epilepsy. Epilepsia 2008; 49:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/57\">",
"      Iqbal N, Caswell HL, Hare DJ, et al. Neuropsychological profiles of patients with juvenile myoclonic epilepsy and their siblings: a preliminary controlled experimental video-EEG case series. Epilepsy Behav 2009; 14:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/58\">",
"      Roebling R, Scheerer N, Uttner I, et al. Evaluation of cognition, structural, and functional MRI in juvenile myoclonic epilepsy. Epilepsia 2009; 50:2456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/59\">",
"      Wandschneider B, Kopp UA, Kliegel M, et al. Prospective memory in patients with juvenile myoclonic epilepsy and their healthy siblings. Neurology 2010; 75:2161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/60\">",
"      Swartz BE, Simpkins F, Halgren E, et al. Visual working memory in primary generalized epilepsy: an 18FDG-PET study. Neurology 1996; 47:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/61\">",
"      Trinka E, Kienpointner G, Unterberger I, et al. Psychiatric comorbidity in juvenile myoclonic epilepsy. Epilepsia 2006; 47:2086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/62\">",
"      de Ara&uacute;jo Filho GM, Pascalicchio TF, Sousa Pda S, et al. Psychiatric disorders in juvenile myoclonic epilepsy: a controlled study of 100 patients. Epilepsy Behav 2007; 10:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/63\">",
"      Plattner B, Pahs G, Kindler J, et al. Juvenile myoclonic epilepsy: a benign disorder? Personality traits and psychiatric symptoms. Epilepsy Behav 2007; 10:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/64\">",
"      Karachristianou S, Katsarou Z, Bostantjopoulou S, et al. Personality profile of patients with juvenile myoclonic epilepsy. Epilepsy Behav 2008; 13:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/65\">",
"      Moschetta S, Fiore LA, Fuentes D, et al. Personality traits in patients with juvenile myoclonic epilepsy. Epilepsy Behav 2011; 21:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/66\">",
"      de Araujo Filho GM, Pascalicchio TF, Lin K, et al. Neuropsychiatric profiles of patients with juvenile myoclonic epilepsy treated with valproate or topiramate. Epilepsy Behav 2006; 8:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/67\">",
"      Gigli GL, Calia E, Luciani L, et al. Eye closure sensitivity without photosensitivity in juvenile myoclonic epilepsy: polysomnographic study of electroencephalographic epileptiform discharge rates. Epilepsia 1991; 32:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/68\">",
"      Baise-Zung C, Guilhoto LM, Grossmann RM. Juvenile myoclonic epilepsy: non-classic electroencephalographical presentation in adult patients. Eur J Neurol 2006; 13:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/69\">",
"      Gigli GL, Calia E, Marciani MG, et al. Sleep microstructure and EEG epileptiform activity in patients with juvenile myoclonic epilepsy. Epilepsia 1992; 33:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/70\">",
"      Dhanuka AK, Jain BK, Daljit S, Maheshwari D. Juvenile myoclonic epilepsy: a clinical and sleep EEG study. Seizure 2001; 10:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/71\">",
"      Panayiotopoulos CP, Obeid T, Tahan AR. Juvenile myoclonic epilepsy: a 5-year prospective study. Epilepsia 1994; 35:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/72\">",
"      Appleton R, Beirne M, Acomb B. Photosensitivity in juvenile myoclonic epilepsy. Seizure 2000; 9:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/73\">",
"      Aliberti V, Gr&uuml;newald RA, Panayiotopoulos CP, Chroni E. Focal electroencephalographic abnormalities in juvenile myoclonic epilepsy. Epilepsia 1994; 35:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/74\">",
"      L&eacute;tourneau K, Cieuta-Walti C, Deacon C. Epileptiform asymetries and treatment response in juvenile myoclonic epilepsy. Can J Neurol Sci 2010; 37:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/75\">",
"      Hrachovy RA, Frost JD Jr. The EEG in selected generalized seizures. J Clin Neurophysiol 2006; 23:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/76\">",
"      Williamson R, Hanif S, Mathews GC, et al. Generalized-onset seizures with secondary focal evolution. Epilepsia 2009; 50:1827.",
"     </a>",
"    </li>",
"    <li>",
"     Koutroumanidis M, Tsiptsios D, Kokkinos V, Lysitsas K, Tsiropoulos I. Generalized spike-wave discharges and seizures with focal ictal transformation: mechanisms in absence (CAE) and myoclonic (JME) IGEs. Epilepsia 2009;50(10):2326-9.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/78\">",
"      Camfield PR, Camfield C. What criteria do adult and pediatric neurologists use to diagnose juvenile myoclonic epilepsy? Epilepsy Curr 2011; 12:1.154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/79\">",
"      Lancman ME, Asconap&eacute; JJ, Penry JK. Clinical and EEG asymmetries in juvenile myoclonic epilepsy. Epilepsia 1994; 35:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/80\">",
"      Montalenti E, Imperiale D, Rovera A, et al. Clinical features, EEG findings and diagnostic pitfalls in juvenile myoclonic epilepsy: a series of 63 patients. J Neurol Sci 2001; 184:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/81\">",
"      Gr&uuml;newald RA, Chroni E, Panayiotopoulos CP. Delayed diagnosis of juvenile myoclonic epilepsy. J Neurol Neurosurg Psychiatry 1992; 55:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/82\">",
"      Panayiotopoulos CP, Tahan R, Obeid T. Juvenile myoclonic epilepsy: factors of error involved in the diagnosis and treatment. Epilepsia 1991; 32:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/83\">",
"      Park KI, Lee SK, Chu K, et al. The value of video-EEG monitoring to diagnose juvenile myoclonic epilepsy. Seizure 2009; 18:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/84\">",
"      Destina Yal&ccedil;in A, Forta H, Kili&ccedil; E. Overlap cases of eyelid myoclonia with absences and juvenile myoclonic epilepsy. Seizure 2006; 15:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/85\">",
"      Taylor I, Marini C, Johnson MR, et al. Juvenile myoclonic epilepsy and idiopathic photosensitive occipital lobe epilepsy: is there overlap? Brain 2004; 127:1878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/86\">",
"      Shahwan A, Farrell M, Delanty N. Progressive myoclonic epilepsies: a review of genetic and therapeutic aspects. Lancet Neurol 2005; 4:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/87\">",
"      Nicolson A, Appleton RE, Chadwick DW, Smith DF. The relationship between treatment with valproate, lamotrigine, and topiramate and the prognosis of the idiopathic generalised epilepsies. J Neurol Neurosurg Psychiatry 2004; 75:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/88\">",
"      Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 2007; 369:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/89\">",
"      Bodenstein-Sachar H, Gandelman-Marton R, Ben-Zeev B, et al. Outcome of lamotrigine treatment in juvenile myoclonic epilepsy. Acta Neurol Scand 2011; 124:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/90\">",
"      Verrotti A, Cerminara C, Coppola G, et al. Levetiracetam in juvenile myoclonic epilepsy: long-term efficacy in newly diagnosed adolescents. Dev Med Child Neurol 2008; 50:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/91\">",
"      Specchio N, Boero G, Michelucci R, et al. Effects of levetiracetam on EEG abnormalities in juvenile myoclonic epilepsy. Epilepsia 2008; 49:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/92\">",
"      Levisohn PM, Holland KD. Topiramate or valproate in patients with juvenile myoclonic epilepsy: a randomized open-label comparison. Epilepsy Behav 2007; 10:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/93\">",
"      Biton V, Sackellares JC, Vuong A, et al. Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizures. Neurology 2005; 65:1737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/94\">",
"      Kothare SV, Valencia I, Khurana DS, et al. Efficacy and tolerability of zonisamide in juvenile myoclonic epilepsy. Epileptic Disord 2004; 6:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/95\">",
"      O'Rourke D, Flynn C, White M, et al. Potential efficacy of zonisamide in refractory juvenile myoclonic epilepsy: retrospective evidence from an Irish compassionate-use case series. Ir Med J 2007; 100:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/96\">",
"      Marinas A, Villanueva V, Gir&aacute;ldez BG, et al. Efficacy and tolerability of zonisamide in idiopathic generalized epilepsy. Epileptic Disord 2009; 11:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/97\">",
"      Mantoan L, Walker M. Treatment options in juvenile myoclonic epilepsy. Curr Treat Options Neurol 2011; 13:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/98\">",
"      Morris GL, Hammer AE, Kustra RP, Messenheimer JA. Lamotrigine for patients with juvenile myoclonic epilepsy following prior treatment with valproate: results of an open-label study. Epilepsy Behav 2004; 5:509.",
"     </a>",
"    </li>",
"    <li>",
"     Biraben A, Allain H, Scarabin JM, Schuck S, Edan G. Exacerbation of juvenile myoclonic epilepsy with lamotrigine. Neurology 2000;55(11):1758.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/100\">",
"      Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000; 342:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/101\">",
"      Noachtar S, Andermann E, Meyvisch P, et al. Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology 2008; 70:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/102\">",
"      Berkovic SF, Knowlton RC, Leroy RF, et al. Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Neurology 2007; 69:1751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/103\">",
"      Rosenfeld WE, Benbadis S, Edrich P, et al. Levetiracetam as add-on therapy for idiopathic generalized epilepsy syndromes with onset during adolescence: analysis of two randomized, double-blind, placebo-controlled studies. Epilepsy Res 2009; 85:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/104\">",
"      Kostov H, Larsson PG, R&oslash;ste GK. Is vagus nerve stimulation a treatment option for patients with drug-resistant idiopathic generalized epilepsy? Acta Neurol Scand Suppl 2007; 187:55.",
"     </a>",
"    </li>",
"    <li>",
"     Knott C, Panayiotopoulos CP. Carbamazepine in the treatment of generalised tonic clonic seizures in juvenile myoclonic epilepsy. J Neurol Neurosurg Psychiatry 1994;57(4):503.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/106\">",
"      Genton P, Gelisse P, Thomas P, Dravet C. Do carbamazepine and phenytoin aggravate juvenile myoclonic epilepsy? Neurology 2000; 55:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/107\">",
"      Baykan B, Altindag EA, Bebek N, et al. Myoclonic seizures subside in the fourth decade in juvenile myoclonic epilepsy. Neurology 2008; 70:2123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/108\">",
"      Geithner J, Schneider F, Wang Z, et al. Predictors for long-term seizure outcome in juvenile myoclonic epilepsy: 25-63 years of follow-up. Epilepsia 2012; 53:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15849/abstract/109\">",
"      Gelisse P, Genton P, Thomas P, et al. Clinical factors of drug resistance in juvenile myoclonic epilepsy. J Neurol Neurosurg Psychiatry 2001; 70:240.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17192 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-1759BFA714-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_30_15849=[""].join("\n");
var outline_f15_30_15849=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6579030\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6578890\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6578904\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H88578578\">",
"      PATHOPHYSIOLOGY AND GENETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H88577538\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H88578549\">",
"      Seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2859352\">",
"      Cognition and behavior",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2859523\">",
"      Psychiatric comorbidity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H63733735\">",
"      ELECTROENCEPHALOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H63733775\">",
"      Interictal EEG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H63733782\">",
"      Ictal EEG",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H63733789\">",
"      NEUROIMAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6578918\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H88578471\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6578974\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1409477\">",
"      Valproate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1409484\">",
"      Other AEDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H982451\">",
"      Adjunctive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1409491\">",
"      Lifestyle modification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1409498\">",
"      AEDs to avoid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6579016\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6579030\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/57/921?source=related_link\">",
"      Benign partial epilepsies of childhood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7689?source=related_link\">",
"      Classification and evaluation of myoclonus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33769?source=related_link\">",
"      Epilepsy syndromes in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31818?source=related_link\">",
"      Initial treatment of epilepsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/1/23578?source=related_link\">",
"      Localization-related (partial) epilepsy: Causes and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=related_link\">",
"      Overview of the management of epilepsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=related_link\">",
"      Pharmacology of antiepileptic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22633?source=related_link\">",
"      Risks associated with epilepsy and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/34/30249?source=related_link\">",
"      Symptomatic (secondary) myoclonus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/7/19578?source=related_link\">",
"      Vagus nerve stimulation therapy for the treatment of epilepsy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_30_15850="The ketogenic diet";
var content_f15_30_15850=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The ketogenic diet",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/30/15850/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/30/15850/contributors\">",
"     Eric HW Kossoff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/30/15850/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/30/15850/contributors\">",
"     Douglas R Nordli, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/30/15850/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/30/15850/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/30/15850/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H21467804\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiepileptic drugs (AEDs) are the primary treatment for epileptic seizures, and are effective in controlling seizures in most patients. However, approximately one-third of patients will not become seizure-free with medications and require nonpharmacologic treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/1\">",
"     1",
"    </a>",
"    ]. Although epilepsy surgery is usually considered for these patients, there are many families and patients who are either unwilling to consider or are not candidates for epilepsy surgery, either because surgery would lead to intolerable motor, language, or memory deficits or for other reasons. In these patients, treatments such as vagus nerve stimulation (VNS) and diets are then considered.",
"   </p>",
"   <p>",
"    This topic will review the ketogenic diet and alternative diets for the treatment of epilepsy. Some of the preliminary evidence for use of the ketogenic diet in other neurologic conditions will also be briefly reviewed. Other treatments for seizures and epilepsy in adults and children with epilepsy are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=see_link\">",
"     \"Overview of the management of epilepsy in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/32/37386?source=see_link\">",
"     \"Overview of the treatment of seizures and epileptic syndromes in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/7/19578?source=see_link\">",
"     \"Vagus nerve stimulation therapy for the treatment of epilepsy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31818?source=see_link\">",
"     \"Initial treatment of epilepsy in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/39/41593?source=see_link\">",
"     \"Surgical therapy of epilepsy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21468627\">",
"    <span class=\"h1\">",
"     MECHANISMS OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Published reports of the ketogenic diet as an effective treatment for epilepsy date to the early 1920s [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/2\">",
"     2",
"    </a>",
"    ]. However, the mechanism(s) by which the ketogenic diet suppresses seizures remains unclear and is likely multifactorial [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ketogenic diet utilizes a high fat, adequate-protein (1",
"    <span class=\"nowrap\">",
"     gram/kg),",
"    </span>",
"    low-carbohydrate diet that produces metabolic changes often associated with the starvation state. Often started with a brief fasting period, changes in plasma ketones, insulin, glucose, glucagon, and free fatty acids can occur within hours of starting the diet and can be quite profound [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Which of these metabolic changes are responsible for the improvement in seizure frequency is not known. The ketogenic diet was so called based upon the theory that ketone bodies (acetoacetate, acetone, and beta-hydroxybutyrate), created in the liver from long and medium-chain fatty acids, are directly anticonvulsant when crossing the blood-brain barrier. Urine and occasionally serum ketone levels are generally checked in patients on the ketogenic diet to ensure the diet is being managed correctly, in a manner analogous to following antiepileptic drug levels [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the importance of ketosis in the mechanism of action of the ketogenic diet is increasingly questioned. Increased mitochondrial biogenesis, oxidative phosphorylation, enhanced gamma aminobutyric acid (GABA) levels, reduced neuronal excitability and firing, and stabilized synaptic function have been shown to occur in patients on the ketogenic diet [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/3,5\">",
"     3,5",
"    </a>",
"    ]. While these may be induced by ketosis, alternative mechanisms proposed include elevated plasma free fatty acids (including polyunsaturated fatty acids), reduced glucose fluctuations, increased activation of ATP-sensitive potassium channels, caloric restriction, and elevated brain amino acids. It is probable that the ketogenic diet has multiple mechanisms of action, with some more important than others for different forms or etiologies of epilepsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21468634\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21468642\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ketogenic diet is an effective treatment for patients with epilepsy, regardless of age or seizure type [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/4\">",
"     4",
"    </a>",
"    ]. A 2006 meta-analysis of 19 observational studies (1084 patients) found that after six months, approximately 60 percent of children started on the ketogenic diet had a greater than 50 percent seizure reduction, with 30 percent having greater than 90 percent seizure reduction [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/6\">",
"     6",
"    </a>",
"    ]. Other meta-analyses and reviews have come to similar conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. While more often considered a treatment in children rather than adults with epilepsy, the growing available (nonrandomized) evidence suggests that adults may also achieve benefit while on the diet; adults are more commonly offered the modified Atkins diet [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21468923\">",
"     'Modifed Atkins diet'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The first randomized trial of the ketogenic diet was reported in 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/11\">",
"     11",
"    </a>",
"    ]. One hundred and forty-five children (ages 2 to 16 years) with intractable epilepsy (failure of at least two AEDs) were assigned to immediate implementation of the ketogenic diet or to a control group in whom implementation was delayed for three months [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/11\">",
"     11",
"    </a>",
"    ]. At three months, 103 remained in the trial, 54 in the active treatment group. In these patients, treatment with the diet was associated with a lower mean percentage of baseline seizures (62 versus 137 percent) and a higher percentage with greater than 50 percent seizure reduction (38 versus 6 percent).",
"   </p>",
"   <p>",
"    Based upon the available evidence, most (21 of 26) members of a 2009 expert consensus panel felt that the ketogenic diet should be considered in children with intractable epilepsy after unsuccessful treatment trials of two or three AEDs [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with specific conditions that appear to be particularly responsive to the ketogenic diet, it is reasonable to consider this treatment earlier. The expert consensus group identified conditions with strong versus suggested evidence of benefit of the ketogenic diet [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/4\">",
"     4",
"    </a>",
"    ]. These are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H186115\">",
"    <span class=\"h2\">",
"     Specific conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conditions with a probable indication (multiple reports of benefit) for the ketogenic diet include [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Infantile spasms",
"      </strong>",
"      &mdash; A number of case series have shown that the ketogenic diet may control infantile spasms in patients refractory to first-line treatments [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/12\">",
"       12",
"      </a>",
"      ]. This is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/28/30154?source=see_link&amp;anchor=H27#H27\">",
"       \"Management and prognosis of infantile spasms\", section on 'Ketogenic diet'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Myoclonic-astatic epilepsy (Doose syndrome)",
"      </strong>",
"      &mdash; A generalized epilepsy of early childhood with a high frequency of intractability, myoclonic-astatic epilepsy and head-drop seizures has been reported to respond rapidly and often completely to the ketogenic diet in a number of case series [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/13-15\">",
"       13-15",
"      </a>",
"      ]. Up to 5 percent of patients with syndrome may have GLUT-1 deficiency, another condition that responds to the ketogenic diet as discussed below [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Rett syndrome",
"      </strong>",
"      &mdash; The ketogenic diet may improve intractable seizures in patients with Rett syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/17-19\">",
"       17-19",
"      </a>",
"      ]. However, in view of the frequent occurrence of growth failure in this syndrome, a ketogenic diet should be used with some caution. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/29/32218?source=see_link&amp;anchor=H41#H41\">",
"       \"Rett syndrome\", section on 'Seizures'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Tuberous sclerosis complex",
"      </strong>",
"      &mdash; Many patients with tuberous sclerosis complex are refractory to medical treatment but have multiple tubers that can be epileptogenic making surgery impossible. In these patients, a ketogenic diet may help control seizures and should be considered along with other nonpharmacologic interventions [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/20-23\">",
"       20-23",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32328?source=see_link&amp;anchor=H140860313#H140860313\">",
"       \"Tuberous sclerosis complex: Management\", section on 'Seizure control'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Severe myoclonic epilepsy of infancy (Dravet syndrome)",
"      </strong>",
"      &mdash; Intractable epilepsy is one of the characteristics of the Dravet syndrome. Case series suggest that the ketogenic diet may reduce seizure frequency in many of these patients, especially the atypical absence seizures noted in this condition [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/24-28\">",
"       24-28",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33769?source=see_link&amp;anchor=H6#H6\">",
"       \"Epilepsy syndromes in children\", section on 'Severe myoclonic epilepsy of infancy (Dravet syndrome)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       GLUT1 deficiency",
"      </strong>",
"      &mdash; GLUT1 deficiency syndrome is a genetic disorder characterized by impaired glucose transport across the blood brain barrier resulting in generalized epilepsy, developmental delay, and an associated movement disorder [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/16,29-32\">",
"       16,29-32",
"      </a>",
"      ]. A low cerebrospinal fluid glucose level suggests this diagnosis. The diagnosis can be confirmed in most cases with genetic testing (SLC2A1 mutation).",
"      <br/>",
"      <br/>",
"      The ketogenic diet is a first-line treatment for this disorder and provides ketones as an alternative energy source for the brain. While seizures typically remit with this treatment, the effects on neurodevelopment are less apparent [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/33,34\">",
"       33,34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Pyruvate dehydrogenase (PDH) deficiency",
"      </strong>",
"      &mdash; The ketogenic diet may also serve to provide an alternative energy source for the brain in PDH deficiency, a mitochondrial disease characterized by lactic acidosis, severe neurologic impairments, and occasionally, intractable epilepsy [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/35,36\">",
"       35,36",
"      </a>",
"      ]. In uncontrolled reports, patients on the ketogenic diet appear to have an improved neurologic outcome.",
"     </li>",
"     <li>",
"      <strong>",
"       Gastrostomy-tube or formula fed children",
"      </strong>",
"      &mdash; Poor compliance, a major limiting factor in the effective use of the ketogenic diet, is not a significant problem in patients who receive all of their nutrition via formula or gastrostomy feedings. In one case series, 12 patients with intractable epilepsy and a static encephalopathy were maintained on the ketogenic diet administered via a gastrostomy tube; only two patients did not improve; six patients achieved a more than 90 percent reduction in seizures [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/37\">",
"       37",
"      </a>",
"      ]. A retrospective study found that 61 children who were administered the ketogenic diet via formula (31 formula fed infants; 30 gastrostomy tube fed children) had better rates of &gt;90 percent seizure remission with the diet than children administered the diet through solid food: 59 versus 27 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Specific epilepsy disorders in which there have been somewhat more isolated reports of efficacy using the ketogenic diet include [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Landau Kleffner syndrome",
"      </strong>",
"      or acquired epileptic aphasia is sometimes associated with intractable epilepsy that has been reported to benefit from the ketogenic diet [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/39\">",
"       39",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33769?source=see_link&amp;anchor=H10#H10\">",
"       \"Epilepsy syndromes in children\", section on 'Landau-Kleffner syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Lennox Gastaut syndrome (LGS)",
"      </strong>",
"      has many causes and is characterized by intractable epilepsy with multiple seizure types. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33769?source=see_link&amp;anchor=H8#H8\">",
"       \"Epilepsy syndromes in children\", section on 'Lennox-Gastaut syndrome'",
"      </a>",
"      .) The ketogenic diet appears to be helpful in some cases [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/25,40\">",
"       25,40",
"      </a>",
"      ]. In one case series of 71 children with LGS, 50 percent achieved a greater than 50 percent seizure reduction after six months on the diet; while 23 percent achieved a greater than 90 percent seizure reduction [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/41\">",
"       41",
"      </a>",
"      ]. Seizure freedom was rare.",
"      <br/>",
"      <br/>",
"      In a blinded-crossover study in 20 children with LGS and intractable seizures, patients were treated with the ketogenic diet after a 36 hour fast and randomized to a treatment solution of 60 g per day of glucose (to negate the effects of the diet) versus saccharin [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/42,43\">",
"       42,43",
"      </a>",
"      ]. Ketosis was incompletely eliminated in the glucose-added group. Patients in the saccharin group had somewhat fewer seizures than did those in the glucose arm, but this did not quite achieve statistical significance (p = 0.07).",
"     </li>",
"     <li>",
"      <strong>",
"       Absence Epilepsy",
"      </strong>",
"      may respond to the ketogenic diet, when antiepileptic drugs are incompletely effective [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/28,44\">",
"       28,44",
"      </a>",
"      ]. In a case series of 21 patients with childhood and juvenile absence epilepsy, use of the ketogenic or modified Atkins diet was associated with a &gt;50 percent seizure reduction in 82 percent and compete seizure remission in 19 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/44\">",
"       44",
"      </a>",
"      ]. In the same report, a review of published studies that included 133 patients with absence epilepsy found similar results; 69 percent had a &gt;50 percent seizure reduction and 34 percent became seizure free.",
"     </li>",
"     <li>",
"      <strong>",
"       Subacute sclerosis panencephalitis (SSPE)",
"      </strong>",
"      is a progressive neurologic disorder that can occur as a late complication of measles infection. Intractable myoclonus is a common feature. In one case, implementation of the ketogenic diet appeared to be associated with reduced myoclonic jerks, but the apparent benefit was only temporary [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/45\">",
"       45",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/11/43192?source=see_link&amp;anchor=H14#H14\">",
"       \"Clinical presentation and diagnosis of measles\", section on 'Subacute sclerosing panencephalitis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Mitochondrial respiratory chain complex defects",
"      </strong>",
"      &mdash; In a case series of 14 patients with epilepsy associated with one of the mitochondrial respiratory chain complex defects who were treated with the ketogenic diet, seven patients became seizure free, four showed no response or could not tolerate the diet [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/46\">",
"       46",
"      </a>",
"      ]. There were no severe adverse effects.",
"     </li>",
"     <li>",
"      <strong>",
"       Refractory status epilepticus",
"      </strong>",
"      &mdash; There have been several case reports of the ketogenic diet successfully treating prolonged, medically refractory nonconvulsive and partial status epilepticus in adults and children [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/47-49\">",
"       47-49",
"      </a>",
"      ]. One case series describes efficacious use of the ketogenic diet in seven of nine patients with febrile infection-related refractory epileptic encephalopathy (FIRES) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/50\">",
"       50",
"      </a>",
"      ]. An additional case report describes successful use of the modified Atkins diet in two children with nonconvulsive status epilepticus [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/51\">",
"       51",
"      </a>",
"      ]. These cases all use ketogenic formulas provided through enteral (eg, gastric) tubes to administer the ketogenic diet and achieve ketosis.",
"      <br/>",
"      <br/>",
"      One study also found that the ketogenic diet was a useful adjunctive treatment in patients with intractable focal epilepsy who had had a recent (within the past month) worsening of seizure control and neurologic deterioration [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some studies also suggest that patients taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/2/10279?source=see_link\">",
"       zonisamide",
"      </a>",
"      or those having a vagus nerve stimulator are particularly likely to respond to the ketogenic diet at diet onset [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/53,54\">",
"       53,54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In one single center case series, other syndromes responsive to the ketogenic diet included migrating partial epilepsy of infancy and epilepsy with myoclonic-atonic seizures [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/28\">",
"       28",
"      </a>",
"      ]. Children with lissencephaly and hypoxic ischemic encephalopathy (four and eight patients, respectively) were also often likely to respond to the diet.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21468805\">",
"    <span class=\"h2\">",
"     Partial versus generalized epilepsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some anecdotal and published evidence have suggested that the ketogenic diet may be less effective in partial compared with generalized epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/55\">",
"     55",
"    </a>",
"    ]. However, there are many reports in which patients with focal epilepsy appear to respond to the ketogenic diet [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/28,52,56-58\">",
"     28,52,56-58",
"    </a>",
"    ], and in the randomized clinical trial discussed above, the subgroups of partial versus generalized epileptic syndromes appeared to experience similar benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, it is important to note that patients with intractable focal epilepsy who are candidates for epilepsy surgery are more likely to achieve complete seizure remission with epilepsy surgery than with the ketogenic diet [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. It is not unreasonable to attempt the ketogenic diet for children who are candidates for surgery, however, if the family is not ready or the child is very young.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21468812\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS AND SCREENING EVALUATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fasting or implementation of the ketogenic diet in individuals with inborn errors of metabolism that affect the transport or oxidation of long chain fatty acids can lead to a devastating catabolic crisis. The ketogenic diet can also exacerbate acute intermittent porphyria.",
"   </p>",
"   <p>",
"    Absolute contraindications to the ketogenic diet include [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Primary",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       carnitine",
"      </a>",
"      deficiency",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       Carnitine",
"      </a>",
"      palmitoyltransferase I or II deficiency",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       Carnitine",
"      </a>",
"      translocase deficiency",
"     </li>",
"     <li>",
"      Porphyria",
"     </li>",
"     <li>",
"      Fatty acid oxidation defects",
"     </li>",
"     <li>",
"      Pyruvate carboxylase deficiency",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with clinical features suggesting one of these diagnoses (cardiomyopathy, hypotonia, exercise intolerance, myoglobinuria, easy fatigability) should be tested in order to exclude one of these conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/4\">",
"     4",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    Recommended tests are included in the Table (",
"    <a class=\"graphic graphic_table graphicRef67745 \" href=\"UTD.htm?1/63/2045\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=see_link\">",
"     \"Inborn errors of metabolism: Metabolic emergencies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, patients with mitochondrial respiratory chain complex defects and epilepsy have been safely and effectively treated with the ketogenic diet [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H186115\">",
"     'Specific conditions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A number of other conditions may make the diet difficult to implement, interfere with compliance, increase the risk of adverse events, or suggest that alternative treatments may be more effective:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Epilepsy surgery candidates &mdash; Patients with intractable focal epilepsy who are candidates for epilepsy surgery are likely to have a better response to epilepsy surgery than to the ketogenic diet [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/57\">",
"       57",
"      </a>",
"      ]. An EEG and MRI are useful in the evaluation of potential epilepsy surgery candidates, but are likely to have been performed prior to consideration of the ketogenic diet.",
"     </li>",
"     <li>",
"      Inability to ensure adequate nutritional status (poor oral intake), failure to thrive &mdash; Baseline weight, height, body mass index should be measured and compared with age-specific norms [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Special dietary requirements or preferences (eg, vegan diet) &mdash; Potential food allergies or intolerances,",
"      <span class=\"nowrap\">",
"       cultural/religious",
"      </span>",
"      dietary needs should also be carefully reviewed [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/4\">",
"       4",
"      </a>",
"      ]. A review of a three-day food record can also be helpful in identifying potential problems. Most religions and cultures can be successfully accommodated with the ketogenic diet, however.",
"     </li>",
"     <li>",
"      Parent or caregiver noncompliance &mdash; A discussion should be held with family to ensure they understand the complexity of diet management and the importance of strict adherence to the diet as well as vitamin and mineral supplements [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Medical conditions that may be aggravated by the diet &mdash; These include a history of kidney stones, dyslipidemia, liver disease, gastroesophageal reflux disease, constipation, cardiomyopathy, and chronic metabolic acidosis. A renal ultrasound and nephrology consult are recommended if there is a personal or family history of kidney stones [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/4\">",
"       4",
"      </a>",
"      ]. These conditions do not preclude the diet&rsquo;s use, but make it more difficult.",
"     </li>",
"     <li>",
"      Certain antiepileptic drug regimens &mdash; There is one report suggesting that patients taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"       phenobarbital",
"      </a>",
"      may be less likely to respond to the ketogenic diet [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21468843\">",
"    <span class=\"h1\">",
"     IMPLEMENTATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21468851\">",
"    <span class=\"h2\">",
"     Initiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ketogenic diet should be supervised by a trained dietitian in an epilepsy center who is familiar with the ketogenic diet.",
"   </p>",
"   <p>",
"    The traditional ketogenic diet is started in the hospital following a 24 to 48 hour fasting period [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/4\">",
"     4",
"    </a>",
"    ]. Then, daily calorie intake",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the ketogenic diet ratio is gradually increased until the full ketogenic diet for home use is achieved. After an average hospital duration of four days, the child is discharged home.",
"   </p>",
"   <p>",
"    During the hospitalization, serum glucose is often monitored every six to eight hours and urine ketones are monitored daily [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/4\">",
"     4",
"    </a>",
"    ]. If serum glucose falls below 30",
"    <span class=\"nowrap\">",
"     mg/dl,",
"    </span>",
"    small quantities of orange juice are provided. Medications are usually left unchanged for the first month on the diet, although changed to carbohydrate-free preparations [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One of the most important reasons for the admission is to educate the parents and caregivers. Most hospitals will schedule lectures and teaching sessions during the admission.",
"   </p>",
"   <p>",
"    There is evidence that the initiation period can be altered to make it better tolerated for children. Some centers will initiate the ketogenic diet as an outpatient with classes held in various settings [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/60\">",
"     60",
"    </a>",
"    ]. Although only 12 percent of an expert consensus panel routinely starts the diet as an outpatient, the majority (73 percent) also felt that it was possible to do this in select situations [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The initial fasting period is also not required for long-term seizure control. A randomized study that compared initial fasting to a more gradual initiation period found that there was less hypoglycemia, acidosis, or weight loss with a gradual approach, but the incidence of vomiting was unchanged [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/61\">",
"     61",
"    </a>",
"    ]. Fasting does appear to lead to a more rapid onset of ketosis and seizure control, however [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The traditional ketogenic diet consists of four parts fat to one part protein and carbohydrate (ie, 4:1 lipid to nonlipid ratio) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/4\">",
"     4",
"    </a>",
"    ]. Total calories are restricted to 80 to 90 percent of recommended values for age, but typically dietitians match calories to the pre-ketogenic diet baseline. Modification of the diet to a somewhat lower fat content (3:1 lipid:nonlipid ratio from the traditional 4:1 ratio) improves tolerability of the diet, but may reduce its efficacy during the initial three months [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alternatively, the diet can be given as a liquid-based formula to bottle-fed infants and enterally fed patients. There are a number of commercially available products. Because the diet is easy to administer in this form, compliance and efficacy are generally excellent in this population. (See",
"    <a class=\"local\" href=\"#H186115\">",
"     'Specific conditions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    All children are started routinely on a carbohydrate-free multivitamin, calcium, and vitamin D supplement. At our center, based on evidence for reduced kidney stone risk, all children are also started on a potassium citrate supplement (2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21468868\">",
"    <span class=\"h2\">",
"     Maintenance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once children are started on the ketogenic diet, they should be seen in clinic for follow-up every three months for the first year of treatment, with more frequent (at times monthly) visits for infants and those nutritionally at higher risk [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/4\">",
"     4",
"    </a>",
"    ]. Calorie intake, height and weight are monitored at each visit. Calorie intake should be adjusted for excessive weight loss or gain. Email and phone contact in between clinic appointments is also recommended.",
"   </p>",
"   <p>",
"    Laboratory studies, including complete blood count, comprehensive metabolic profile, fasting lipid profile,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    profile, urinalysis, urine calcium, and urine creatinine are recommended every three months [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/4\">",
"     4",
"    </a>",
"    ]. Measurement of urine ketones by parents is recommended several times per week [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some children may also require laxatives if constipation is a problem,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    extra",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    , salt, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    , if they develop relevant abnormal laboratory parameters. The ketogenic ratio can be adjusted if there is loss of seizure control or decreased ketosis.",
"   </p>",
"   <p>",
"    A clinical response to the diet is quick, usually within a few weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/52,62\">",
"     52,62",
"    </a>",
"    ]. Its efficacy can generally be established in individual patients within two to three months of initiation.",
"   </p>",
"   <p>",
"    Optional laboratory studies include serum",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    , zinc, beta-hydroxybutyrate levels as well as renal ultrasounds and DEXA scans [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21468888\">",
"    <span class=\"h2\">",
"     Antiepileptic drug management",
"    </span>",
"    &nbsp;&mdash;&nbsp;No antiepileptic drug regimens are known to be contraindicated with the ketogenic diet, nor is there convincing evidence that a combination of any specific antiepileptic drug with the ketogenic diet is more efficacious than any other [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      While the combination of carbonic anhydrase inhibitors (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"       topiramate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/2/10279?source=see_link\">",
"       zonisamide",
"      </a>",
"      ) and the ketogenic diet might be expected to increase the risk of kidney stones, this does not appear to be the case. In one series of 221 children on the diet, kidney stones were no more common in children on these antiepileptic drugs than on any other regimen [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/65\">",
"       65",
"      </a>",
"      ]. However, metabolic acidosis may worsen with this combination, and should be monitored for, especially in the first",
"      <span class=\"nowrap\">",
"       weeks/months",
"      </span>",
"      after diet initiation [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      in the setting of the ketogenic diet does not appear to increase the risk of hepatotoxicity, but may increase the risk of secondary",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       carnitine",
"      </a>",
"      deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/67,68\">",
"       67,68",
"      </a>",
"      ]. Increased monitoring of liver function tests and carnitine levels may be prudent in children on this therapeutic combination. Pancreatitis has been reported a few cases of children on the ketogenic diet who were also taking valproate [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/67,69,70\">",
"       67,69,70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In one report of 115 patients on the ketogenic diet, a greater than 50 percent reduction in seizure frequency was more common in patients on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/2/10279?source=see_link\">",
"       zonisamide",
"      </a>",
"      , while those on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"       phenobarbital",
"      </a>",
"      were less likely to achieve this benefit [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Implementation of the ketogenic diet was not associated with altered plasma concentrations of AEDs in one case series of 51 children, suggesting that no dose adjustments or additional monitoring of drug levels beyond what is otherwise required is necessary in patients on the ketogenic diet [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If seizure control is obtained on the ketogenic diet, then AEDs should be gradually reduced in dose and eliminated if possible. The results of one case series suggest that this can begin as early as the first month [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/72\">",
"     72",
"    </a>",
"    ]. In approximately 20 percent of patients, AEDs were successfully eliminated. Transient worsening was more likely when the tapered AED was",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    or a benzodiazepine; slow taper of these medications seems advisable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21468908\">",
"    <span class=\"h1\">",
"     ALTERNATIVE DIETS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21468916\">",
"    <span class=\"h2\">",
"     Medium chain triglyceride diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the classic ketogenic diet, fat comes primarily from long chain triglycerides obtained through standard foods; protein intake is based on that required for growth; and carbohydrates are restricted. In an alternative form of the ketogenic diet,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/51/19250?source=see_link\">",
"     medium chain triglycerides",
"    </a>",
"    (MCTs) provided in an oil supplement are utilized as a major fat source [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/11\">",
"     11",
"    </a>",
"    ]. These MCTs yield more ketones, are more efficiently absorbed, and are carried directly to the liver. As a result, less total fat is needed in the diet and more protein and carbohydrates can be allowed.",
"   </p>",
"   <p>",
"    A randomized controlled study found no difference in efficacy or tolerability between the traditional ketogenic diet and the MCT diet [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/73\">",
"     73",
"    </a>",
"    ]; however, there may be individual differences.",
"   </p>",
"   <p>",
"    Originally, 60 percent of the energy source in the MCT diet was derived from MCT [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/4\">",
"     4",
"    </a>",
"    ]. In some children, this needs to be reduced to 30 to 50 percent in order to minimize gastrointestinal symptoms, with the resulting decrement in energy source to be made up from long chain fat.",
"   </p>",
"   <p>",
"    MCTs should be given with each meal or even divided up between several smaller meals in order to improve tolerance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21468923\">",
"    <span class=\"h2\">",
"     Modifed Atkins diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative version of the ketogenic diet entitled the modified Atkins diet was first described in the treatment of six patients with intractable epilepsy in 2003 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This diet is designed to mimic some aspects of the ketogenic diet but allows ad lib protein, fluids, and calories [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/75\">",
"     75",
"    </a>",
"    ]. This diet is initiated as an outpatient without a fast. Carbohydrates are initially restricted to 10 grams per day (15 to 20 grams per day in adolescents and adults) with patients counseled to increase their use of high fat foods (at the expense of protein). When implemented, most parents will provide an approximately 1:1 - 2:1 ketogenic diet (although there is no weighing and measuring of foods recommended in this regimen) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/75\">",
"     75",
"    </a>",
"    ]. A ketogenic liquid supplement (KetoCal shake) can be used during the first month to increase the ketogenic ratio [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/76\">",
"     76",
"    </a>",
"    ]. All children are started on a multivitamin and calcium, and lab studies are obtained identically to the traditional ketogenic diet. After one to three months, the carbohydrate restrictions can be loosened",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    AEDs reduced as clinically indicated.",
"   </p>",
"   <p>",
"    This less restrictive diet has been used successfully in adults who are not typically offered the ketogenic diet [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/77,78\">",
"     77,78",
"    </a>",
"    ], in countries with limited financial and dietitian resources [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/79\">",
"     79",
"    </a>",
"    ], in children on the ketogenic diet for many years who desire fewer restrictions [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/74\">",
"     74",
"    </a>",
"    ], and as an early treatment for epilepsy before intractability is established [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/75\">",
"     75",
"    </a>",
"    ]. One center reported that the diet could be successfully maintained in selected adults using electronic communication (email) rather than in-person clinic visits [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/80\">",
"     80",
"    </a>",
"    ]. This may be particularly useful in resource-poor regions of the world.",
"   </p>",
"   <p>",
"    The efficacy of the diet has been reported in more than 25 studies, including one randomized trial in children [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/33,34,56,74,77-79,81-89\">",
"     33,34,56,74,77-79,81-89",
"    </a>",
"    ]. Overall, 175 of 390 total reported patients (45 percent) have had at least a &gt;50 percent reduction in seizures after six months; of these, 96 (25 percent) had &gt;90 percent seizure reduction. When this cohort is specifically analyzed for adults, the results are less robust, with 26 of 90 (29 percent) having &gt;50 percent seizure reduction and 10 (11 percent) with &gt;90 percent seizure reduction.",
"   </p>",
"   <p>",
"    In the only randomized trial to date, 102 children ages 2 to 14 (mean age 5 years) with refractory epilepsy (daily seizures despite three or more AEDs) were assigned to receive a modified Atkins diet or no dietary intervention for three months [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/88\">",
"     88",
"    </a>",
"    ]. Four out of 50 patients discontinued the diet before the study endpoint (two due to frequent chest infections, one due to hyperammonemic encephalopathy, one due to patient and family preference). In an intention-to-treat analysis, treatment with the diet was associated with decreased mean seizure frequency as a percentage of baseline (59 versus 100 percent) and increased proportion of patients with &gt;50 percent reduction in seizure frequency (52 versus 12 percent). Five children (10 percent) became seizure free on the diet, compared with none in the control arm. The most common side effects in the diet group were constipation (46 percent) and anorexia (18 percent).",
"   </p>",
"   <p>",
"    These results are similar to those reported for the ketogenic diet (see",
"    <a class=\"local\" href=\"#H21468642\">",
"     'Efficacy'",
"    </a>",
"    above). When patients are able to remain on diet therapy for more than six months, rates of seizure reduction are also similar to those reported for the ketogenic diet [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/87\">",
"     87",
"    </a>",
"    ]. A retrospective (nonrandomized) comparison of the two diets found that the traditional diet was more successful at three months (65 versus 20 percent achieved &gt;50 percent seizure reduction); at six months the difference was no longer statistically significant (41 versus 20 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A case series reviewed the experience of 27 patients treated with the modified Atkins diet who subsequently were switched to the ketogenic diet. Ten patients achieved additional benefit with the ketogenic diet; five of these became seizure-free [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/90\">",
"     90",
"    </a>",
"    ]. Additional benefit occurred in a greater proportion of children with myoclonic-astatic epilepsy than other epilepsy syndromes. The five children who had no response to the Atkins diet did not respond to the ketogenic diet. This information suggests that the modified Atkins diet may represent a &ldquo;low dose&rdquo; of dietary treatment and the ketogenic diet a &ldquo;high dose&rdquo; (rather than two unique diets).",
"   </p>",
"   <p>",
"    Ketosis will occur with the modified Atkins diet and may correlate with seizure control, but only initially, during the first month [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/56\">",
"     56",
"    </a>",
"    ]. Side effects include weight loss, constipation, and elevations in serum cholesterol and blood urea nitrogen [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/81,88\">",
"     81,88",
"    </a>",
"    ]. Long-term side effects include gastroesophageal reflux and elevations in serum cholesterol [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/87\">",
"     87",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21468930\">",
"    <span class=\"h2\">",
"     Low glycemic index diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;An even less restrictive diet, the low glycemic index diet restricts carbohydrates to 40 to 60 grams per day, does not restrict fluids or protein, and loosely monitors fat and calories [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/91\">",
"     91",
"    </a>",
"    ]. It is started as an outpatient without a fasting period. As with the other diets, most children eat significantly more fat on this regimen than they did before. Unlike the modified Atkins diet, the type of carbohydrates is important in this diet, with only carbohydrates with low glycemic indices (&lt;50) allowed. These carbohydrates include strawberries and whole grain breads as opposed to potatoes, white bread and most citrus fruits. In patients on this diet, there is nearly no serum ketosis noted. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/47/38649?source=see_link&amp;anchor=H3#H3\">",
"     \"Dietary carbohydrates\", section on 'Glycemic index'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Results from a single center have demonstrated early benefit with this diet in 74 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/92\">",
"     92",
"    </a>",
"    ]. Using an intent-to-treat analysis, 32 percent had a &gt;50 percent seizure reduction after three months of implementation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21468937\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dietary treatments for epilepsy are neither healthy nor free of potential side effects. A substantial proportion of patients who have a substantial benefit in seizure reduction on the diet discontinue the diet early because of intolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/69,93\">",
"     69,93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Parents and caregivers should be counseled as to the common, occasional, and rare adverse effects that can happen in the short-term when using dietary treatments, specifically the ketogenic diet. Fortunately, most adverse effects are predictable, often preventable, and only rarely in themselves lead to diet discontinuation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Relative common adverse effects include [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/4,69\">",
"     4,69",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gastrointestinal symptoms: diarrhea, constipation, nausea, vomiting, and exacerbation of gastroesophageal reflux are among the most common side effects, occurring in more than half of children on the ketogenic diet [4,8,63]. These are generally managed symptomatically with proton pump inhibitors, laxatives, and other treatments as needed.",
"     </li>",
"     <li>",
"      While abnormal lipid parameters are frequently seen, significant hypercholesterolemia and hypertriglyceridemia are less common [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/69,94,95\">",
"       69,94,95",
"      </a>",
"      ]. Most levels improve spontaneously even without dietary or other intervention; and only a minority of patients require medication. Atherogenic consequences of the ketogenic diet, if any, are not known, but do not appear to happen in children followed years after the ketogenic diet has been discontinued.",
"     </li>",
"     <li>",
"      Abnormal laboratory parameters (hypoglycemia, hyperuricemia, hypoproteinemia, hypomagnesemia, hyponatremia, hepatitis, metabolic acidosis) are sometimes seen and should be monitored for (see",
"      <a class=\"local\" href=\"#H21468868\">",
"       'Maintenance'",
"      </a>",
"      above), but are usually minor [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/4,69\">",
"       4,69",
"      </a>",
"      ]. Significant metabolic acidosis requiring treatment may be more common in children who are also taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"       topiramate",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/2/10279?source=see_link\">",
"       zonisamide",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Most children on the ketogenic diet fall into lower height and weight percentiles [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/96-98\">",
"       96-98",
"      </a>",
"      ]. Younger children on the diet for longer periods of time appear to be the most at risk. In one small series, height velocity was most affected in those with the most pronounced ketosis [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/99\">",
"       99",
"      </a>",
"      ]. The higher protein content in the MCT diet does not appear to ameliorate this [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/100\">",
"       100",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     Carnitine",
"    </a>",
"    levels typically decline in the first months on the ketogenic diet; however, carnitine deficiency is not common (&lt;20 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/69,101\">",
"     69,101",
"    </a>",
"    ]. Levels typically stabilize or improve spontaneously without supplementation. We recommend supplementation for those who are symptomatic with fatigue and lethargy associated with low carnitine levels.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Osteopenia, osteoporosis, and bone fractures are a concern for children maintained on the ketogenic diet, as they are for children on chronic AEDs [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/69,97,102,103\">",
"       69,97,102,103",
"      </a>",
"      ]. Prophylactic supplementation with calcium and vitamin D is mandatory for all children on the diet, but sometimes fails to prevent continued bone loss. As yet, there is no well-defined role for the use of bone scanning",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      other treatments in this setting to reduce the risk of bone loss and fracture [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Kidney stones may occur in as many as 7 percent of children [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/65,69\">",
"       65,69",
"      </a>",
"      ]; if fluid intake is normal, the incidence is likely lower, and in one study was reduced to less than 1 percent with the addition of a potassium citrate supplement [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/64\">",
"       64",
"      </a>",
"      ]. The risk for kidney stones is highest in those with baseline urologic abnormalities or a personal or family history of nephrolithiasis [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"       Selenium",
"      </a>",
"      deficiency has been found in up to 20 percent of children on the ketogenic diet and has produced an irreversible cardiomyopathy and sudden death in a few case reports of children on the ketogenic diet [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/104,105\">",
"       104,105",
"      </a>",
"      ]. Cardiomyopathy and prolonged AT intervals have also been described in patients on the ketogenic diet who were not selenium deficient [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/106\">",
"       106",
"      </a>",
"      ]. While selenium levels can be checked, this is not done routinely by all experts [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pancreatitis has been reported in a few children on the ketogenic diet [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/67,69,70\">",
"       67,69,70",
"      </a>",
"      ]. Most cases, but not all, had another risk factor for pancreatitis, usually",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      administration.",
"     </li>",
"     <li>",
"      Seizure worsening has been anecdotally reported, similar to the potential with any anticonvulsant medication. The incidence is unknown.",
"     </li>",
"     <li>",
"      Iron-deficiency anemia has been observed in a small number of patients on the ketogenic diet [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/69\">",
"       69",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An increase in bruising and mild bleeding has been reported in patients on the ketogenic diet, suggesting an impact of the diet on platelet function [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/107\">",
"       107",
"      </a>",
"      ]. This typically does not require any specific intervention.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Once the diet is discontinued, most of these adverse effects resolve. In a follow-up study of 101 children who had discontinued the diet a median of six years prior, height, weight, cholesterol, and food preferences were all normal [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/108\">",
"     108",
"    </a>",
"    ]. There was no increased risk of late reported cardiovascular disease, bone fractures, or kidney stones. Most patients were eating normal foods years later as well.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21469017\">",
"    <span class=\"h1\">",
"     DURATION AND DISCONTINUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no clear minimum or maximum duration periods for the ketogenic diet.",
"   </p>",
"   <p>",
"    Observational studies suggest that if successful, the ketogenic diet usually will result in seizure reduction within two to three months [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/62\">",
"     62",
"    </a>",
"    ]. We therefore recommend discontinuing the ketogenic diet as a treatment failure only after it has been used for at least three months.",
"   </p>",
"   <p>",
"    In children who benefit from the diet, we re-evaluate the relative value of the ketogenic diet after one and two continuous years of use, especially in those who have become seizure-free [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/4\">",
"     4",
"    </a>",
"    ]. Eighty percent of those who discontinue the ketogenic diet after two years of seizure freedom will continue to remain seizure-free [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The impact of discontinuing the diet in those with seizure frequency reduction but not seizure remission is not known. In one study, outcomes at three to six years were evaluated in 54 children who discontinued the diet within one year of initiation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/93\">",
"     93",
"    </a>",
"    ]. Almost half of these children had &gt;50 percent reduced seizure frequency compared to baseline; 22 percent were seizure free without surgery. Children who had had some improvement while on the diet were more likely to have a favorable long-term outcome. At our center, approximately 0.5 percent of our ketogenic diet patients are on the ketogenic diet for over six years; some have been on the diet for more than 20 years [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Discontinuation of the ketogenic diet is done in a manner similar to AEDs, with a slow wean over two to three months, reducing the fat to protein plus carbohydrate ratio gradually to 1:1; at this point carbohydrate-containing foods can be rapidly introduced [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/4\">",
"     4",
"    </a>",
"    ]. The benefit to this approach is that the ketogenic ratio can be increased should seizures recur or worsen during the weaning period. In one case series, seizure recurrence could be effectively managed in most (58 percent) children with resuming the diet, or adding AEDs [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some situations, particularly if the diet is either unsuccessful or possibly worsening seizures, it can be weaned much more rapidly. In a retrospective chart review of 183 children on the diet, speed of diet discontinuation (&lt;1 week, 1 to 6 weeks, or &gt;6 weeks) was not associated with incidence of seizure worsening [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/109\">",
"     109",
"    </a>",
"    ]. &nbsp;We have reduced the ratio weekly for some children, and even abruptly returned to standard diets for children in intensive care unit settings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21469024\">",
"    <span class=\"h1\">",
"     POTENTIAL NON-EPILEPSY INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although preliminary, there is evidence that suggests that, as with AEDs, the ketogenic and similar diets may have efficacy for other neurologic conditions than epilepsy. These conditions include autism, brain tumors, depression, narcolepsy, glycogenosis type V, Alzheimer's disease, traumatic brain injury, Parkinson's syndrome, ALS, migraines, sleep disorders, post-hypoxic myoclonus, post-anoxic brain injury, and schizophrenia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glycogen storage disorders associated with exercise intolerance, muscle cramps, and weakness. Individual case reports have observed benefit from the ketogenic diet in glycogenosis type V (McArdle's disease) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/111\">",
"       111",
"      </a>",
"      ] and phosphofructokinase deficiency (glycogen storage disease VII, Tarui disease) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/112\">",
"       112",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/23/23928?source=see_link\">",
"       \"Muscle phosphorylase deficiency (glycogen storage disease V, McArdle disease)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28596?source=see_link\">",
"       \"Phosphofructokinase deficiency (glycogen storage disease VII, Tarui disease)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Evidence for the benefits of ketosis in Alzheimer's disease in both mice [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/113\">",
"       113",
"      </a>",
"      ] and humans [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/114\">",
"       114",
"      </a>",
"      ] has led to the product Axona&trade; to be approved by the FDA for sale in the United States in March 2009. At this time, the only studies have been performed by the sponsoring company [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/113,114\">",
"       113,114",
"      </a>",
"      ] and the Alzheimer's Association regards medical foods as a subject \"of concern\".",
"     </li>",
"     <li>",
"      Brain tumors appear in mouse and human studies to be reduced in size by a ketogenic, calorie-restricted diet [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/115\">",
"       115",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A single study of autism showed a modest benefit in autism rating scales in select patients treated with the ketogenic diet [",
"      <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/116\">",
"       116",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further studies of all of these conditions are underway, but as of 2009, the expert consensus guideline members stated \"there is insufficient evidence to recommend the use of the ketogenic diet for these conditions other than on an investigational basis\" [",
"    <a class=\"abstract\" href=\"UTD.htm?15/30/15850/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/54/38754?source=see_link\">",
"       \"Patient information: Epilepsy in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21469046\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dietary therapies are effective, safe, nonpharmacologic treatments for intractable childhood epilepsy. A greater than 50 percent seizure reduction occurs in 38 to 60 percent of patients, with as many as 30 percent achieving a greater than 90 percent seizure reduction. (See",
"      <a class=\"local\" href=\"#H21468642\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most experts believe that the ketogenic diet is a valid treatment option for patients who have failed at least two antiepileptic drugs. There are specific conditions in which the ketogenic diet is particularly efficacious and can be offered earlier (See",
"      <a class=\"local\" href=\"#H186115\">",
"       'Specific conditions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is important to note that patients with intractable focal epilepsy who are candidates for epilepsy surgery are likely to have a better response to epilepsy surgery than to the ketogenic diet. (See",
"      <a class=\"local\" href=\"#H21468805\">",
"       'Partial versus generalized epilepsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prior to initiating the ketogenic diet, patients need to be screened for potential contraindications",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      factors that may complicate it use. (See",
"      <a class=\"local\" href=\"#H21468812\">",
"       'Contraindications and screening evaluations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The ketogenic diet should be supervised by a trained dietitian in an epilepsy center. (See",
"      <a class=\"local\" href=\"#H21468843\">",
"       'Implementation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      It is traditionally started as an inpatient with a 24 to 48 hours fasting period. In some situations, hospitalization",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fasting may not be required.",
"     </li>",
"     <li>",
"      Patients are followed closely with frequent monitoring of laboratory tests, height and weight, and seizure frequency.",
"     </li>",
"     <li>",
"      Multivitamins (including minerals such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"       selenium",
"      </a>",
"      and zinc), calcium, and vitamin D supplements are given to all patients on the diet. Some children will require additional supplements.",
"     </li>",
"     <li>",
"      Efficacy of the diet is usually apparent in the first one to three months. If seizure control is achieved, antiepileptic drugs may be slowly tapered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Alternative diets include the medium chain triglyceride diet, whose efficacy appears similar to the traditional diet. The modified Atkins diet and a low glycemic index diet also appear to be effective, and may be useful for children and adults. (See",
"      <a class=\"local\" href=\"#H21468908\">",
"       'Alternative diets'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Side effects are usually mild, predictable, preventable, and rarely lead to diet discontinuation. Important ones include constipation, acidosis, slowed height velocity, dyslipidemia, kidney stones, and bone fractures. (See",
"      <a class=\"local\" href=\"#H21468937\">",
"       'Adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The ketogenic diet is generally recommended for a minimum of three months and maximum of two years; however, longer periods of effective use have been described. In the absence of severe adverse sequelae, slow taper is advised. (See",
"      <a class=\"local\" href=\"#H21469017\">",
"       'Duration and discontinuation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The use of ketogenic diets for indications other than epilepsy (eg, autism, brain tumors, and Alzheimer's disease) have been reported in small case series. Further study is required before they can be recommended. (See",
"      <a class=\"local\" href=\"#H21469024\">",
"       'Potential non-epilepsy indications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/1\">",
"      Kwan P, Brodie MJ. Effectiveness of first antiepileptic drug. Epilepsia 2001; 42:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/2\">",
"      Wilder RM. The effect of ketonemia on the course of epilepsy. Mayo Clin Bulletin 1921; 2:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/3\">",
"      Bough KJ, Rho JM. Anticonvulsant mechanisms of the ketogenic diet. Epilepsia 2007; 48:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/4\">",
"      Kossoff EH, Zupec-Kania BA, Amark PE, et al. Optimal clinical management of children receiving the ketogenic diet: recommendations of the International Ketogenic Diet Study Group. Epilepsia 2009; 50:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/5\">",
"      Bough KJ, Wetherington J, Hassel B, et al. Mitochondrial biogenesis in the anticonvulsant mechanism of the ketogenic diet. Ann Neurol 2006; 60:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/6\">",
"      Henderson CB, Filloux FM, Alder SC, et al. Efficacy of the ketogenic diet as a treatment option for epilepsy: meta-analysis. J Child Neurol 2006; 21:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/7\">",
"      Lefevre F, Aronson N. Ketogenic diet for the treatment of refractory epilepsy in children: A systematic review of efficacy. Pediatrics 2000; 105:E46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/8\">",
"      Levy RG, Cooper PN, Giri P. Ketogenic diet and other dietary treatments for epilepsy. Cochrane Database Syst Rev 2012; 3:CD001903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/9\">",
"      Klein P, Janousek J, Barber A, Weissberger R. Ketogenic diet treatment in adults with refractory epilepsy. Epilepsy Behav 2010; 19:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/10\">",
"      Payne NE, Cross JH, Sander JW, Sisodiya SM. The ketogenic and related diets in adolescents and adults--a review. Epilepsia 2011; 52:1941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/11\">",
"      Neal EG, Chaffe H, Schwartz RH, et al. The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial. Lancet Neurol 2008; 7:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/12\">",
"      Kossoff EH, Hedderick EF, Turner Z, Freeman JM. A case-control evaluation of the ketogenic diet versus ACTH for new-onset infantile spasms. Epilepsia 2008; 49:1504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/13\">",
"      Kilaru S, Bergqvist AG. Current treatment of myoclonic astatic epilepsy: clinical experience at the Children's Hospital of Philadelphia. Epilepsia 2007; 48:1703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/14\">",
"      Caraballo RH, Cers&oacute;simo RO, Sakr D, et al. Ketogenic diet in patients with myoclonic-astatic epilepsy. Epileptic Disord 2006; 8:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/15\">",
"      Oguni H, Tanaka T, Hayashi K, et al. Treatment and long-term prognosis of myoclonic-astatic epilepsy of early childhood. Neuropediatrics 2002; 33:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/16\">",
"      Mullen SA, Marini C, Suls A, et al. Glucose transporter 1 deficiency as a treatable cause of myoclonic astatic epilepsy. Arch Neurol 2011; 68:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/17\">",
"      Haas RH, Rice MA, Trauner DA, Merritt TA. Therapeutic effects of a ketogenic diet in Rett syndrome. Am J Med Genet Suppl 1986; 1:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/18\">",
"      Giampietro PF, Schowalter DB, Merchant S, et al. Widened clinical spectrum of the Q128P MECP2 mutation in Rett syndrome. Childs Nerv Syst 2006; 22:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/19\">",
"      Liebhaber GM, Riemann E, Baumeister FA. Ketogenic diet in Rett syndrome. J Child Neurol 2003; 18:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/20\">",
"      Kossoff EH, Thiele EA, Pfeifer HH, et al. Tuberous sclerosis complex and the ketogenic diet. Epilepsia 2005; 46:1684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/21\">",
"      Kossoff EH, Turner Z, Bergey GK. Home-guided use of the ketogenic diet in a patient for more than 20 years. Pediatr Neurol 2007; 36:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/22\">",
"      Martinez CC, Pyzik PL, Kossoff EH. Discontinuing the ketogenic diet in seizure-free children: recurrence and risk factors. Epilepsia 2007; 48:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/23\">",
"      Coppola G, Klepper J, Ammendola E, et al. The effects of the ketogenic diet in refractory partial seizures with reference to tuberous sclerosis. Eur J Paediatr Neurol 2006; 10:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/24\">",
"      Caraballo RH, Cers&oacute;simo RO, Sakr D, et al. Ketogenic diet in patients with Dravet syndrome. Epilepsia 2005; 46:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/25\">",
"      Dressler A, St&ouml;cklin B, Reithofer E, et al. Long-term outcome and tolerability of the ketogenic diet in drug-resistant childhood epilepsy--the Austrian experience. Seizure 2010; 19:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/26\">",
"      Korff C, Laux L, Kelley K, et al. Dravet syndrome (severe myoclonic epilepsy in infancy): a retrospective study of 16 patients. J Child Neurol 2007; 22:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/27\">",
"      Nabbout R, Copioli C, Chipaux M, et al. Ketogenic diet also benefits Dravet syndrome patients receiving stiripentol: a prospective pilot study. Epilepsia 2011; 52:e54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/28\">",
"      Thammongkol S, Vears DF, Bicknell-Royle J, et al. Efficacy of the ketogenic diet: which epilepsies respond? Epilepsia 2012; 53:e55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/29\">",
"      Klepper J, Leiendecker B. GLUT1 deficiency syndrome--2007 update. Dev Med Child Neurol 2007; 49:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/30\">",
"      Leen WG, Klepper J, Verbeek MM, et al. Glucose transporter-1 deficiency syndrome: the expanding clinical and genetic spectrum of a treatable disorder. Brain 2010; 133:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/31\">",
"      Klepper J, Scheffer H, Leiendecker B, et al. Seizure control and acceptance of the ketogenic diet in GLUT1 deficiency syndrome: a 2- to 5-year follow-up of 15 children enrolled prospectively. Neuropediatrics 2005; 36:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/32\">",
"      Striano P, Weber YG, Toliat MR, et al. GLUT1 mutations are a rare cause of familial idiopathic generalized epilepsy. Neurology 2012; 78:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/33\">",
"      Ito S, Oguni H, Ito Y, et al. Modified Atkins diet therapy for a case with glucose transporter type 1 deficiency syndrome. Brain Dev 2008; 30:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/34\">",
"      Slaughter L, Vartzelis G, Arthur T. New GLUT-1 mutation in a child with treatment-resistant epilepsy. Epilepsy Res 2009; 84:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/35\">",
"      Wexler ID, Hemalatha SG, McConnell J, et al. Outcome of pyruvate dehydrogenase deficiency treated with ketogenic diets. Studies in patients with identical mutations. Neurology 1997; 49:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/36\">",
"      Weber TA, Antognetti MR, Stacpoole PW. Caveats when considering ketogenic diets for the treatment of pyruvate dehydrogenase complex deficiency. J Pediatr 2001; 138:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/37\">",
"      Hosain SA, La Vega-Talbott M, Solomon GE. Ketogenic diet in pediatric epilepsy patients with gastrostomy feeding. Pediatr Neurol 2005; 32:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/38\">",
"      Kossoff EH, McGrogan JR, Freeman JM. Benefits of an all-liquid ketogenic diet. Epilepsia 2004; 45:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/39\">",
"      Bergqvist AG, Chee CM, Lutchka LM, Brooks-Kayal AR. Treatment of acquired epileptic aphasia with the ketogenic diet. J Child Neurol 1999; 14:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/40\">",
"      Freeman JM, Vining EP. Seizures decrease rapidly after fasting: preliminary studies of the ketogenic diet. Arch Pediatr Adolesc Med 1999; 153:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/41\">",
"      Lemmon ME, Terao NN, Ng YT, et al. Efficacy of the ketogenic diet in Lennox-Gastaut syndrome: a retrospective review of one institution's experience and summary of the literature. Dev Med Child Neurol 2012; 54:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/42\">",
"      Freeman JM, Vining EP, Kossoff EH, et al. A blinded, crossover study of the efficacy of the ketogenic diet. Epilepsia 2009; 50:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/43\">",
"      Freeman JM. The ketogenic diet: additional information from a crossover study. J Child Neurol 2009; 24:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/44\">",
"      Groomes LB, Pyzik PL, Turner Z, et al. Do patients with absence epilepsy respond to ketogenic diets? J Child Neurol 2011; 26:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/45\">",
"      Bautista RE. The use of the ketogenic diet in a patient with subacute sclerosing panencephalitis. Seizure 2003; 12:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/46\">",
"      Kang HC, Lee YM, Kim HD, et al. Safe and effective use of the ketogenic diet in children with epilepsy and mitochondrial respiratory chain complex defects. Epilepsia 2007; 48:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/47\">",
"      Wusthoff CJ, Kranick SM, Morley JF, Christina Bergqvist AG. The ketogenic diet in treatment of two adults with prolonged nonconvulsive status epilepticus. Epilepsia 2010; 51:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/48\">",
"      Bodenant M, Moreau C, Sejourn&eacute; C, et al. [Interest of the ketogenic diet in a refractory status epilepticus in adults]. Rev Neurol (Paris) 2008; 164:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/49\">",
"      Nam SH, Lee BL, Lee CG, et al. The role of ketogenic diet in the treatment of refractory status epilepticus. Epilepsia 2011; 52:e181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/50\">",
"      Nabbout R, Mazzuca M, Hubert P, et al. Efficacy of ketogenic diet in severe refractory status epilepticus initiating fever induced refractory epileptic encephalopathy in school age children (FIRES). Epilepsia 2010; 51:2033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/51\">",
"      Kumada T, Miyajima T, Kimura N, et al. Modified Atkins diet for the treatment of nonconvulsive status epilepticus in children. J Child Neurol 2010; 25:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/52\">",
"      Villeneuve N, Pinton F, Bahi-Buisson N, et al. The ketogenic diet improves recently worsened focal epilepsy. Dev Med Child Neurol 2009; 51:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/53\">",
"      Morrison PF, Pyzik PL, Hamdy R, et al. The influence of concurrent anticonvulsants on the efficacy of the ketogenic diet. Epilepsia 2009; 50:1999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/54\">",
"      Kossoff EH, Pyzik PL, Rubenstein JE, et al. Combined ketogenic diet and vagus nerve stimulation: rational polytherapy? Epilepsia 2007; 48:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/55\">",
"      Maydell BV, Wyllie E, Akhtar N, et al. Efficacy of the ketogenic diet in focal versus generalized seizures. Pediatr Neurol 2001; 25:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/56\">",
"      Kang HC, Lee HS, You SJ, et al. Use of a modified Atkins diet in intractable childhood epilepsy. Epilepsia 2007; 48:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/57\">",
"      Stainman RS, Turner Z, Rubenstein JE, Kossoff EH. Decreased relative efficacy of the ketogenic diet for children with surgically approachable epilepsy. Seizure 2007; 16:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/58\">",
"      Jung da E, Kang HC, Kim HD. Long-term outcome of the ketogenic diet for intractable childhood epilepsy with focal malformation of cortical development. Pediatrics 2008; 122:e330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/59\">",
"      Feldstein TJ. Carbohydrate and alcohol content of 200 oral liquid medications for use in patients receiving ketogenic diets. Pediatrics 1996; 97:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/60\">",
"      Vaisleib II, Buchhalter JR, Zupanc ML. Ketogenic diet: outpatient initiation, without fluid, or caloric restrictions. Pediatr Neurol 2004; 31:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/61\">",
"      Bergqvist AG, Schall JI, Gallagher PR, et al. Fasting versus gradual initiation of the ketogenic diet: a prospective, randomized clinical trial of efficacy. Epilepsia 2005; 46:1810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/62\">",
"      Kossoff EH, Laux LC, Blackford R, et al. When do seizures usually improve with the ketogenic diet? Epilepsia 2008; 49:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/63\">",
"      Seo JH, Lee YM, Lee JS, et al. Efficacy and tolerability of the ketogenic diet according to lipid:nonlipid ratios--comparison of 3:1 with 4:1 diet. Epilepsia 2007; 48:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/64\">",
"      McNally MA, Pyzik PL, Rubenstein JE, et al. Empiric use of potassium citrate reduces kidney-stone incidence with the ketogenic diet. Pediatrics 2009; 124:e300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/65\">",
"      Kossoff EH, Pyzik PL, Furth SL, et al. Kidney stones, carbonic anhydrase inhibitors, and the ketogenic diet. Epilepsia 2002; 43:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/66\">",
"      Takeoka M, Riviello JJ Jr, Pfeifer H, Thiele EA. Concomitant treatment with topiramate and ketogenic diet in pediatric epilepsy. Epilepsia 2002; 43:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/67\">",
"      Lyczkowski DA, Pfeifer HH, Ghosh S, Thiele EA. Safety and tolerability of the ketogenic diet in pediatric epilepsy: effects of valproate combination therapy. Epilepsia 2005; 46:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/68\">",
"      Coppola G, Epifanio G, Auricchio G, et al. Plasma free carnitine in epilepsy children, adolescents and young adults treated with old and new antiepileptic drugs with or without ketogenic diet. Brain Dev 2006; 28:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/69\">",
"      Kang HC, Chung DE, Kim DW, Kim HD. Early- and late-onset complications of the ketogenic diet for intractable epilepsy. Epilepsia 2004; 45:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/70\">",
"      Stewart WA, Gordon K, Camfield P. Acute pancreatitis causing death in a child on the ketogenic diet. J Child Neurol 2001; 16:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/71\">",
"      Dahlin MG, Beck OM, Amark PE. Plasma levels of antiepileptic drugs in children on the ketogenic diet. Pediatr Neurol 2006; 35:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/72\">",
"      Kossoff EH, Pyzik PL, McGrogan JR, Rubenstein JE. The impact of early versus late anticonvulsant reduction after ketogenic diet initiation. Epilepsy Behav 2004; 5:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/73\">",
"      Neal EG, Chaffe H, Schwartz RH, et al. A randomized trial of classical and medium-chain triglyceride ketogenic diets in the treatment of childhood epilepsy. Epilepsia 2009; 50:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/74\">",
"      Kossoff EH, Krauss GL, McGrogan JR, Freeman JM. Efficacy of the Atkins diet as therapy for intractable epilepsy. Neurology 2003; 61:1789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/75\">",
"      Kossoff EH, Dorward JL. The modified Atkins diet. Epilepsia 2008; 49 Suppl 8:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/76\">",
"      Kossoff EH, Dorward JL, Turner Z, Pyzik PL. Prospective study of the modified atkins diet in combination with a ketogenic liquid supplement during the initial month. J Child Neurol 2011; 26:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/77\">",
"      Kossoff EH, Rowley H, Sinha SR, Vining EP. A prospective study of the modified Atkins diet for intractable epilepsy in adults. Epilepsia 2008; 49:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/78\">",
"      Carrette E, Vonck K, de Herdt V, et al. A pilot trial with modified Atkins' diet in adult patients with refractory epilepsy. Clin Neurol Neurosurg 2008; 110:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/79\">",
"      Kossoff EH, Dorward JL, Molinero MR, Holden KR. The modified Atkins diet: a potential treatment for developing countries. Epilepsia 2008; 49:1646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/80\">",
"      Cervenka MC, Terao NN, Bosarge JL, et al. E-mail management of the modified Atkins Diet for adults with epilepsy is feasible and effective. Epilepsia 2012; 53:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/81\">",
"      Kossoff EH, McGrogan JR, Bluml RM, et al. A modified Atkins diet is effective for the treatment of intractable pediatric epilepsy. Epilepsia 2006; 47:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/82\">",
"      Porta N, Vall&eacute;e L, Boutry E, et al. Comparison of seizure reduction and serum fatty acid levels after receiving the ketogenic and modified Atkins diet. Seizure 2009; 18:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/83\">",
"      Weber S, M&oslash;lgaard C, Uldall P. Modified Atkins diet to children and adolescents with medical intractable epilepsy. Seizure 2009; 18:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/84\">",
"      Kossoff EH, Turner Z, Bluml RM, et al. A randomized, crossover comparison of daily carbohydrate limits using the modified Atkins diet. Epilepsy Behav 2007; 10:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/85\">",
"      Chapman K, Cardenas JF. Hemimegalencephaly in a patient with a neurocutaneous syndrome. Semin Pediatr Neurol 2008; 15:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/86\">",
"      Smith M, Politzer N, Macgarvie D, et al. Efficacy and tolerability of the modified Atkins diet in adults with pharmacoresistant epilepsy: a prospective observational study. Epilepsia 2011; 52:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/87\">",
"      Chen W, Kossoff EH. Long-term follow-up of children treated with the modified Atkins diet. J Child Neurol 2012; 27:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/88\">",
"      Sharma S, Sankhyan N, Gulati S, Agarwala A. Use of the modified Atkins diet for treatment of refractory childhood epilepsy: A randomized controlled trial. Epilepsia 2013; 54:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/89\">",
"      Kossoff EH, Henry BJ, Cervenka MC. Efficacy of dietary therapy for juvenile myoclonic epilepsy. Epilepsy Behav 2013; 26:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/90\">",
"      Kossoff EH, Bosarge JL, Miranda MJ, et al. Will seizure control improve by switching from the modified Atkins diet to the traditional ketogenic diet? Epilepsia 2010; 51:2496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/91\">",
"      Pfeifer HH, Thiele EA. Low-glycemic-index treatment: a liberalized ketogenic diet for treatment of intractable epilepsy. Neurology 2005; 65:1810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/92\">",
"      Muzykewicz DA, Lyczkowski DA, Memon N, et al. Efficacy, safety, and tolerability of the low glycemic index treatment in pediatric epilepsy. Epilepsia 2009; 50:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/93\">",
"      Marsh EB, Freeman JM, Kossoff EH, et al. The outcome of children with intractable seizures: a 3- to 6-year follow-up of 67 children who remained on the ketogenic diet less than one year. Epilepsia 2006; 47:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/94\">",
"      Kwiterovich PO Jr, Vining EP, Pyzik P, et al. Effect of a high-fat ketogenic diet on plasma levels of lipids, lipoproteins, and apolipoproteins in children. JAMA 2003; 290:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/95\">",
"      Nizamuddin J, Turner Z, Rubenstein JE, et al. Management and risk factors for dyslipidemia with the ketogenic diet. J Child Neurol 2008; 23:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/96\">",
"      Vining EP, Pyzik P, McGrogan J, et al. Growth of children on the ketogenic diet. Dev Med Child Neurol 2002; 44:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/97\">",
"      Groesbeck DK, Bluml RM, Kossoff EH. Long-term use of the ketogenic diet in the treatment of epilepsy. Dev Med Child Neurol 2006; 48:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/98\">",
"      Williams S, Basualdo-Hammond C, Curtis R, Schuller R. Growth retardation in children with epilepsy on the ketogenic diet: a retrospective chart review. J Am Diet Assoc 2002; 102:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/99\">",
"      Spulber G, Spulber S, Hagen&auml;s L, et al. Growth dependence on insulin-like growth factor-1 during the ketogenic diet. Epilepsia 2009; 50:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/100\">",
"      Neal EG, Chaffe HM, Edwards N, et al. Growth of children on classical and medium-chain triglyceride ketogenic diets. Pediatrics 2008; 122:e334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/101\">",
"      Berry-Kravis E, Booth G, Sanchez AC, Woodbury-Kolb J. Carnitine levels and the ketogenic diet. Epilepsia 2001; 42:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/102\">",
"      Bergqvist AG, Schall JI, Stallings VA. Vitamin D status in children with intractable epilepsy, and impact of the ketogenic diet. Epilepsia 2007; 48:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/103\">",
"      Bergqvist AG, Schall JI, Stallings VA, Zemel BS. Progressive bone mineral content loss in children with intractable epilepsy treated with the ketogenic diet. Am J Clin Nutr 2008; 88:1678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/104\">",
"      Bank IM, Shemie SD, Rosenblatt B, et al. Sudden cardiac death in association with the ketogenic diet. Pediatr Neurol 2008; 39:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/105\">",
"      Bergqvist AG, Chee CM, Lutchka L, et al. Selenium deficiency associated with cardiomyopathy: a complication of the ketogenic diet. Epilepsia 2003; 44:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/106\">",
"      Best TH, Franz DN, Gilbert DL, et al. Cardiac complications in pediatric patients on the ketogenic diet. Neurology 2000; 54:2328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/107\">",
"      Berry-Kravis E, Booth G, Taylor A, Valentino LA. Bruising and the ketogenic diet: evidence for diet-induced changes in platelet function. Ann Neurol 2001; 49:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/108\">",
"      Patel A, Pyzik PL, Turner Z, et al. Long-term outcomes of children treated with the ketogenic diet in the past. Epilepsia 2010; 51:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/109\">",
"      Worden LT, Turner Z, Pyzik PL, et al. Is there an ideal way to discontinue the ketogenic diet? Epilepsy Res 2011; 95:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/110\">",
"      Bara&ntilde;ano KW, Hartman AL. The ketogenic diet: uses in epilepsy and other neurologic illnesses. Curr Treat Options Neurol 2008; 10:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/111\">",
"      Busch V, Gempel K, Hack A, et al. Treatment of glycogenosis type V with ketogenic diet. Ann Neurol 2005; 58:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/112\">",
"      Swoboda KJ, Specht L, Jones HR, et al. Infantile phosphofructokinase deficiency with arthrogryposis: clinical benefit of a ketogenic diet. J Pediatr 1997; 131:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/113\">",
"      Van der Auwera I, Wera S, Van Leuven F, Henderson ST. A ketogenic diet reduces amyloid beta 40 and 42 in a mouse model of Alzheimer's disease. Nutr Metab (Lond) 2005; 2:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/114\">",
"      Henderson ST, Vogel JL, Barr LJ, et al. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr Metab (Lond) 2009; 6:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/115\">",
"      Seyfried TN, Kiebish M, Mukherjee P, Marsh J. Targeting energy metabolism in brain cancer with calorically restricted ketogenic diets. Epilepsia 2008; 49 Suppl 8:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/30/15850/abstract/116\">",
"      Evangeliou A, Vlachonikolis I, Mihailidou H, et al. Application of a ketogenic diet in children with autistic behavior: pilot study. J Child Neurol 2003; 18:113.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14438 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-BD889E7001-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_30_15850=[""].join("\n");
var outline_f15_30_15850=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21469046\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21467804\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21468627\">",
"      MECHANISMS OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21468634\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21468642\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H186115\">",
"      Specific conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21468805\">",
"      Partial versus generalized epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21468812\">",
"      CONTRAINDICATIONS AND SCREENING EVALUATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21468843\">",
"      IMPLEMENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21468851\">",
"      Initiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21468868\">",
"      Maintenance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21468888\">",
"      Antiepileptic drug management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21468908\">",
"      ALTERNATIVE DIETS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21468916\">",
"      Medium chain triglyceride diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21468923\">",
"      Modifed Atkins diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21468930\">",
"      Low glycemic index diet",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21468937\">",
"      ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21469017\">",
"      DURATION AND DISCONTINUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21469024\">",
"      POTENTIAL NON-EPILEPSY INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21469046\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/14438\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/14438|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/63/2045\" title=\"table 1\">",
"      Laboratory evaluation for inborn errors of metabolism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/11/43192?source=related_link\">",
"      Clinical presentation and diagnosis of measles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/47/38649?source=related_link\">",
"      Dietary carbohydrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33769?source=related_link\">",
"      Epilepsy syndromes in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=related_link\">",
"      Inborn errors of metabolism: Metabolic emergencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31818?source=related_link\">",
"      Initial treatment of epilepsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/28/30154?source=related_link\">",
"      Management and prognosis of infantile spasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/23/23928?source=related_link\">",
"      Muscle phosphorylase deficiency (glycogen storage disease V, McArdle disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=related_link\">",
"      Overview of the management of epilepsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/32/37386?source=related_link\">",
"      Overview of the treatment of seizures and epileptic syndromes in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/54/38754?source=related_link\">",
"      Patient information: Epilepsy in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28596?source=related_link\">",
"      Phosphofructokinase deficiency (glycogen storage disease VII, Tarui disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/29/32218?source=related_link\">",
"      Rett syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/39/41593?source=related_link\">",
"      Surgical therapy of epilepsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32328?source=related_link\">",
"      Tuberous sclerosis complex: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/7/19578?source=related_link\">",
"      Vagus nerve stimulation therapy for the treatment of epilepsy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_30_15851="Grading severity mucositis according to the NCI CTCAE";
var content_f15_30_15851=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F60597&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F60597&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    National Cancer Institute Common Terminology Criteria for mucositis severity version 4",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Grade",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Description",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1",
"       </td>",
"       <td>",
"        Asymptomatic or mild symptoms; intervention not indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2",
"       </td>",
"       <td>",
"        Moderate pain, not interfering with oral intake; modified diet indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3",
"       </td>",
"       <td>",
"        Severe pain, interfering with oral intake",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4",
"       </td>",
"       <td>",
"        Life-threatening consequences; urgent intervention indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        5",
"       </td>",
"       <td>",
"        Death",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     With permission from: Common Terminology Criteria for Adverse Events, version 4.0, June 2010, National Institutes of Health, National Cancer Institute, file://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_30_15851=[""].join("\n");
var outline_f15_30_15851=null;
var title_f15_30_15852="Bisphosphonate chem struc";
var content_f15_30_15852=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F77918&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F77918&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Basic bisphosphonate chemical structure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 295px; height: 199px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The two phosphonate (PO",
"    <sub>",
"     3",
"    </sub>",
"    ) groups covalently linked to carbon determine both the name \"bisphosphonate\" and the function. Bisphosphonates differ from each other at the two side chains, R",
"    <sub>",
"     1",
"    </sub>",
"    and R",
"    <sub>",
"     2",
"    </sub>",
"    , which determine their chemical properties and pharmacokinetics.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_30_15852=[""].join("\n");
var outline_f15_30_15852=null;
var title_f15_30_15853="Electrophysiological study for syncope";
var content_f15_30_15853=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F81195&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F81195&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Electrophysiological study for syncope",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Recommendations",
"       </td>",
"       <td class=\"subtitle1\">",
"        Class*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Level",
"        <span class=\"small\">",
"         &bull;",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Indications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        In patients with ischemic heart disease, EPS is indicated when initial evaluation suggests an arrhythmic cause of syncope (listed in Table 10) unless there is already an established indication for ICD",
"       </td>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        In patients with BBB, EPS should be considered when noninvasive tests have failed to make the diagnosis",
"       </td>",
"       <td>",
"        IIa",
"       </td>",
"       <td>",
"        B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        In patients with syncope preceded by sudden and brief palpitations, EPS may be performed when other noninvasive tests have failed to make the diagnosis",
"       </td>",
"       <td>",
"        IIb",
"       </td>",
"       <td>",
"        B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        In patients with Brugada syndrome, ARVC and hypertrophic cardiomyopathy an EPS may be performed in selected cases",
"       </td>",
"       <td>",
"        IIb",
"       </td>",
"       <td>",
"        C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        In patients with high-risk occupations, in whom every effort to exclude a cardiovascular cause of syncope is warranted, an EPS may be performed in selected cases",
"       </td>",
"       <td>",
"        IIb",
"       </td>",
"       <td>",
"        C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        EPS is not recommended in patients with normal ECG, no heart disease, and no palpitations",
"       </td>",
"       <td>",
"        III",
"       </td>",
"       <td>",
"        B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Diagnostic criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"3\">",
"        EPS is diagnostic, and no additional tests are required, in the following cases:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        - Sinus bradycardia and prolonged CSNRT (&gt;525 ms)",
"       </td>",
"       <td class=\"sublist_other\">",
"        I",
"       </td>",
"       <td class=\"sublist_other\">",
"        B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        - BBB and either a baseline HV interval of &ge;100 ms, or second or third degree His&mdash;Purkinje block is demonstrated during incremental atrial pacing, or with pharmacological challenge",
"       </td>",
"       <td class=\"sublist_other\">",
"        I",
"       </td>",
"       <td class=\"sublist_other\">",
"        B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        - Induction of sustained monomorphic VT in patients with previous myocardial infarction",
"       </td>",
"       <td class=\"sublist_other\">",
"        I",
"       </td>",
"       <td class=\"sublist_other\">",
"        B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        - Induction of rapid SVT which reproduces hypotensive or spontaneous symptoms",
"       </td>",
"       <td class=\"sublist_other\">",
"        I",
"       </td>",
"       <td class=\"sublist_other\">",
"        B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        An HV interval between 70 and 100 ms should be considered diagnostic",
"       </td>",
"       <td>",
"        IIa",
"       </td>",
"       <td>",
"        B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        The induction of polymorphic VT or ventricular fibrillation in patients with Brugada syndrome, ARVC, and patients resuscitated from cardiac arrest may be considered diagnostic",
"       </td>",
"       <td>",
"        IIb",
"       </td>",
"       <td>",
"        B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        The induction of polymorphic VT or ventricular fibrillation in patients with ischemic cardiomyopathy or DCM cannot be considered a diagnostic finding",
"       </td>",
"       <td>",
"        III",
"       </td>",
"       <td>",
"        B",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ARVC: arrhythmogenic right ventricular cardiomyopathy; BBB: bundle branch block; CSNRT: corrected sinus node recovery time; DCM: dilated cardiomyopathy; EPS: electrophysiological study; ICD: implantable cardioverter defibrillator; HV: His-ventricle; SVT: supraventricular tachycardia; VT: ventricular tachycardia.",
"     <br>",
"      * Class of recommendation.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Level of evidence.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: European Heart Rhythm Association (EHRA), Heart Failure Association (HFA), Heart Rhythm Society (HRS), et al. Guidelines for the diagnosis and management of syncope (version 2009): the Task Force for the Diagnosis and Management of Syncope of the European Society of Cardiology (ESC). Eur Heart J 2009; 30:2631. Copyright &copy; 2009 Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_30_15853=[""].join("\n");
var outline_f15_30_15853=null;
var title_f15_30_15854="Intrauterine pressure catheter";
var content_f15_30_15854=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F75267&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F75267&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intrauterine pressure catheter",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Clinical Innovations, LLC. Koala&reg; Intrauterine Pressure Catheter IPC-5000.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_30_15854=[""].join("\n");
var outline_f15_30_15854=null;
var title_f15_30_15855="Physalia physalis print";
var content_f15_30_15855=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F67949&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F67949&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Physalia physalis print",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 485px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Print from a Physalia physalis tentacle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Junghanss, T, Bodio, M. Medically important venomous animals: Biology, prevention, first aid, and clinical management. CID 2006; 32:1309. Copyright &copy; 2006 University of Chicago Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_30_15855=[""].join("\n");
var outline_f15_30_15855=null;
 